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ABSTRACT 
 
 
IDENTIFICATION OF  
PUTATIVE PROTEIN KINASE INHIBITORS  
ACTING ON LIVER CANCER CELLS 
 
Ebru Bilget Güven 
PhD. in Molecular Biology and Genetics 
Supervisor: Assoc. Prof. Dr. Rengül Çetin-Atalay 
August 2012, 204 Pages 
 
Hepatocellular carcinoma (HCC) as a, heterogeneous, multi-step, slow-
progressing disease, has very limited treatment options due to its chemoresistant 
nature and late diagnosis. According to World Health Organization (WHO)  
reports HCC is a major public health problem. Each year, 748,000 new cases 
appear and 696,000 people lose their lives, all due to liver cancer alone. Sorafenib, 
the multi-tyrosine kinase inhibitor, is still the only (Food and Drug 
Administration) FDA-approved drug available for treatment. Therefore, there is 
an urgent need for novel, target-specific drugs based on the underlying molecular 
mechanisms of liver carcinogenesis. 
 
In this Ph.D. dissertation, synthetic purine, purine nucleoside analogs, 
aminotriazole and thiadiazine derivatives were evaluated for their cytotoxic 
activities and mechanisms of action against liver cancer. These novel molecules 
were selected because of their potential kinase inhibitory activity. Protein kinases, 
involved in signaling pathways, are the main enzymes of target-specific drug 
discovery; therefore, discovery of novel, putative protein kinase inhibitors as drug 
candidates can be promising for the treatment of primary liver cancer.  
 
Initially, sulforhodamine B (SRB) assay was used to screen the novel small-
molecules for their cytotoxic activities against breast, colon and liver cancer cell 
lines. Active molecules, then, were further exploited on a panel of HCC cell lines. 
The differential IC50 (half-maximal inhibitory concentration) values obtained, 
might indicate that these small-molecules interfere with cell signaling; since, these 
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cell lines have individual characteristics of cell signaling activities. Further 
investigations are envisaged for the identification of the molecular mechanisms 
that these putative kinase inhibitors are involved in.   
 
Among the 228 newly synthesized putative kinase inhibitors, 3 small-
molecules were identified as promising anti-cancer agents against liver cancer 
with druggable cytotoxic activities and remarkable kinase inhibition  potentials.   
The purine analogue, AUM32, and the purine nucleoside analogue, AUM42, were 
revealed as pro-senescence therapeutic agents in liver cancer. Both drug 
candidates were shown to initiate senescence-induced cell death and the 
underlying mechanism was confirmed for AUM42 as the induction of 
p15(INK4b) and the correlated decrease in Rb phosphorylation. 
 
Synthetic 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine derivative, ClAT-TM, is 
the other effective small-molecule with kinase inhibition potential. Upon ClAT-
TM treatment, liver cancer cells experience a growth inhibition accompanying 
with dramatic morphological changes. Rounded, swollen and eventually detached 
cells were shown to be arrested in the G2/M stage of the cell cycle and eventually 
undergo apoptosis. Moreover, ROS (reactive oxygen species) accumulation and 
the activation of JNK signaling pathway were found as associated with the 
mechanism of action ClAT-TM cytotoxicity. 
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ÖZET 
 
 
POTANSİYEL PROTEİN KİNAZ İNHİBİTÖRLERİNİN 
KARACİĞER KANSERİNE KARŞI  
İLAÇ ADAYI OLARAK TANIMLANMASI 
 
Ebru Bilget Güven 
Moleküler Biyoloji ve Genetik Doktorası 
Tez Yöneticisi: Doç. Dr. Rengül Çetin-Atalay 
Ağustos 2012, 204 Sayfa 
 
Hepatosellüler karsinom (HSK), heterojen, çok aşamalı, yavaş gelişen bir 
hastalık olup, kemoterapiye dirençli yapısı ve sıklıkla geç teşhis edilmesi 
nedeniyle tedavi seçenekleri sınırlıdır. Dünya Sağlık Örgütü’nün raporlarına göre 
HSK önemli bir toplum sağlığı sorunudur. Her yıl, dünya genelinde 748,000 yeni 
kanser vakası ve 696,000 ölüm sadece karaciğer kanserine bağlı olarak 
gelişmektedir. Çoklu-tirozin kinaz inhibitörü olan Sorafenib, ileri seviyede HSK 
için hala FDA onayı olan tek ilaçtır. Bu nedenlerle, karaciğer kanser gelişiminin 
altında yatan moleküler mekanizmaları hedef alan, yeni ilaç adaylarının tespit 
edilmesine acil olarak gereksinim vardır. 
 
Bu doktora tez çalışmasında, sentetik pürin ve pürin nükleozid analogları ile 
aminomerkaptotriazol ve triazolotiyadiazin türevleri, karaciğer kanseri üzerindeki 
sitotoksik etkileri ve hareket mekanizmaları açısından değerlendirilmiştir. Bu yeni 
moleküller, potansiyel kinaz inhibisyon aktiviteleri nedeniyle seçilmişlerdir. 
Hücre sinyal yolaklarında yer alan protein kinazlar, hedef-odaklı ilaç keşfinde 
temel enzimler olup, yeni keşfedilecek potansiyel kinaz inhibitörleri, HSK 
tedavisinde umut veren ilaç adaylarıdır. 
 
Öncelikle, yeni sentezlenen küçük-moleküllerin sitotoksik etkileri, 
sülforadamin B (SRB) yöntemi kullanılarak meme, kolon ve karaciğer kanseri 
hücrelerinde incelenmiştir. Aktif olduğu tespit edilen moleküller, daha sonra HSK 
hücre hatlarına karşı değerlendirilmiştir. Farklı kanser hücre hatlarında, farklı 
IC50 değerlerine ulaşılması ve kanser hücrelerinde sinyalizasyonun hücre hattına 
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özgü, ayırt edici özelikler taşıdığının bilinmesi, bu küçük-moleküllerin sinyal 
yolaklarına müdahale ettiklerini düşündürmüştür. Potansiyel protein kinaz 
inhibitörlerinin moleküler mekanizmalarını tanımlayacak ileri analizler 
öngörülmüştür.    
 
Bu doktora tez çalışması kapsamında, yeni sentezlenen 228 adet potansiyel 
protein kinaz inhibitöründen 3 küçük-molekül, düşük dozlarda gösterdikleri 
sitotoksik etki ve dikkate değer kinaz inhibisyon potansiyelleri ile kuvvetli ilaç 
adayları olarak saptanmıştır. Nükleozid analoglarından AUM32 ve AUM42, 
karaciğer kanserinde erken-yaşlanmaya yol açan terapötik ajan olarak 
gösterilmişlerdir. Her iki ilaç adayının da yaşlanmanın tetiklediği hücre ölümüne 
yol açtığı, hatta AUM42 molekülünün, p15(INK4b) artışına bağlı olarak düşen 
fosforile-Rb üzerinden etki ettiği ortaya konmuştur 
 
Sentetik 1,2,4-triazol[3,4-b]-1,3,4-tiyadiazin türevi, ClAT-TM, bir diğer 
etkin, potansiyel protein kinaz inhibitörüdür. Karaciğer kanser hücreleri, ClAT-
TM varlığında, yapısal bozulmaların yanında büyümede de gerileme göstermiştir. 
Yuvarlaklaşarak şişen ve nihayetinde kültür ortamından kopan hücreler, apoptoza 
girmeden önce hücre döngüsünün G2/M aşamasında tutulma yaşamaktadırlar. 
Üstelik ROS (reaktif oksijen türleri) birikmesi ve JNK sinyal yolağının aktif hale 
geçmesi, ClAT-TM molekülünün etki mekanizmasıyla ilişkilendirilmiştir. 
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CHAPTER 1. INTRODUCTION 
 
 
1.1 Protein phosphorylation: 
 
The form of life we know gives privilege to phosphate group not only to 
link the nucleosides of DNA and RNA but also to be part of the primary cellular 
energy source, ATP. These privileges provide phosphates a vital role in living 
organisms. Phosphorus atom uses its 5 valence electrons to form bonds with 
oxygen atoms and yields phosphate group (-PO4). Oxygens offer phosphate group 
a hydrated ionic shell and high solubility in water. Moreover, a phosphate has 3 
ionizable groups which facilitate preserving nucleic acids within cell membrane. 
Phosphate group is reactive at physiological temperature which is another cellular 
advantage. The question Weistheimer asked 25 years ago, “Why nature chose 
phosphates?” highlighted a developing research field (Weistheimer FH, 1987).  
 
Protein phosphorylation, a common post-translational modification, was 
first discovered when Levene showed vitelline, an egg yolk protein, contains 
phosphate (Levene PA and Alsberg CL, 1906). Subsequently, Levene had 
identified phosphoserine in 1932 and achieved to synthesize phosphotyrosine in 
1933 (Lipmann FA and Levene PA, 1932; Levene PA and Schormüller A, 1933). 
After that, Burnett and Kennedy described the first protein kinase activity when 
they discovered an enzyme capable of catalyzing the transfer of phosphate from 
ATP to protein in 1954 (Burnett G and Kennedy EP, 1954). Edwin Krebs and 
Edmond Fischer were able to demonstrate that -phosphate of ATP was 
incorporated into a particular serine residue of phosphorylase b producing the 
activated, phosphorylase a, form (Krebs EG et al., 1959).  Today it is well-
described that, through chemically adding the -phosphate of ATP to target 
proteins, many cellular processes such as cell growth, proliferation, division, 
differentiation, adhesion, metabolism and apoptosis are regulated (Figure 1.1).  
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Figure 1.1 The transfer of -phosphate of ATP to the hydroxyl group of an 
amino acid residue: (R: Ser/Thr/Tyr) (Schwartz PA and Murray BW, 2011)  
 
1.1.1 Protein kinases: 
 
Protein kinases (PK), as being responsible for the post-translational 
phosphorylation of various proteins, are one of the largest gene families sharing 
the same molecular action. The protein kinase complement of the human genome, 
namely the human kinome, encodes more than 500 protein kinases corresponding 
to almost 2% of the entire genome (Manning G et al., 2002). Seven main groups 
are labeled and positioned on the kinome tree by comparing the sequence of their 
catalytic domains: the spatial distance between two kinases represents the 
divergence between their sequences (Figure 1.2).  
 
PKs can be broadly classified according to their substrate specificity: 
serine/threonine (Ser/Thr) kinases and tyrosine (Tyr) kinases. There are some 
dual-specific PKs able to phosphorylate both hydroxyl groups of (Ser/Thr) and 
(Tyr) residues (Bogoyevitch MA and Fairlie DP, 2007). The (Ser/Thr) kinases are 
four-fold of (Tyr) kinases in number while the latter are involved in key signaling 
mechanisms (Arena S et al., 2005). Although cAMP-dependent protein kinase 
(PKA) is the second discovered, it is the first sequenced PK (Shoji S et al., 1981). 
Then, the transforming protein from Rous sarcoma virus, Src was shown to be 
related to the catalytic chain of PKA. Moreover, it was shown that Src is a Tyr 
kinase while PKA is a Ser/Thr kinase (Barker WC and Dayhoff MO, 1982). 
Further analysis on the sequences of PKA and Src demonstrated that these two 
share a common precursor. The conserved subdomains, each with a unique motif, 
have been accepted in time as a definition of PK core (Hanks SK et al., 1988). 
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Figure 1.2 The human kinome tree: Groups are AGC Containing PKA, PKG, 
PKC families; CAMK Calcium/calmodulin-dependent protein kinase; CK1 
Casein kinase 1; CMGC Containing CDK, MAPK, GSK3, CLK families; STE 
Homologs of yeast Sterile 7, Sterile 11, Sterile 20 kinases; TK Tyrosine kinase; 
TKL Tyrosine kinase-like. The Kinase Knowledgebase is Eidogen-Sertanty's 
database of biological activity data, structure-activity relationships (SAR), and 
chemical synthesis data focused on protein kinases. (www.eidogen-sertanty.com) 
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The conserved catalytic core of PKs is composed of two lobes: N-terminal 
domain and C-terminal domain which are associated with ATP binding and 
peptide binding respectively (Figure 1.3). Protein kinases are molecular switches 
regulating numerous cellular processes; even protein kinases themselves are under 
the control of other upstream kinases. In such a system, the essential feature of PK 
activation is the spatial assembly of its domains (Kornev AP et al., 2006). 
 
 
Figure 1.3 Structure of the conserved protein kinase core: Protein kinases 
(PK) are composed of two domains. The N-terminal domain has Glycine-rich 
loop, 5 β strands (green) and the  C-helix. C-terminal domain is generally helical 
(red). Catalytically important loops are colored yellow. Glycine-rich loop 
coordinates the phosphates. The P-loop accommodates the residues of their 
peptide substrate (Taylor SS and Kornev AP, 2011). 
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The mostly helical C-terminal domain is more stable when compared to N-
terminal domain and accommodates the substrate proteins. The activation 
fragment has a Mg-binding loop at its N-terminal beginning with Asp-Phe-Gly 
(DFG) motif, followed by the most diverse fragment: the activation loop. The 
phosphorylation site is protected by the “P-loop” which forms a hydrophobic 
pocket in order to accommodate the residue of the substrate protein positioned just 
after the residue (Ser/Thr/Tyr) to be phosphorylated. (Kornev AP and Taylor SS, 
2010; Taylor SS and Kornev AP, 2011). 
 
1.1.2 Protein kinase inhibitors: 
 
Dysregulation of protein kinase activity rise as a major mechanism in 
disease conditions, especially in cancer. To date, amplification, translocation, 
missense mutation and deletion of certain PK genes have been associated with 
numerous cancers. Analysis on the human kinome showed that 244 of the 
catalogued 518 putative protein kinase genes are mapped to disease loci or cancer 
amplicons (Manning G et al., 2002). Thus, human kinome offers an important 
opportunity to the drug discovery field.  
 
Type I inhibitors: This group of “first generation” of small molecule kinase 
inhibitors are ATP-competitive compounds targeting the active DFG motifs of 
PKs (Zuccotto F et al., 2010). They typically include a heterocyclic ring system in 
order to be able to imitate the interactions of the adenine moiety and bind to the 
kinase via H-bonds (Zhang J et al., 2009). The region occupied by type I 
inhibitors is composed of subregions as illustrated in Figure 1.4.  Some of the type 
I kinase inhibitors prefer the inactive conformation of the PK and there are 
significant structural differences of the type I inhibitor-kinase complex depending 
on the characteristics of the inhibitor. Gefitinib, erlotinib, dasatinib, sunitinib, and 
most notably staurosporine are the typical examples for this type I inhibitors 
(Fabbro D et al., 2012). 
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A) 
 
 
B) 
 
 
Figure 1.4 The binding modes of protein kinase inhibitors: A) The subregions 
of the ATP binding site. H-bonds are represented by dashed lines B) Allosteric 
binding site (Liu Y and Gray NS, 2006).  
 
Type II inhibitors: This group of inhibitors targets the DFG motif 
projected-out conformation to occupy the hydrophobic region that is adjacent to 
ATP binding site, in other words, they are designed to recognize the inactive form 
of the kinase (Zuccotto F et al., 2010). The first (Food and Drug Administration) 
FDA approved small molecule kinase inhibitor, imatinib, and others nilotinib, 
sorafenib and vatalinib are the well-known examples of type II inhibitors (Fabbro 
D et al., 2012). 
 
Type III inhibitors: This group of compounds can be named as non-ATP-
competitive or allosteric kinase inhibitors since they do not interact with ATP 
binding domain (Figure 1.4.). Considering that the binding site exploited is 
relatively kinase-specific, type III inhibitors show the highest degree of 
selectivity. The number of type III inhibitors discovered so far is very limited. The 
most well-defined allosteric kinase inhibitor (of MEK) is CI-1040 and some 
others are rapamycin analogs and Abl, IKK, Akt, Chek1, MEK, Src, IGF1R 
inhibitors (Zhang J et al., 2009). 
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1.1.3 Protein kinase drug discovery: 
 
Cancer cells sustain their malignant phenotype by extensively tangled 
signaling pathways. Therefore, the identification of the critical and functional 
nodes of this network is the key step to a successful therapy. FDA approved 
(Table 1.1) or in preclinical / clinical development chemicals target all stages of 
signal transduction.  
 
Table 1.1 FDA approved protein kinase inhibitors  
Compound Kinase Target Cancer target Company 
Approval 
date 
Imatinib  
(Glivec,  
Gleevec,  
STI571) 
Abl 1-2, 
PDGFR,  
Kit 
CML, Ph+ B-
ALL, NML, 
CEL, GIST 
Novartis 05 / 2001 
Gefitinib 
(Iressa,  
ZD1839) 
EGFR NSCLC AstraZeneca 05 / 2003 
Erlotinib 
(Tarceva,  
OSI-774) 
EGFR 
NSCLC, 
pancreatic 
cancer 
OSI, Genentech 
Inc, Roche 
11 / 2004 
Lapatinib 
(Tykerb,  GW2016) 
EGFR, 
Erbb2 
Breast     
cancer 
Glaxo Smith Kline 07 / 2007 
Dasatinib 
(Sprycel,  
BM-354825) 
Abl 1-2, 
PDGFR, 
Kit, Src 
CML Bristol Myers 06 / 2006 
Nilotinib  
(Tasigna, AMN107) 
Abl 1-2, 
PDGFR, Kit 
CML Novartis 10 / 2007 
Sunitinib  
(Sutent,  
SU11248) 
VEGFR1-3,  
Kit, PDGFR, 
Ret, CSFIR,  
Flt3 
RCC,  
GIST 
Pfizer 01 /2006 
Sorafenib 
(Nexavar,  
Bay 43-9006) 
VEGFR2,  
Kit, PDGFR, 
Braf, Flt3 
RCC,  
HCC 
Onyx and Bayer 
Pharmaceuticals 
12 /2005 
Pazopanib 
(Votrient,  
GW-786034) 
VEGFR1-3, 
PDGFR, Kit 
RCC Glaxo Smith Kline 04 / 2012 
Everolimus 
(Afinitor,  
Rad001) 
mTOR RCC Novartis 03 / 2009 
Temsirolimus 
(Torisel,  
CCI-779) 
mTOR RCC Wyeth 05 / 2007 
Axitinib  
(Inlyta,  
AG013736) 
VEGF RCC Phizer 01 / 2012 
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The complexity of the rewired pathways of cancer cells cause them to 
become more dependent on the activity of a specific oncogene since during 
carcinogenesis they have lost the function of another gene that normally performs 
a similar function (Weinstein IB and Joe AK, 2006). Targeting one of the 
synthetic lethal genes, known as their mutations lead to death if they exist 
simultaneously, is an elegant strategy for small molecule kinase inhibitors (Kaelin 
WG, 2005). 
 
Another major challenge for kinase drug discovery is the rising resistance to 
kinase inhibition. A combinatorial drug treatment approach could be considered as 
a strategy to improve the therapy. In oncogenic resistance, although the drug fits 
into its target, inhibitors of apoptosis block the cell death. In order to overcome 
this resistance, the block should be released or the apoptotic pathways 
downstream of the block should be taken as a supplementary target (Figure 1.5) 
(Blagosklonny MV, 2004). 
 
Figure 1.5 Non-oncogenic and oncogenic drug resistance: Inhibitory 
concentration 50 (IC50) is the drug concentration leading to 50% decrease in cell 
growth. In case of non-oncogenic drug resistance, dose-response curve shifts to 
the right with an increase in the IC50 value. If the resistance is oncogenic, the 
IC50 value does not change; but, since the dose-response curve reaches a plateau, 
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the drug does not kill the cells although it interacts with its target. Therefore, 
inhibitory concentrations corresponding below the plateau cannot be achieved.  
(adapted from Blagosklonny MV, 2004) 
 
1.2 Cell death: 
 
Cancer cells show resistance to cell death due to the defects in signaling 
pathways developed during tumorigenesis. Chemotherapies stimulate these 
pathways as an attempt to create cytotoxicity with an ultimate aim to lead to 
cancer cell death. In addition to apoptosis, non-apoptotic mechanisms such as 
necrosis, autophagy, mitotic catastrophe and senescence are the cellular activities 
that anti-cancer drugs initiate (Okada H and Mak TW, 2004). 
 
 
 
 
Figure 1.6 Morphological features of cells confronting apoptotic and non-
apoptotic cell deaths: A) normal, B) autophagic, C) apoptotic, D) mitotic 
catastrophic, E) necrotic and F) senescent cells. The scale bars represent 1m for 
A), B), C), E); 5 m for D) and 50 m for F). (Edinger AL and Thompson CB, 
2004; Leontieva OV and Blagosklonny MV, 2010; Vitale I et al., 2011).  
10 
 
Apoptosis is strictly regulated, “programmed” cell death and can be initiated 
by either intracellular signals or extracellular ligands. In early apoptosis, cells 
round up, loose contact to their neighbors and shrink with blebbing cell 
membranes (Figure 1.6). The chromatin condenses and DNA fragmentation starts. 
The nucleus becomes tangled, disintegrates into encapsulated, compact fragments 
called “apoptotic bodies” (Lawen A, 2003). Signals originating from death 
receptors initiate the Death Inducing Signaling Complex (DISC) which activates 
caspase-8 (Gewies A, 2003; de Bruin EC and Medema JP, 2008). Cysteinyl 
aspartate proteinases, caspases, are inactive enzyme precursors involved in the 
cleavage of Asp residue containing substrates (Lavrik IN et al., 2005; Kumar S, 
2007). Apoptotic stimuli trigger the initiator group of caspases (caspase-8, -9, -10) 
which consequently activates the executioner group of caspases (caspase-3, -6, -7) 
(Kurokawa M and Kornbluth S, 2009).  
 
This direct caspase cascade which is sufficient to start apoptosis is called the 
extrinsic pathway. If the apoptotic signal from DISC needs to be amplified, 
caspase-8 activates BH3-only protein Bid which subsequently induces the 
mitochondria to release cytochrome c (Gewies A, 2003; Ricci MS and Zong WX, 
2006). This small, mobile molecule, known as an electron carrier, associates with 
the Apaf-1 (apoptosis protease activating factor-1) and forms apoptosome 
(Goodsell DS, 2004). The heptameric apoptosome activates caspase-9, another 
initiator caspase, able to activate caspase cascade through caspase-3 (Gewies A, 
2003). Another proapoptotic factor released from mitochondria is Smac/DIABLO 
(second mitochondria-derived activator of caspases / direct IAP-binding protein 
with a low isoelectric point) which mainly targets the inhibitor of apoptosis (IAP) 
to prevent the blockage of caspase cascade (Herr I and Debatin KM, 2010).  
 
Bcl-2 family members, both pro- and anti-apoptotic Bcl-2 proteins, are 
located upstream of mitochondria and play an essential role in determining 
whether the cell will live or die (Gross A et al., 1999). The ratio between the anti-
apoptotic Bcl-2 members (Bcl-2, Bcl-xL) and the pro-apoptotic ones (Bid, Bax, 
Bak, Puma, Noxa) helps to decide the cell’s fate. Puma (p53 upregulated 
modulator of apoptosis) and Noxa are involved in p53-mediated apoptosis. DNA 
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damage as a consequence of irradiation, drugs or other external stress activates the 
tumor suppressor protein, p53, which performs in favor of apoptosis (Elmore S, 
2007) 
 
Cell death by autophagy is a self-degradation process, in which double-
membrane vesicles sequester the organelles with cytoplasm to form 
autophagosomes that fuse with lysosomes (Figure 1.6). Eventually, vesicles 
breakdown and the contents are hydrolytically digested (Edinger AL and 
Thompson CB, 2004; Coates JM et al., 2009). Autophagy, “self-eating” is a 
ubiquitous, evolutionarily conserved process, which is activated in normal tissue, 
in order to maintain not only cellular homeostasis but also ATP levels during 
starvation (Jin S and White E, 2007; Coates JM et al., 2009). Although in normal 
cells autophagy has a tumor suppressive role, in cancer cells its function is 
complex and context dependent (Cheong H et al., 2012). 
 
 Autophagy starts with the formation of phagophore which is regulated by 
numerous signaling pathways. In mammalian cells phagophore membranes are 
originated from endoplasmic reticulum (ER) and expand to sequester the 
organelles with cytoplasm to form autophagosomes (Glick D, 2010).  After 
inhibiting the negative regulator of autophagy, energy-sensing mTOR 
(mammalian target of rapamycin) kinase, Atg13/FIP200/ULK (Autophagy-related 
gene/focal adhesion kinase family interacting protein of 200 kDa/UNC-51-like 
kinase) complex is stimulated and this initiates phagophore formation 
Phosphatidylinositol 3 (PI3) kinase complex, composed of Vps34 (vesicular 
protein sorting 34), Atg14L, Becn1, regulates the vesicle nucleation step (Cheong 
H et al., 2012).   
 
In contrast to apoptosis and autophagy, necrosis is an unrestrained form of 
cell death. Necrotic cells swell, lose the membrane integrity and morphologically 
recognized by vacuolation of their cytoplasm (Figure 1.6) (de Bruin EC and 
Medema JP, 2008). Necrosis, which has been considered as an uncontrolled cell 
death, is weakly characterized at the molecular level (Portugal J, 2010). Until 
recently, necrotic cells were distinguished by the swollen organelles, randomly 
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degraded nuclear DNA, lacking chromatin condensation, ruptured plasma 
membrane and eventually total cell collapse (Zhivotovsky B, 2004). Earlier 
studies define necrosis as a traumatic cellular response to severe toxicity without a 
stimulating signaling cascade (Okada H and Mak TW, 2004). On the contrary, the 
following studies evidently showed that depending on the context, necrosis is a 
tightly controlled interaction of signaling pathways, originated from various 
stimuli (Duprez L et al., 2009).  
 
Poly-(ADP-ribose) polymerase (PARP-1) is an 113kDa nuclear enzyme. 
Under normal circumstances, PARP-1 detects and repairs DNA damages; but, 
massive DNA damage hyperactivates PARP-1, reduces NAD
+
 levels, leads to 
ATP shortage and eventually causes necrosis (Duprez L et al., 2009; Chaitanya 
GV et al., 2010). 
 
Table 1.2 Proteolytic fragments of PARP-1 (Chaitanya GV et al., 2010) 
Caspase-3 and -7 
24kDa N-terminal fragment 
89kDa C-terminal fragment 
Calpain-1  70 – 40 kDa N-terminal fragments 
Cathepsin-B and -D 
89, 74, 62 kDa N-terminal fragments 
55, 44 kDa C-terminal fragments 
Cathepsin-G 
74, 62 kDa N-terminal fragments 
55, 44 kDa C-terminal fragments 
Granzyme-A 
55 kDa N-terminal fragment 
 55 kDa C-terminal fragment 
Granzyme-B 
64, 61 kDa N-terminal fragments 
54, 42 kDa C-terminal fragments 
MMP-2 
<48 kDa fragment 
66 kDa fragment 
 
Caspases, calpains, cathepsins, granzymes and matrix metalloproteinases 
(MPPs), in other words suicide proteases, create PARP-1 fragments specific to the 
type of cell death (Table 1.2). Cleavage of PARP-1 by means of caspases occurs 
during apoptosis and therefore of 89kDa cleaved-PARP is considered as an 
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apoptosis marker (Chaitanya GV et al., 2010). On the other hand, the major 
fragment obtained during necrosis is 50 kDa (Gobeil S et al., 2001).  
 
Mitotic catastrophe (MC) is occasionally accepted as an aberrant mitosis 
eventually leading cell irreversibly to death rather than a form of death (Ricci MS 
and Zong WX, 2011). Abnormal mitosis drives cells to mitotic catastrophe (MC) 
through several different pathways but finally the enlarged, multi-nucleated cells  
share a common, characteristic morphology. They lack the nuclear envelope, have 
fragmented nuclei as in apoptotic cells but contain uncondensed chromatin 
(Figure 1.6) (Roninson IB et al., 2002). Additionally, MC has been evaluated as a 
distinctive subset of apoptosis due to the common biochemical features both 
apoptosis and MC share, such as caspase activation and the permeabilization of 
mitochondrial membrane (Castedo M et al., 2004). There are also accumulated 
data describing MC as a survival mechanism that the tumor cells exploit. Another 
currently supported opinion is that MC is a preliminary process leading to 
apoptosis or necrosis (Vakifahmetoglu et al., 2008). 
 
Mitotic catastrophe does not occur in a thoroughly established homogenous 
manner; instead, depending on the duration between mitotic arrest and the cell 
death, MC can happen in various modes. Recently, three different fates for cells 
experiencing mitotic arrest have been described. First, the cells can undergo 
mitotic death; in other words, they can die during mitosis following mitotic arrest. 
Second, the cell death can happen during the interphase of the subsequent cell 
cycle. Third, instead of cell death, the cells can be subjected to senescence during  
the interphase of the next cell cycle (Vitale I et al., 2011).    
 
1.2.1 Senescence: 
 
Senescence was described long ago after the  observation of the limited life 
span of normal human embryonic fibroblasts in culture dish. Senescent cells are 
large, flattened and multi-nucleated with granular cytoplasms. A commonly used 
senescence biomarker is the increased senescence associated-β-gal (SA-β-gal) 
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activity, which can be detected by X-gal, forming a blue precipitate at pH 6.0 
(Figure 1.6) (Dimri GP et al., 1995; Dimri GP 2005). 
 
The phenomenon named as “replicative senescence” and defined as 
irreversible cell cycle arrest (Hayflick L and Moorhead PS, 1961; Hayflick L, 
1965). Different from quiescent cells, senescent cells do not enter S phase in the 
presence of mitogenic stimuli. Unlike apoptotic cells, they remain alive if fresh 
culture medium is supplied; namely senescence provides them resistance to 
apoptosis (Zhang H, 2007). Additionally, they develop a senescence associated 
secretory phenotype (SASP) including various cytokines, growth factors and 
proteases containing strong autocrine and paracrine effects (Rodier F and Campisi 
J, 2011).  
 
1.2.1.1  Replicative senescence: 
 
The underlying molecular mechanism for cultured cells halting replication 
after a finite number of passaging is explained by telomere shortening (Harley C 
et al., 1990). The repetitive DNA sequence (TTAGGG) and its specific proteins 
are called telomeres. These DNA-protein complexes cap and therefore protect the 
ends of human chromosomes. Since most of the human cells lack telomerase, 
responsible for the de novo synthesis of telomeric DNA, telomeres shorten after 
each cell cycle. When the telomere size reaches to a threshold, cells stop 
replicating permanently; in other words, they undergo senescence due to damaged  
DNA at the ends of the chromosomes (Campisi J, 2001; Campisi J and d’Adda di 
Fagagna F, 2007).  Not only telomere shortening but also oncogene activation, 
DNA-damage, oxidative stress, PTEN (phosphatase and tensin homolog deleted 
on chromosome 10) loss and cytotoxic drugs can lead to senescence (Collado M 
and Serrano M, 2006; Kuilman T et al., 2010).  
 
1.2.1.2  Oncogene-induced  senescence: 
 
Oncogene-induced senescence (OIS) emerges as a tumor-suppressive 
response to hyper-replication of oncogene proteins such as myc and H-ras (Lee S 
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et al., 2011) Oncogenic ras-dependent transformation of normal cells to tumor 
cells requires the cooperation of an additional oncogene or the lack of tumor 
suppressor genes. Otherwise, with the accumulation of p53 and/or p16, oncogenic 
ras drives cells to G1 arrest and eventually senescence (Serrano M et al., 1997).   
 
The expression levels of the oncogene determine the future of senescence. 
Surprisingly, OIS requires overexpressed oncogene; whereas, basal levels are 
capable of inducing neither senescence nor tumorigenesis. In other words, when 
the tumor have already been installed but have not yet been completely malignant, 
senescence can be induced. This phenomenon makes oncogene-induced 
senescence markers available to detect tumorigenesis at early stages (Collado M 
and Serrano M, 2006).  
 
1.2.1.3  DNA damage-induced  senescence: 
 
DNA damage-induced senescent cells follow the same pathways of  
replicative senescence (Shay JW and Roninson IB, 2004). They are continuously 
cell cycle arrested, secrete inflammatory cytokines and accommodate permanent 
nuclear foci including DNA damage response (DDR) related proteins (Rodier F, 
2011). Double strand breaks (DSB) on  DNA strands, ruin the integrity of the 
genome and should be immediately fixed by means of the interacting pathways 
generally called DDR (Mah L et al., 2010). DDR signaling is vital to provoke 
senescence (Roider F et al., 2011). Therefore, the inactivation of the cell cycle 
checkpoint kinases (e.g. ATM, Chek2), blocks the  p53-dependent senescence; 
moreover, impedes p53-independent secretion of inflammatory cytokines which 
compose the SASP (Rodier F et al., 2009; Rodier F et al., 2011). 
 
1.2.1.4  ROS-induced cellular senescence: 
 
Oxygen concentration, which is directly related to the formation of reactive 
oxygen species (ROS), limits cellular lifespan (Lu T and Finkel T, 2008). The 
large fraction of ROS production (90%) takes place at mitochondria (Irmak MB et 
al., 2003). Mitochondrial ROS generation initiates with an oxygen molecule (O2) 
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which can be turned into singlet oxygen (
1
O2) or by a single electron (e
-
) reduction 
to superoxide anion (
–
O2
•
). Either superoxide dismutase (SOD) provides another 
single e
-
 or spontaneously, superoxide anion (
–
O2
•
). can be further reduced and 
form hydrogen peroxide (H2O2), a more stable molecule which can pass through 
the lipid membranes of cells. H2O2 can oxidize ferrous iron to ferric iron in a 
Fenton reaction and consequently get reduced to hyroxyl radical (OH
•
). ROS can 
be neutralized and form water, oxygen and hypochlorous acid. Mitochondria, 
intends to increase the energy output to its maximum level while trying to 
minimize the excess ROS in a mediating redox state (Figure 1.7) (Aon MA et al., 
2010; Chen L et al., 2012).  
 
Figure 1.7 ROS (reactive oxygen species) generation  
 
The hindered senescence process in the presence of antioxidants and the 
early initiation of senescence upon inhibiting the cellular oxidant scavengers, 
clearly demonstrates the contribution of ROS to induce senescence (Chen Q et al., 
1995; Yuan H et al., 1995). Recently, it was shown that, induction of senescence 
requires a dynamic feedback loop, between p21 and  ROS, triggered by a DDR 
(Passos JF et al., 2010). Significantly, ROS have been detected as a key 
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intermediary between replicative and oncogene-induced senescence. High O2 
concentrations lead cells to replicative senescence; whereas under low O2 
conditions their lifespan expands (Ozturk M et al., 2008).  
 
 
Figure 1.8 Mitochondrial ROS levels and the cell’s fate (modified from 
Hamanaka RB and Chandel NS, 2010)  
 
ROS, as a key player of signaling pathways, influence the  cell’s fate 
according to its cellular levels. While low levels of ROS involve in proliferation  
and differentiation, increasing ROS production first upregulates antioxidant genes, 
then induce senescence and finally cause cell death. With extreme ROS levels, 
cellular contents experience permanent damage beyond the signaling interactions 
(Figure 1.8) (Hamanaka RB and Chandel NS, 2010). 
 
1.2.1.5  PTEN loss-induced cellular senescence: 
 
In premalignancies, loss of a tumor suppressor gene leads to senescence. In 
this telomere-independent form of senescence, in addition to the absence of 
hyperreplication, as seen in OIS,  DNA damage response is also missing  
(Nardella C et al., 2011). Due to its distinctive features, this form of senescence 
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was named as PTEN loss-induced cellular senescence (PICS); since, it was first 
observed  rapidly after   PTEN  inactivation (Alimonti A et al., 2010). PI3K/Akt 
pathway, known to be one of the major survival pathways cancer cells exploit, 
becomes constitutively active in the absence of  PTEN (Song MS et al., 2012).  In 
addition to PTEN, loss of other tumor suppressor genes, such as NF1, VHL and 
Rb, also induce senescence (Acosta JC and Gil J, 2012). Resembling OIS, PICS is 
associated with amplified p53 translation (Alimonti A et al., 2010). Nevertheless, 
in PICS mTOR  mediates the p53 upregulation; whereas, p53 activation is 
promoted by the phosphorylation of DDR and ARF in OIS (Nardella C et al., 
2011; Acosta JC and Gil J, 2012). 
 
1.2.1.6  Drug-induced cellular senescence: 
 
Senescence is a potent barrier to tumor development which recently started 
to be considered as a promising approach for cancer therapy (Ewald JA et al., 
2010).  Recent findings reveal that cancer cells can also undergo senescence. 
Thus, inducing senescence in tumors; namely, pro-senescence therapy, is a new 
strategy in the fight against cancer.   Senescence can prevent immortalization; thus 
senescence-inducing drugs emerge rapidly (Cairney CJ et al., 2012). Small-
molecule inhibitors dominate the market of pro-senescence drugs and can be 
categorized according to their therapeutic approaches. p53-enhancing approaches 
include both inhibiting the MDM2-p53 interaction and restoring the mutant p53. 
Therapeutic modulation of cell cycle machinery approach can be achieved by 
inhibiting either the S phase kinase associated protein-2 (SKP2) or cyclin 
dependent kinase 2 (CDK2). Oncogene addiction approach exploits  the inhibition 
of the oncogene, known that the tumor is addicted to, which induces senescence. 
The approach for the compounds enhancing PICS is to inhibit PTEN and  activate 
p53 indirectly. Utilizing telomerase inhibitors, in order to let the telomeres of 
cancer cells get shorter, is also another approach guiding to senescence (Nardella 
C et al., 2011) 
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1.2.1.7  Senescence pathways : 
 
Replicative senescence and telomere-independent forms of senescence use  
one of the two major tumor suppressor pathways, p53 and p16. Activation of p53,  
including not only its induction but also the post-translational modifications p53  
encounter, is essential in senescence (Caino MC et al., 2009). Despite the 
unchanged p53 mRNA and protein levels, during senescence p53 gets 
phosphorylated and activated (Zhang  H, 2007). Throughout the pathway initiated 
with p53, one of the downstream activated proteins is p21, a member of the 
Cip/Kip family of CDK inhibitors (Sherr CJ and Roberts JM, 1999). It is 
demonstrated that, independent from p53 activation, p21 can induce senescence;  
moreover, p21 deletion delays senescence (Larsson O, 2005).  
 
In senescence pathways, p53 cooperates with Rb, which represses E2F-DP 
transcription factors; therefore, keeps cells away from entering S phase of cell 
cycle. To inactivate Rb; in other words, to phosphorylate Rb, CDK activity is 
required. In senescent cells p16, a member of the INK4 family of CDK inhibitors, 
is mainly responsible for the hypophosphorylated status of Rb (Wei W et al., 
2003). Other than p16, p21 upregulation can directly prevent Rb phosphorylation 
and this finding supports the idea of a linear p53-Rb pathway (Figure 1.9) (Ben-
Porath I and Weinberg RA, 2005). 
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Figure 1.9 Senescence pathways  
(modified Ben-Porath I and Weinberg RA, 2005) 
 
 
1.2.1.8  The cell cycle and its regulation: 
 
Healthy cells traverse the cell cycle in strictly-regulated phases of two main 
stages: mitosis (M) and interphase, the interval between two consecutive M 
phases (Vermeulen K et al., 2003). Mitosis is composed of  karyokinesis, the 
process in which the nucleus divides into two, and cytokinesis, the further division 
of the cytoplasm . Karyokinesis also has ensuing stages: prophase, prometaphase, 
metaphase, anaphase and telophase. As soon as M-phase has been accomplished, 
G1 (Gap1) phase initiates the interphase. Cellular contents other than 
chromosomes are duplicated during G1, where the cells commit to enter another 
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cell cycle (Ma HT and Poon RYC, 2011). DNA replication occurs in the S 
(synthesis) phase preceding G2 (Gap2) phase (Vermeulen K et al., 2003).  
     The quality control mechanisms of  the cell cycle are located all through the 
process. DNA damage checkpoints take place before entering the S phase (G1-S 
checkpoint), after the duplication of DNA (G2-M checkpoint) and also during S 
and M phases (Dipaola RS, 2002; Vermeulen K et al., 2003). M phase 
checkpoints detect malformed spindle assemblies and incorrect spindle alignments 
(Okada H and Mak TW, 2004). For the induction of S phase arrest, ataxia-
telangiecstasia-mutated (ATM)-mediated phosphorylation of Nijmegen breakage 
syndrome 1 (NBS1) is required (Lim DS et al., 2000). If the genes involved in the 
induction of mitotic catastrophe are faulty, tumor formation can be accelerated. 
These genes encode the protein kinases regulating the cell cycle (Okada H and 
Mak TW, 2004). In response to DNA damage, ATM and ATM-and Rad3-related 
(ATR) get activated in order to initiate a kinase cascade. Finally, CDK1, the chief 
conductor of M phase, become inactivated leading to G2/M arrest (Dipaola RS, 
2002). 
 
Another important regulator of the cell cycle is the retinoblastoma gene 
product (Rb). In its active form, Rb, the tumor suppressor gene, is 
hypophosphorylated and forms an inhibitory complex with transcription factor, 
E2F-DP (E2F-1, E2F-2, and E2F-3). Hyperphosphorylation of Rb by CDK2, 
CDK4 and CDK6 inactivates Rb and releases E2F-DP. Initiation of the 
transcription of various S phase proteins facilitates the G1-S transition (Schwartz 
GK and Shah MA, 2005). 
 
1.2.1.9 Cyclin-dependent kinases (CDKs): 
 
Cyclin-dependent kinases (CDKs) are fundamental regulators of cell cycle. 
They belong to the Ser/Thr kinase family and are active during the  cell cycle if 
associated with cyclins. Although CDK levels remain constant, their activating 
proteins, cyclins, fluctuate as the cell cycle proceeds (Vermeulen K et al., 2003). 
Cell cycle phase-specific assembly of CDK-cyclin complex depends on the 
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accurate completion of the preceding step; namely, cell cycle checkpoints 
(Knockaert M et al., 2002). 
 
1.2.1.10 Cyclin-dependent kinase inhibitors (CKIs):  
 
In addition to cyclins, two distinct families of CKIs also regulate the activity 
of CDKs. The INK4 family members p15 (INK4b), p16 (INK4a), p18 (INK4c) 
and p19 (INK4d) negatively regulates the G1-specific CDKs, CDK4 and CDK6. 
The Cip/Kip family includes p21 (Waf1, Cip1), p27 (Cip2) and p57 (Kip2), 
general inhibitors of CDK-cyclin complex (Denicourt C and Dowdy SF, 2004; 
Cánepa ET et al.,2007).  
 
1.3 Hepatocellular carcinoma (HCC): 
 
Liver is the second largest organ after skin and that makes it the largest 
internal organ in human. It has a distinguishing blood supply coming directly not 
only from the heart but also from the digestive tract. Corresponding to its superior 
physical features, liver is a vital organ responsible  homeostasis of human body.  
The majority of the cells in liver are hepatocytes, macrophages (Kupffer cells) and 
stellate cells (fat-storing cells). In a healthy liver stellate cells store vitamin A, 
preserve the liver membrane; most importantly stay inactive. In case of liver 
injury, they become activated; thus, use their vitamin A stocks to produce fibrous 
scar tissue. The accumulation of the scar tissue, leads to liver diseases depending 
on its severity (Kolios G et al., 2006). Although it was a controversial issue 
formerly, now it is accepted that liver contains progenitor stem cells. In cases of 
chronic and severe liver injuries, a subgroup of liver cells (oval cells) is induced 
not only to proliferate but also to differentiate according to conditions (Qin AL et 
al., 2004). 
 
Benign growths in liver, which do not transform into cancer, are a common 
issue. They can be treated with or without surgery successfully; whereas, liver 
cancer treatment options are limited and mostly palliative (Lau WY and Lai EC, 
2008). The major type of primary liver cancer, Hepatocellular carcinoma (HCC), 
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is the sixth most common and the third lethal cancer (Forner A et al., 2012). 
HCCs are characterized as heterogeneous tumors both phenotypically and 
genetically (Blum HE and Spangenberg HC, 2007). Generally, HCC is a though 
cancer type with poor prognosis and low overall survival rate. 
 
1.3.1 Hepatocarcinogenesis: 
 
Hepatocarcinogenesis is a slow, multi-step process which involves various 
genetic and epigenetic alterations, chromosomal abnormalities, pathway 
dysregulations and  mutations (Alves RC et al., 2011). The major etiologies of 
HCC include chronic hepatitis B (HBV), C (HCV)and D (HDV), alcohol abuse, 
aflatoxin-B1-intoxication, hereditary metabolic liver diseases and obesity (Farazi 
PA and DePinho RA, 2006; Blum HE and Spangenberg HC, 2007).  
 
Following the hepatic injury initiated by any one of these etiologies, a 
closed- loop system composed of hepatocyte-necrosis and -proliferation takes 
place. This continuous destructive-regenerative cycles, prepare the liver for 
cirrhosis, which is characterized by structurally abnormal nodules surrounded by 
scarring tissue. As a further step in hepatocarcinogenesis, hyperplastic nodules are 
observed which transform into dysplastic nodules with moderate genomic 
instability. Loss of p53 and increase in the level of genomic instability leads to 
HCC (Bressac B et al., 1990; Farazi PA and DePinho RA, 2006). While telomere 
shortening has been considered as a marker of hyperproliferative liver disease, the 
reactivation of telomerase has been associated with hepatocarcinogenesis (Ozturk 
M et al., 2008).        
 
1.3.2 Cell signaling pathways involved in HCC: 
 
The principal signaling pathways implicated in the pathogenesis of HCC 
can be classified according to the biological process they have been involved in 
(Figure 1.10). The molecular abnormalities responsible from the dysregulation of 
signaling pathways (i.e. protein kinases) accommodate the key targets for HCC 
therapy (Llovet JM and Bruix J, 2008). 
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Figure 1.10 Dysregulated signaling pathways in HCC (Zender L et al., 2010) 
 
 
1.3.2.1  EGF/EGFR pathway: 
 
Epidermal growth factor receptor (EGFR; Her1/ErbB1) belongs to a family 
of four (Her2/Neu, ErbB2, ErbB4) receptor tyrosine kinases (RTKs). All have an 
extracellular  ligand-binding domain, single-pass transmembrane domain and an 
intracellular domain with a TK activity (Cervello M et al., 2012). EGFR is highly 
expressed in HCC with two major ligands, TGF- (transforming growth factor-
alpha) and EGF, stimulating its activation (Harada K et al., 1999). Ligand binding 
stimulates the homo- or  hetero- dimerization of EGFR, which results in auto-
phosphorylation of specific tyrosine residues in the C-terminal (Tao RH and 
Maruyama IN, 2008). These phospho-tyrosines serve as docking sites for 
intracellular mediators which eventually activate several signaling pathways such 
as, Ras/MAPK, PI3K/Akt, PKC and STATs pathways  (Brand TM et al., 2011).  
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1.3.2.2 Ras/Raf/MEK/ERK pathway: 
 
Mitogen-activated protein kinases (MAPKs) have at least five distinct 
subgroups: ERK1/2 (extracellular signal-regulated kinase), ERK5 (also known as 
the big MAPK-1 or BMK-1), SAPK1/JNK1/2/3 (stress-activated protein kinase/c-
Jun N-terminal kinase), and SAPK2 homologs: ,β,δ (p38/β/δ) and ERK6 
(p38) (Pimienta G and Pascual J, 2007).  
 
ERK1 and ERK2 are homologous Ser/Thr kinases with 88% similarity in 
protein sequence (Min L et al., 2011). ERK1/2 can be activated by RTKs (e.g. 
EGFR). The ligand stimulated RTK undergoes dimerization and by auto-
phosphorylation generates binding sites for adaptor proteins and activates Ras. 
Activated Ras, Ras:GTP, recruits Raf to the membrane in order to activate for 
further and subsequent phosphorylations of MEK1/2 and ERK1/2 (Steelman LS et 
al., 2011). Activated ERK1 and ERK2 phosphorylate more than 160 substrates 
which are known to be related with cell proliferation. Moreover, ERK activity 
also suppresses apoptosis and supports survival (Min L et al., 2010). 
 
1.3.2.3 PI3K/PTEN/Akt/mTOR pathway: 
 
Phosphatidylinositol-3-kinase (PI3K) is a lipid kinase, consisting of an 85 
kDa regulatory subunit and a 110 kDa catalytic subunit, is recruited to the 
membrane after growth factor stimulation. The activated catalytic subunit of 
PI3K, phosphorylates membrane phospholipids, phosphotidylinositol-4-phosphate 
(PtdIns(4)P) and phosphotidylinositol-4,5-biphosphate (PtdIns(4,5)P2);  generates 
phosphotidylinositol-3,4-biphosphate (PIP2) and phosphotidylinositol-3,4,5-
triphosphate (PIP3). PIP2 and PIP3 serve as second messengers and activate 
phosphotidylinositol-dependent kinases (PDKs). PDKs are responsible from the 
activation of Akt, a Ser/Thr kinase, which is also known as protein kinase B, PKB 
(Franke TF, 2008; Liu P et al., 2009).  
 
Following its activation, Akt departs from the membrane and 
phosphorylates its intracellular substrates in order to promote cell survival. The 
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deficiency of PTEN, the negative regulator of Akt, supports its constitutive 
activation (Buontempo F et al., 2010). Moreover, activated Akt is a positive 
regulator of mTOR which phosphorylates p70S6 kinase (40S ribosomal protein 
kinase) and 4E-BP1 (the translation repressor eukaryotic initiation factor 4E-
binding protein-1) in order to promote the translation of significant  factors 
involved not only in cell proliferation but also in angiogenesis (Cervello M et al., 
2012).  
 
1.3.2.4 IGF/IGFR pathway: 
 
The insulin-like growth factor family consists of two circulating ligands, 
IGF-1 and IGF-2, both are vital regulators of cell growth, proliferation, 
differentiation, development and apoptosis (Pollak MN et al., 2004). While the 
insulin receptor have two isoforms (IRA, IRB), IGF-1R has only one and it is a 
heterotetramer with two ligand-binding extracellular domains and two TK 
intracellular domains. Half of each receptor dimerize with each other as they 
finally form six receptor species with altering ligand-binding affinities. Cancer 
cells and tissues which are neither insulin-target nor IGF1-R-responsive express 
all the six types of receptors (Pollak MN, 2012). After the stimulation of 
receptors, the recruitment of insulin-receptor substrates (IRS) precedes the 
activation of PI3K/Akt/mTOR and Ras/Raf/MEK/ERK pathways (Cervello M et 
al., 2012). 
 
1.3.2.5 TGF- β pathway: 
 
Transforming growth factor-beta (TGF-β) superfamily, consisting of 
structurally related dimeric proteins, involve in cell proliferation, differentiation, 
motility, adhesion, development and cell death (Massagué J, 1998). Seven of the 
twelve members of TGF-β receptors are type I (TβRI) and the rest is type II 
(TβRII) and all are Ser/Thr kinases. The signaling pathway is initiated with ligand 
binding to TβRII, on the cell membrane, which recruits TβRI and phosphorylates 
Ser/Thr residues in the TTSGSGSG motif of TβRI. Prior to this, an inhibitory 
protein associated with TβRI, keeps it inactive. Following its activation, TβRI, 
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recruits Smad2/3 in the presence of an anchoring protein, SARA (Smad anchor for 
receptor activation). Activated (i.e. phosphorylated) Smad2/3 associates with 
Smad4 to form a heterocomplex, which translocates into the nucleus to promote 
the transcription of target genes (Huang F and Chen YG, 2012). It is known that, 
TGF-β signaling pathway suppresses hepatocarcinogenesis (Gupta GP and 
Massagué J, 2006; Baek HJ et al., 2008). Paradoxically, a recent study reveals that  
TGF-β signaling promotes liver tumor formation in the lack of p53 (Morris SH et 
al., 2012). 
 
1.3.2.6 Wnt/β-catenin pathway: 
 
Wnt/β-catenin signaling pathway is crucial not only in hepatocarcinogenesis 
but also in normal liver tissue development and maintenance, during  
embryogenesis and adulthood (Dahmani R et al., 2011). The receptors for the 
Wnts, which are lipid-modified morphogens, are seven-pass transmembrane 
proteins (Janda CY et al., 2012). In the absence Wnt signaling, a degradation 
complex including APC (adenomatous polyposis coli), GSK-3β (glycogen 
synthase kinase-3β) and axin, maintains β-catenin inactive (i.e. phosphorylated). 
β-catenin  is the key player of the pathway and its phosphorylation causes its 
degradation through ubiquitylation (Giles RH et al., 2003). When the Wnt ligands 
bind to their receptor, Frizzled (FZD7), a series of events initiate to inactivate the 
degradation complex (APC-GSK-3β-axin) and keep β-catenin away from 
degradation. Translocation of β-catenin to the nucleus follows its accumulation in 
the cytoplasm. Eventually, β-catenin stimulates the transcription of Wnt-target 
genes (Dahmani R et al., 2011). Upregulated FZD7 gene expression is the most 
common abnormality of Wnt pathway associated with hepatocarcinogenesis. 
Besides, β-catenin gene mutations, which keep it constitutively active, were 
demonstrated in 20% - 40% of the HCC patients (Cervello M et al., 2012). 
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1.4 c-Jun-N-terminal kinases and  liver: 
 
c-Jun-N-terminal kinases (JNKs) constitute one of the sub-groups of MAPK 
family (Weston CR and Davis RJ, 2007). They are Ser/Thr kinases with a dual 
phosphorylation Thr-Pro-Tyr motif conserved between the domains seven and 
eight (out of 11 PK subdomains) for full kinase activation. JNKs have a common 
docking domain for their substrates in the C-terminal and a glutamate/aspartate 
domain in the N-terminal, in order to mediate their interactions with other players. 
There are three JNK isoforms, JNK1, JNK2 and JNK3 (encoded by MAPK8, 
MAPK9 and MAPK10 respectively) corresponding to ten alternative splicing 
variants (Figure 1.11) (Manning AM and Davis RJ, 2003; Seki E et al., 2012).    
 
 
 
 
Figure 1.11 c-Jun-N-terminal kinases (JNKs) (Seki E et al., 2012) 
 
 
1.4.1 JNK pathway : 
 
The long list of diverse stimuli, consisting of growth factors (e.g. TGFβ, 
PDGF, EGF), cytokines (e.g. TNF-, IL-1), ROS, pathogens, toxins, ER-stress, 
drugs and metabolic changes), initiates the JNK signaling pathway (Figure 1.12). 
JNKs locate on the lowest level of a three levels signaling cascade. There are at 
least fourteen MAP3Ks (including ASK1, DLK, LZK, MEKK1, MEKK2, 
MEKK4, MLK1, MLK2, MLK3, MLK4, TAK1, TAO1, TAO2, ZAK) 
confronting the stimuli first, and activate MAP2Ks next. MAP2Ks, MKK4 and 
MKK7, are dual-specificity PKs (Seki E et al., 2012). The initiative stimulus 
determines which MAP2K activate JNKs; in other words, MKK4 generally 
29 
 
responds to environmental stress and MKK7 feedback to cytokines (Min L et al., 
2010). Moreover, MKK4 phosphorylates both JNKs and p38 homologs but 
MKK7 phosphorylates only JNKs (Haeusgen W et al., 2011). Among the 
approximately 50 substrates of JNKs, c-Jun is the representative target which 
forms the activating protein (AP-1), a dimeric transcription factor, with JunB, 
JunD or Fos (Shaulian E, 2010).  
 
 
 
 
Figure 1.12 JNK signaling pathway (Seki E et al., 2012 ) 
 
NF-κB is a transcription factor in a dimeric structure, associated with its 
inhibitor protein, IκB. After the phosphorylation of IκB by activated IKK (IκB 
kinase) complex, first IκB degrades  and second NF-κB gets activated. (Hayden 
MS and Ghosh S, 2008). TNF- (tumor necrosis factor-alpha), is the common 
denominator of the two intricately interacting pathways: JNK and NF-B. 
Furthermore, TNF- is a double-crosser which can be either survival or apoptotic 
depending on the context (Wang X and Lin Y, 2008). In addition to all, TNF- 
can activate caspase 8, NF-B and JNK, simultaneously (Deng Y et al., 2003). 
Inhibited NF-B, allows TNF- to activate JNK permanently and this prolonged 
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JNK activation leads the cell to apoptosis (Tang G et al., 2001 ; De Smaele E et 
al., 2001). TNF- initiates the transient JNK activation; but, blocking NF-B is 
required to upgrade JNK activation (Bubici C et al., 2004). Whether JNK acts pro-
survival or pro-apoptotic depends on cell type, stimulus and mostly the duration 
time of its activation (Liu J and Lin A, 2005).  
 
1.4.2 ROS mediates crosstalk between JNK and NF-κB: 
 
Prolonged JNK activation  is TRAF-independent  but depends on the ROS 
generation. ROS induces JNK activation and JNK induces ROS accumulation 
(Nakano H, 2004). A mutual antagonism was previously shown between NF- κB 
signaling pathway and the aryl hydrocarbon receptor (AhR) (Tian Y et al., 1999; 
Ke S et al., 2001). Inhibition of NF- κB, blocks this antagonism and consequently 
upregulates the p450 family members, which promote the ROS generation. The 
accumulated ROS prolongs the JNK activation which leads cell to apoptosis 
(Zhang Y and Chen F, 2004). ROS also inhibits MAPK phosphatases in order to 
promote TNF- induced apoptosis associated with prolonged activation of JNK 
(Kamata H et al., 2005). 
 
1.5 Targeted therapy of hepatocellular carcinoma:  
 
Hepatocellular carcinoma (HCC), the fifth most common cancer worldwide, 
has one and only FDA approved drug, sorafenib. Less than 30-40% of the HCC 
patients are suitable for curative therapies while the rest receive only palliative 
ones. Systemic chemotherapies become the best option despite the  high 
probability of collateral damage they may cause (Cao H et al., 2012). Sorafenib, 
the first small molecule multikinase inhibitor approved by the FDA, prolongs 
median survival and the time to progression by nearly 3 months in patients with 
advanced HCC (Galle PR, 2008). Consequently, it is essential to discover drug 
candidates for HCC. In the last years, sorafenib was also combined with agents, 
previously used for advanced  HCC, such as PR-104, a pre-prodrug of the 
bioreductive prodrug PR-104A, (Abou-Alfa GK et al., 2011), interferon-alpha 
(IFN-), (Wang L et al., 2012), panobiostat, pan-HDAC inhibitor, (Lachenmayer 
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A et al., 2012), transarterial chemoembolization (TACE) with doxorubicin-eluting 
beads (DEB), (Pawlik TM et al., 2011), cisplatin/doxorubicin (PLADO) (Schmid I 
et al., 2012).  
 
Since the 1950s, conventional chemotherapy has been considered 
controversial due to the harm they cause in order to heal. Cytotoxic chemotherapy 
drugs are deadly not only for cancer cells but also for normal, healthy cells 
surrounding the tumor. Therefore, severe side effects accompany the benefits of 
standard chemotherapy drugs. Among the known cancer types, hepatocellular 
carcinoma is the third most common cause of cancer death due to its late 
diagnosis (Tanaka S and Arii S, 2010). Moreover, the tolerability of  HCC 
patients to chemotherapy is significantly low because of their chronic liver 
diseases (Chan SL and Yeo W, 2012). Chemotherapy drugs can be classified as :  
 
Antimetabolites : Drugs interfering with the usual metabolic processes of a 
cell. This group of drugs eventually interrupts DNA replication (Kaye SB, 1998). 
Nucleoside analogs, which are effective for the treatment of solid tumors and 
hematological malignancies, comprise the major sub-group of the antimetabolites 
(Karran P, 2006). 
 
Alkylating drugs : Drugs adding an alkyl group to some or all of the 
proteins which bond together to form the double helix structure of a DNA 
molecule. This leads to breakage of the DNA strands which precedes the cancer 
cell death (Ben-Efraim S, 2001) . 
 
Antitumor antibiotics : Drugs which bind and uncoil DNA in order to stop 
RNA synthesis; thus prevent the synthesis of essential proteins for survival (De 
Beer EL, 2001).  
 
Plant alkaloids : These plant-derived drugs act either throughout the cell 
cycle or are effective during the S and M phases of cell cycle, in order to prevent 
cell division (Kim J and Park EJ, 2002). 
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Steroid hormones : Drugs which change the three-dimensional shape of a 
cell receptor and consequently prevent the ligand-binding to that receptor 
eventually inactivates the receptor (Howell Sj et al., 2004). 
 
On the contrary, targeted cancer therapies include drugs which interfere 
with the key members of aberrant molecular pathways involved in tumorigenesis. 
The distinctive features of healthy and cancer cells allow for the development of 
targeted therapies. The hallmarks of cancer, suggested as six acquired capabilities 
of cancer cells, are self-sufficiency in growth signaling, insensitivity to anti-
growth signaling, evading apoptosis, activating tissue invasion and metastasis, 
gaining replicative immortality and sustaining angiogenesis (Hanahan D and 
Weinberg RA, 2000). The rapidly increasing data creates new hallmarks which 
drug discovery can exploit (Figure 1.13). 
 
 
Figure 1.13 Therapeutic targets for drug candidates 
(Hanahan D and Weinberg RA, 2011) 
 
Identifying the target is the first step of developing innovative cancer 
therapies. Next step is discovering agents that can exploit these targets.  
Monoclonal antibodies and small molecule kinase inhibitors constitute the 
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majority of drug candidates currently in preclinical and clinical trials (Ma WW 
and Adjei AA, 2009; Huynh H, 2010 ). Sorafenib is the one and the only drug 
with an FDA approval for the treatment of advanced HCC. Sorafenib is a tyrosine 
kinase inhibitor which involves not only Raf/MEK/ERK pathway but also 
VEGF/VEGFR (vascular endothelial growth factor receptor) pathway (Cao H et 
al., 2012). Monotherapy of Sorafenib prolongs median survival almost three 
months in advanced HCC patients(Llovet JM et al., 2008). Therefore, combined 
therapies of Sorafenib with various conventional chemotherapy drugs and novel 
targeted agents have been initiated to enhance its therapeutic effect (Cao H et al., 
2012). As a result, identification of putative kinase inhibitors acting on liver 
cancer cells is a promising research field needs to be explored (Figure 1.14 and 
Figure 1.15). 
 
 
Figure 1.14 The molecular targeted agents currently tested in preclinical and 
clinical HCC trials (Cervello Met al., 2012)  
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Figure 1.15 PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK signaling 
pathways and the molecular targeted agents involved (Cervello M et al., 2012) 
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CHAPTER 2. MATERIALS AND METHODS 
2.1 REAGENTS 
2.1.1 Cell lines: 
Liver cancer cell lines Colon cancer cell lines Breast cancer cell lines 
Huh7 HCT116 T47D 
HepG2  MCF7 
Hep3B   
PLC   
SK-Hep1   
Mahlavu   
FOCUS   
Snu182   
Snu387   
Snu475   
 
2.1.2 Cell culture reagents:  
Dulbecco's Modified Eagle Medium (DMEM) 31885 GIBCO 
RPMI 1640 31870 GIBCO 
fetal bovine serum (FBS) 102700 GIBCO 
non-essential amino acid (NEAA) BE13-114E Lonza 
penicillin/streptomycin solution (P/S) 15140 GIBCO 
0.25% Trypsin-EDTA 1x 25200 GIBCO 
L-Glutamine 200mM 100x 25030 GIBCO 
1xPhosphate Buffer Saline (1xPBS)               
(CaCl2 , MgCl2 free)  
14190 GIBCO 
Dimethyl sulfoxide (DMSO) A3672 
AppliChem  
Biochemica 
 
2.1.3 Drug screening reagents: 
Dimethyl sulfoxide (DMSO) A3672 
AppliChem 
Biochemica 
(S)-(+)-Camptothecin C9911 Sigma 
5-Fluorouracil 8699828770237 Kocak Farma 
1xPBS  
    NaCl 
    KCl 
    Na2HPO4.2H2O 
    KH2PO4 
 
1.06404.1000 
471177 
480227 
1.04873 
 
MERCK 
Carlo Erba 
Carlo Erba 
MERCK 
Trichloroacetic acid (TCA) 1.00810.1000 MERCK 
Sulforhodamine B (SRB)  sodium salt S1402 Sigma 
Acetic Acid 27225 Riedel-de Haen 
Tris 0826 Amresco 
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2.1.4 Nuclear staining reagents: 
Hoechst 33258, pentahydrate 
(bis-benzimide) 
861405 Sigma 
1xPBS  
    NaCl 
    KCl 
    Na2HPO4.2H2O 
    KH2PO4 
 
1.06404.1000 
471177 
480227 
1.04873 
 
MERCK 
Carlo Erba 
Carlo Erba 
MERCK 
Formaldehyde 310356 Carlo Erba 
Glycerol 346165 Carlo Erba 
 
2.1.5 Cell lysis reagents: 
1xPBS  
    NaCl 
    KCl 
    Na2HPO4.2H2O 
    KH2PO4 
 
1.06404.1000 
471177 
480227 
1.04873 
 
MERCK 
Carlo Erba 
Carlo Erba 
MERCK 
NP-40 lysis buffer 
   NaCl 
   Tris 
   NonidetP-40 
   SDS 
   Protease Inhibitor Cocktail 
   PhosSTOP 
 
1.06404.1000 
0826 
 
L5750 
11 873 580 001 
04 906 837 001 
 
MERCK 
Amresco 
Applichem 
Sigma 
Roche 
Roche 
Phospho lysis buffer 
   HEPES 
   Tetrasodium pyrophosphate 
   EDTA 
   NaF 
   Triton X-100 
   Na3VO4 
   PMSF   
   Protease Inhibitor Cocktail 
   PhosSTOP 
 
H1016 
P8010 
1.08421 
S7920 
T8787 
S6808 
0754 
11 873 580 001 
04 906 837 001 
 
Sigma 
Sigma 
Merck 
Sigma 
Sigma 
Sigma 
Amresco 
Roche 
Roche 
Albumin, from bovine serum (BSA) A7906 Sigma-Aldrich 
Bradford Reagent B6916 Sigma 
 
2.1.6 Kinase assay reagents: 
Kinase reaction buffer 
Tris 
MgCl2.6H2O 
Albumin, from bovine serum (BSA)  
 
0826 
A406233 
A7906 
 
Amresco 
MERCK 
Sigma-Aldrich 
PKLight

 Assay Kit LT07-500 Lonza 
Kinase-Glo Luminescent Kinase Assay V6712 Promega 
MeSAdo 260585 Calbiochem 
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Staurosporine 569397 Calbiochem 
Aminopurvalanol-A 164640 Calbiochem 
 
2.1.7 Western-blot reagents: 
DTT D9779 Sigma 
Nu-PAGE LDS Sample Buffer 4x NP0007 Invitrogen 
Nu-PAGE Bis-Tris 4-12% gels NP0335 Invitrogen 
Nu-PAGE Bis-Tris 10% gels NP0303 Invitrogen 
Nu-PAGE Bis-Tris 12% gels NP0343 Invitrogen 
Nu-PAGE MOPS SDS running buffer 
20x 
NP00001 Invitrogen 
Nu-PAGE MES SDS running buffer 20x NP00002 Invitrogen 
Nu-PAGE Transfer buffer 20x NP0006-1 Invitrogen 
PageRuler
TM
 Prestained Protein Ladder SM0671 Fermentas 
PageRuler
TM
 Prestained Protein Ladder 26616 
Thermo 
Scientific 
PageRuler
TM
 Plus Prestained Protein 
Ladder 
SM1811 Fermentas 
Nu-PAGE Antioxidant NP0005 Invitrogen 
Methanol 24229 Sigma-Aldrich 
Hybond ECL Nitrocellulose Membrane 
(0.2mm pore size) 
RPN3032D 
Amersham, GE 
Healthcare 
Whatman Paper 3030917 GE Healthcare 
Non-fat dry milk  SUTAS 
Albumin, from bovine serum A7906 Sigma-Aldrich 
Ponceau-S P-3504 Sigma 
Acetic acid 27225 Riedel-de Haen 
1xTBS-T (0.1%) 
   NaCl 
   Tris 
   Tween 20 
 
1.06404.1000 
0826 
822184 
 
MERCK 
Amresco 
MERCK 
ECL+ RPN2132 
Amersham, GE 
Healthcare 
 
2.1.8 Antibodies:  
Antibody 
Company & Catalog 
Number 
Western Blot       
(immunoblotting 
details) 
Bcl-2 Santa Cruz sc-7382 1:200 (2 hours; RT) 
-Cytochrome-c Santa Cruz sc-7159 1:200 (2 hours; RT) 
p15 (C-20) Santa Cruz sc-612 1:200 (overnight; +4
o
C) 
Purified mouse Anti-
Human Retinoblastoma 
Protein 
BD Pharmingen 554136 1:300 (2 hours; RT) 
Phospho-Rb (Ser807/811) Cell Signaling #9308 1:200 ((2 hours; RT) 
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-p21 BD-556430 1:200 ((2 hours; RT) 
-phospho H2AX Millipore 05-636 1:200 ((2 hours; RT) 
PARP-1 (F-2) Santa Cruz sc8007 1:200 (2 hours; RT) 
JNK Cell Signaling #9252 1:300 (2 hours; RT) 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
Cell Signaling #9251 1:100 (2 hours; RT) 
-c-Jun (N) Santa Cruz sc-45 1:300 (2 hours; RT) 
p-c-Jun (KM-1) Santa Cruz sc-822 1:100 (2 hours; RT) 
MEK4 antibody [8A8] Abcam ab90092 1:300 (2 hours; RT) 
MEK4  
(Phospho S257+T261) 
Abcam ab4760 1:100 (overnight; +4
o
C) 
MEK7 antibody [EP1455Y] Abcam ab52618 1:300 (2 hours; RT) 
Phospho-MKK7 
(Ser271/Thr275) 
Cell Signaling #4171 1:100 (overnight; +4
o
C) 
ASK1 (Phospho S83) Abcam ab47304 1:100 (overnight; +4
o
C) 
Akt Cell Signaling #9272 1:300 (2 hours; RT) 
Phospho-Akt (Ser475) Cell Signaling #9271 1:100 (2 hours; RT) 
JIK (H-60) Santa Cruz sc-134588 1:100 (overnignt; +4
o
C) 
Calnexin Sigma C4731 1:5000 (2 hours; RT) 
Actin I-19 Santa Cruz sc1616 1:5000 (2 hours; RT) 
anti-goat HRP Sigma A8919 1:5000 (2 hours; RT) 
anti-mouse HRP Sigma A0168 1:5000 (2 hours; RT) 
anti-rabbit HRP Sigma A6154 1:5000 (2 hours; RT) 
 
2.1.9 Senescence Associated-β-gal (SA-β-gal) assay and BrdU proliferation 
co-staining reagents: 
BrdU (5-bromo-2-deoxyuridine) M0744 DAKO 
Formaldehyde 310356 Sigma 
SA-β-gal assay buffer 
   Citric acid (anhydrous) 
   Na2HPO4.2H2O 
   NaH2PO4 
   MgCl2.6H2O 
   NaCl 
   K4Fe(CN)6.3H2O 
   K3Fe(CN)6 
   X-gal 
 
C0759 
480227 
S-0751 
A406233 
K36100804 
P-9387 
P-8131 
X-gal 
 
Sigma 
Carlo Erba 
Sigma 
MERCK 
MERCK 
Sigma 
Sigma 
X-gal 
Ethanol 32221 Sigma 
1xPBS  
    NaCl 
    KCl 
    Na2HPO4.2H2O 
    KH2PO4 
 
1.06404.1000 
471177 
480227 
1.04873 
 
MERCK 
Carlo Erba 
Carlo Erba 
MERCK 
HCl 403872 Carlo Erba 
Albumin, from bovine serum (BSA)    A7906 Sigma-Aldrich 
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Tween 20 822184 MERCK 
Envision
TM 
+ Dual Link System-HRP  K4063 Dako 
Liquid DAB + Substrate Chromogen 
System 
K3468 Dako 
Glycerol 346165 Carlo Erba 
Doxorubicine 7AA015 DABUR 
 
2.1.10 Cell Cycle Analysis with Fluorescence-Activated Cell Sorting (FACS) – 
Propidium Iodide (PI) reagents: 
1xPhosphate Buffer Saline (1xPBS)  
(CaCl2 , MgCl2 free) 
14190 GIBCO 
Ethanol 32221 Sigma 
Propidium Iodide (PI) D4864 Sigma 
RNaseA EN0531 Fermentas 
Triton-X-100 T8787 Sigma 
 
2.1.11 ER (Endoplasmic Reticulum) stress detection assay reagents: 
(RNA extraction, cDNA synthesis, polymerase chain reaction (PCR) and 
agarose gel electrophoresis reagents) 
 
NucleoSpin RNA II Kit  740 955.50 
Macherey-
Nagel 
Fermentas RevertAid First Strand cDNA 
synthesis kit 
K1622 Fermentas 
ER stress detection assay  
Human XBP1 (X box-binding protein 1 )  
F:TTACGAGAGAAAACTCATGGCC  
R:GGGTCCAAGTTGTCCAGAATGC 
GAPDH 
F:GGCTGAGAACGGGAAGCTTGTCAT 
R:CAGCCTTCTCCATGGTGGTGAAGA 
PCR reagents 
 
 
 
 
 
 
 
EP0405 
 
Iontek 
 
 
Iontek 
 
 
Fermentas 
Agorose gel electrophoresis 
Agarose (BASICA LE) 
Tris  
Acetic acid 
EDTA 
Ethidium Bromide 
6x gel loading dye solution 
gene ruler (100bp DNA ladder) 
 
 
0826 
27225 
1.08421 
E7637 
R0611 
SM0241 
 
Prona 
Amresco 
.Riedel-de Haen 
Merck 
Sigma 
Fermentas 
Fermentas 
 
2.1.12 Reactive Oxygen Species (ROS) detection assay reagents: 
1xPhosphate Buffer Saline (1xPBS)   
(CaCl2 , MgCl2 free)  
14190 GIBCO 
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ROS-assay  
   HEPES 
   KOH 
   D-Glucose 
   2',7'-Dichlorofluoresceindiacetate  
(DCFH-DA) 
 
H-1016 
P1767 
0188 
D6883 
 
Sigma 
Sigma 
Amresco 
Sigma 
 
2.1.13 in vivo drug treatment assay reagents: 
Nude mice  Kobay AS 
Simple syrup  
    sugar 
    ddH2O 
 
 
 
 
 
 
2.2 MATERIALS 
Cell-culture plates (100mm) (150mm) 
(633171) 
(639160) 
Greiner 
6-well plates 657160 Greiner 
96-well plate 3599 Corning 
E-96 plate 05 232 368 001 Roche 
White 96-well polypropylene assay plate 07-200-761 Corning 
Serological pipettes (5mL; 10mL; 25mL) 
606180 
607180 
760180 
Greiner 
Pipetting aid  Gilson 
Pipettes  Gilson 
Filter Tips   
Falcon tubes (15mL); (50mL) 188271; 227261 Greiner 
Cryotubes 430289 Corning 
hemocytometer   
Microscope slides (76x26mm)  ISOLAB 
Coverslips (22x22mm)   
Cell lifter 3008 Corning 
Waterbath (thermostat)  yellowline basic 
Vacuum pump    
CO2 air-jacketed incubator  Nuaire 
Biological Safety Cabinet  Nuaire 
Centrifuge  
Hettich 
Universal 320 
xCELLigence  Roche 
Inverted phase microscope  
Olympus 
CKX41 
Fluorescence microscope  
Nikon ECLIPSE 
50i 
Precision balance  
Denver 
Instrument 
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Microplate reader  Biotek 
Multi-purpose rotator  
Bafristead / Lab-
Line 
Spectrophotometer  Biotek 
the Reporter Microplate Luminometer  Turner Designs 
Medical X-ray Film, 18x24 cm 8143059 Kodak 
XCell SureLock
TM 
Mini-Cell & XCell 
II
TM 
Blot Module  
EI0002 Invitrogen 
Sponge pads EI9052 Invitrogen 
Power supply  
Bio-Rad, Power 
pac200 
Hyperprocessor  
Amersham Life 
Science 
BD FACSCalibur   
Inverted phase microscope  
Olympus 
CKX41 
Class II Safety Cabinet  Metisafe 
HEPA-filter top covered cage   
Vernier caliper   
U-100 insulin syringe 1014 Ayset 
Venipuncture Set, 23G 4056353 Braun 
 
 
 
2.3 SOLUTIONS  
 
2.3.1 Cell culture solutions: 
DMEM growth medium 10% FBS, 1% P/S, 1% NEAA 
RPMI-1640 growth medium 10% FBS, 1% P/S, 1% NEAA, 1%L-glutamine 
Freezing medium 10% DMSO, 25% FBS in growth medium 
 
2.3.2 Drug screening solutions: 
10 x PBS 
1.5M NaCl, 30mM KCl, 80mM Na2HPO4, 20mM 
KH2PO4 (pH 7.4)  
10% TCA (v/v) 10% TCA in ddH2O 
SRB dye (w/v) 0.4 % SRB  in  1% acetic acid solution 
1% acetic acid (v/v) 1% acetic acid in ddH2O  
10mM TBS 10mM Tris in ddH2O 
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2.3.3 Nuclear staining solutions: 
Hoechst 33258    
stock solution 
300μg/ml Hoechst dissolved in ddH2O 
Hoechst 33258  
working solution 
1μg/ml Hoechst diluted from 300μg/ml stock    
in 1x PBS 
3% formaldehyde (v/v) 3% formaldehyde in ddH2O 
 
2.3.4 Cell lysis solutions: 
NP-40 lysis buffer 150mM NaCl, 50mM Tris-HCl (pH 7.6), 1% NP-
40, 0.1% SDS, 1xPI, 1xPhosSTOP in ddH2O. 
Phospho lysis buffer 
50mM HEPES, 100mM NaCl, 4mM NaPP, 
10mM EDTA, 10mM NaF, (v/v) 1% Triton-X, 
2mM Na3VO4, 1mM PMSF, 1xPI, 1xPhosSTOP 
in ddH2O.  
BSA (1mg/mL) 1mg BSA in 1mL ddH2O. 
   
2.3.5 Kinase assay solutions: 
Kinase reaction buffer 40mM Tris-HCl (pH 7.6), 20mM MgCl2, 
0.1mg/mL BSA in ddH2O 
 
2.3.6 Western blot solutions: 
DTT 0.5M DTT in ddH2O 
10 x TBS (pH 7.6) 0.1M Tris, 1,5M NaCl in ddH2O 
1 x TBS-T (0.1%) (v/v) 0.1% Tween-20 dissolved in 1x PBS 
Ponceau-S solution (w/v) 0.1% Ponceau-S, (v/v) 5% acetic acid in 
ddH2O 
Blocking Solution (w/v) 5% non-fat dry milk / BSA in 1 x TBS-T 
(0.1%) 
 
2.3.7 Senescence Associated-β-gal (SA-β-gal) assay and BrdU proliferation 
co-staining solutions: 
SA-β-gal assay buffer  
(pH 6.0) 
200mM citric acid, 1M Na-P buffer, 100mM K-
Ferro-CN, 100mM K-Ferri-CN, 2M NaCl, 
100mM MgCl2, 40mg/mL X-gal in ddH2O 
Na-P buffer  
(pH 6.0) 
(1M NaH2PO4 ) and (1M Na2HPO4 ) mixture in 
ddH2O  
HCl 2N HCl in ddH2O 
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2.3.8 ER (Endoplasmic Reticulum) stress detection assay solutions: 
(RNA extraction, cDNA synthesis, polymerase chain reaction (PCR) and 
agarose gel electrophoresis reagents) 
 
50X Tris-acetic acid-EDTA 
(TAE) 
2 M Tris-acetate,  
50 mM EDTA in ddH2O (pH 8.5) 
1X for working solution. 
 
2.3.9 Reactive Oxygen Species (ROS) detection assay solutions: 
ROS assay solution 
10mM HEPES buffer, 10mM glucose, 1M 
DCFH-DA in 1 x PBS 
HEPES buffer (pH 7.5) 
1M HEPES in ddH2O (adjust the pH  with KOH 
solution) 
 
2.3.10 Cell Cycle Analysis with Fluorescence-Activated Cell Sorting (FACS) – 
PI assay solutions: 
Ethanol (v/v) 70% ethanol in ddH2O 
PI staining solution 
50 μg/mL propidium iodide, 0.1mg/mL RNaseA 
and 0.05% Triton-X-100 in 1 x PBS. 
 
2.3.11 in vivo drug treatment assay solutions: 
Simple syrup 16g sugar was dissolved and boiled in 9g ddH2O  
 
 
 
2.4 METHODS 
 
2.4.1 Cell culture protocols: 
 
2.4.1.1 Maintenance of cell lines: 
 
Human liver cancer cell lines Snu182, Snu387 and Snu475 were maintained 
in RPMI-1640 growth medium while the other cell lines (Huh7, HepG2, Hep3B, 
PLC, SK-Hep1, Mahlavu, Focus, HCT116, T47D and MCF7) were cultivated in 
DMEM growth medium. Each cell line has its own splitting agenda according to 
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its proliferation rate. All the cell lines mentioned above are adherent cells growing 
attached to the surface of cell culture dishes. To subculture these cells, trypsin 
(protein degrading enzyme) was used to bring them into cell suspension through 
breaking the protein bridges between the cancer cell and the surface of the dish. 
Prior to trypsinization, the cells were washed twice with 1xPBS to get rid of the 
swimming (i.e. dead) cells and the cell growth medium, containing FBS. Since 
FBS inactivates trypsin, growth medium was re-added just after the cells were 
detached. Depending on the splitting ratio of the cell line, the required amount of 
cell suspension was inoculated to a new cell culture dish with fresh cell growth 
medium. The cell culture dishes were kept at 37 °C in humidified 5% CO2, 95% 
air containing incubators. 
 
2.4.1.2 Freezing of cell lines: 
 
First, cells should be grown to log phase in their regular growth medium. 
After that the cell suspension obtained via trypsinization was centrifuged at 
1200rpm for 5 minutes and the supernatant was discarded. Next, the cell pellet 
was resuspended in cell line-specific freezing medium. Finally, this suspension 
was allocated into screw-capped cryotubes (1mL per each tube). The cryotubes 
were kept at -20°C and -80°C for 1 hour and 24 hours respectively before 
immersing them into liquid nitrogen tank. 
 
2.4.1.3 Thawing of cell lines: 
 
One vial of frozen cell line was taken out of the liquid nitrogen tank and 
placed in 37
o
C water until only a small frozen bit remains. Sufficiently  wiped 
(with 70% ethanol) cryotube was taken rapidly to cell culture hood and transferred 
(dropwise) into 5 mL fresh, cell line-specific growth medium. In order to discard 
the DMSO used as cryoprotectant, the cell suspension was centrifuged at 1200rpm 
for 5 minutes and the supernatant was aspirated off. The cell pellet was 
resuspended in 10ml fresh growth medium, transferred into 100mm culture dish 
and kept at 37 °C in a humidified 5% CO2, 95% air containing incubator. 
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2.4.2 Drug screening protocols: 
 
2.4.2.1 NCI-60 Sulphorhodamine B (SRB) assay: 
 
Cancer cell lines of interest were inoculated (2000cell/well to 
10,000cell/well in 200µL/well) to 96-well plates and left for proliferation at 37oC 
in a humidified 5% CO2 and 95% air incubator. Next day, the media of the wells 
were refreshed and the molecules to be tested which were already dissolved in 
DMSO were applied directly to the first wells in calculated volumes to obtain the 
decided highest drug concentration. Cancer cells were also treated with DMSO-
only simultaneously to avoid its solitary effect. Following the drug treatment, 
plates were incubated again at 37
o
C in a humidified 5% CO2 and 95% air 
incubator for different time periods. At the 24th, 48th and 72th hour of drug 
treatment, cancer cells were fixed with ice-cold TCA (50µL/well) and kept at 
+4
o
C in dark for exactly 1 hour. TCA fixation was terminated by washing the 
wells with ddH2O for 5 times. Air-dried plates were stained with SRB dye 
solution for 10 minutes in dark and at room temperature. The plates which were 
quickly rinsed with 1% acetic acid solution to get rid of the unbound SRB dye 
were left to air dry. The protein-bound and dried SRB dye is then solubilized with 
10mM Tris-Base solution (200µL/well) and homogenized on a shaker for 5-10 
minutes. The absorbance values were obtained at 515nm by means of a microplate 
reader. 
 
2.4.2.2 Real-Time Cell Electronic Sensing (RT-CES) method for cytotoxicity 
profiling (xCELLigence): 
 
The method utilizes the microelectronic plates (E-plates, 96-well) covered 
with gold microelectrodes at the bottom of wells. An electric field forms between 
these electrodes after a low voltage application. Addition of adherent cancer cells 
causes changes in electrical impedance (Z) directly proportional to their numbers. 
These changes are displayed as Cell Index (CI) values reflecting us the adhesion, 
morphology and quantitative status of the cells in the electrode-surrounded well. 
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Prior to cell inoculation, 50µL medium was distributed to each well of the E-96 
plate to obtain background readings for the elimination of any possible 
background noise. Cell suspensions of interest were added (150µL/well) and 
incubated at room temperature for 30 minutes under a laminar flow hood to let the 
cells settle before placing the E-96 plate on the RT-CES station in the humidified 
5% CO2 and 95% air incubator at 37
o
C. The CI values were recorded at every 30 
minutes for the first 24 hours. Next day, 150µL medium from each well was 
replaced with 100µL fresh medium and the molecules to be tested and DMSO-
only as control were administered to wells in decided concentrations. The drug-
treated E-96 plate was again placed on the RT-CES station in the humidified 5% 
CO2 and 95% air incubator at 37
o
C. The CI values were recorded at every 10 
minutes for the first 4 hours and then at every 30 minutes to monitor the fast drug 
response and long-term drug response respectively. 
 
2.4.3 Nuclear staining with Hoechst 33258 protocol: 
 
Cancer cell lines of interest were inoculated onto coverslips placed in 6-well 
plates in 1.5 mL growth medium. The day after, cells were treated with the 
decided concentrations of molecules to be tested and their controls and incubated 
at 37
o
C in 5% CO2. At the end of determined incubation period, the wells were 
washed with ice-cold 1xPBS and fixed with 3% formaldehyde before stained 5 
minutes with Hoechst 33258 working solution at room temperature. The wells 
were destained with ddH2O for 10 minutes. The nuclear morphology was 
examined under a fluorescent microscope after mounting the coverslips onto 
slides with glycerol. 
 
2.4.4 Cell lysis protocol and Bradford assay: 
 
Cancer cell lines of interest were inoculated in 100mm culture dishes with 
10mL growth medium. The day after, cells were washed with 1xPBS and 
incubated at 37
o
C in 5% CO2 with fresh growth medium containing the decided 
concentrations of molecules to be tested and their controls. At the end of 
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determined incubation period, the medium of cells were collected into falcon 
tubes and the remained cells (attached to the surface) were scraped gently (on ice) 
with ice-cold 1xPBS and combined with the previously collected medium. The 
cell suspension was centrifuged at 1500rpm for 5 minutes and the supernatant was 
discarded. The cell pellet was resuspended in 5mL, ice-cold 1xPBS, again 
centrifuged at 1500rpm for 5 minutes and the supernatant was discarded. (The cell 
pellets can be stored at -80
o
C after immersing them into liquid nitrogen until cell 
lysis.) 
 
Either NP-40 lysis buffer or phospho-lysis buffer (approximately three times 
the cell pellet volume) was added on top of cell pellet. The mixture was and 
incubated on ice for 30 minutes with vortexing every 5 minutes. Next, the mixture 
was centrifuged at 13,000rpm for 30 minutes at +4°C. The supernatant (cell 
lysate) was transferred into a new tube and the pellet (cell debris) was discarded. 
 
 Blank 
Tube 
#1 
Tube 
#2 
Tube 
#3 
Tube 
#4 
Tube 
#5 
Tube 
#6 
BSA 
(1mg/mL) 
- 1L 2L 4L 8L 16L 32L 
ddH2O 100L 99L 98L 96L 92L 84L 68L 
Bradford 
Reagent 
900L 900L 900L 900L 900L 900L 900L 
 
To estimate the total protein concentration of cell lysate Bradford assay was 
used. Initially, sequential doubling concentrations of BSA were used (as given 
above) and a standard curve was plotted with the absorbance values obtained at 
595nm with each BSA concentration. Next, the unknown protein concentration of 
the diluted cell lysate was calculated according to the standard curve equation, 
after obtaining its absorbance at 595nm.  
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2.4.5 Kinase assay: 
 
The calculated amount of cell lysate (according to Bradford assay results) 
was mixed with kinase reaction buffer to give a final volume of 40μL in a white, 
96-well, polypropylene assay plate. Then 20μL Lonza reagent or 40μL Kinase-
GLO reagent was added. After 10 minutes dark incubation at room temperature, 
the luminescence was detected through a luminometer. This assay measures the 
consumed ATP by measuring the bioluminescence caused by the remained ATP 
in the well after kinase activity. The enzyme luciferase generates light from 
luciferin and ATP. The intensity of the stable light signal emitted is linearly 
proportional to the concentration of ATP. Hence, high levels of bioluminescence 
depicts the inhibition of protein kinase activity. 
 
2.4.6 Western blotting: 
 
Novex
®
 NuPAGE

 Bis-Tris Electrophoresis system was used according to 
the manufacturer’s protocol for all the western blotting analysis. The pre-cast gel 
percentage and the running buffer type were chosen according to the size (kDa) of 
the protein under investigation. In order to load the samples to each well equally 
their quantified protein contents were taken into consideration. The final volume 
of the samples were decided in accordance with the capacity of the wells. The 
samples were prepared by adding 4x loading dye, 10% 0.5M DTT were added to 
cell lysates and ddH2O was used to complete the total volume and then, denatured 
at70
o
C for 10 minutes. Following electrophoresis, the proteins were transferred to 
nitrocellulose membrane via XCell II
TM 
Blot Module at 30V for 90-150 minutes 
depending on the size (kDa) of the protein under investigation. After checking the 
transfer efficiency with Ponceau staining, the membrane was blocked with either 
5%milk or 5%BSA (both in 1xTBS-T(0.1%)) for 1 hour at room temperature or 
overnight at +4
o
C (both on a shaker) prior to immunoblotting steps. Next, the 
membrane was incubated with the 1
o
 antibody for 2 hours at room temperature (on 
a bench) or overnight at +4
o
C (on a shaker). The unbound antibody was washed 
off from the membrane with 1xTBS-T (0.1%) for 5 times (5min, 10min, 10min, 
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10min, and 5min). Following the incubation with the 2
o
 antibody for 1 hour at 
room temperature (on a bench) another 40 minutes (5min, 10min, 10min, 10min, 
and 5min) were spent to wash the membrane with 1xTBS-T (0.1%). Eventually, 
the expression of the protein levels were visualized via ECL+ kit that is used 
according to the manufacturer’s recommendations. X-ray film was used to capture 
chemiluminesence with different exposure times.  All the 1
o
 antibody-specific 
immunoblotting details were given at section 3.1.8 (pages 39 and 40). 
 
2.4.7 Senescence Associated-β-gal (SA-β-gal) assay and BrdU proliferation 
co-staining: 
 
Huh7 cells were inoculated onto coverslips in 2 identical 6-well plates and 
kept at 37
o
C in a humidified 5% CO2 and 95% air incubator. Next day, the wells 
were washed twice with 1xPBS and the small molecules of interest and their 
corresponding DMSO controls were applied simultaneously to both 6-well plates. 
Following the drug treatment, plates were incubated again at 37
o
C in a humidified 
5% CO2 and 95% air incubator. At the 48th hour of incubation, mediums (both the 
small molecules of interest and their corresponding DMSO control containing) 
were refreshed. For one of the 6-well plates, the freshly prepared mediums were 
also containing 30µM BrdU (5-bromo-2-deoxyuridine). Both 6-well plates were 
again placed in a humidified 5% CO2 and 95% air incubator at 37
o
C. After another 
24 hours of incubation, the 6-well plate with the BrdU containing mediums was 
fixed with 3% formaldehyde initially and left at 37
o
C with 2 mL SA-β-gal assay 
buffer per well. At the end of 12 hour incubation, the SA-β-gal assay buffer was 
aspirated off and the wells were washed with 1xPBS. After that, the cells were 
fixed with ice-cold 70% ethanol and washed gently with 1xPBS for 20 minutes on 
a shaker. Next, the 6-well plate was incubated with 2mL, 2N HCl per well for 20 
minutes at room temperature. Washing the wells with 1xPBS three times on a 
shaker for 15 minutes is followed by blocking the wells with 3% BSA in 1xPBS-T 
on a shaker for an hour. Blocked coverslips were incubated with anti-BrdU 
antibody diluted in 1xPBS (1:1000) for 1 hour at room temperature. Dako 
Envision+Dual Link System-HRP and Dako Liquid DAB+Substrate Chromogen 
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System were used according to the manufacturer’s directions for the rest of the 
steps. Photos taken from the coverslips mounted on to the slides with glycerol. 
For the other 6-well plate, at the 120th hour of incubation (both the small 
molecules of interest and their corresponding DMSO control containing) the BrdU 
proliferation and SA-β-gal assay co-staining performed exactly as done to the 
former 6-well plate. 
 
2.4.8 Cell Cycle Analysis with Fluorescence-Activated Cell Sorting (FACS) – 
PI assay: 
 
Cancer cell lines of interest were inoculated in 100mm culture dishes with 
10mL growth medium. The day after, cells were washed with 1xPBS and their 
mediums were refreshed with 1%FBS containing starvation mediums. After 
another 24 hours at 37
o
C in a humidified 5% CO2 and 95% air incubator, the small 
molecule of interest and its DMSO control were administered to the cancer cells 
in 6mL growth medium per dish. At the end of determined incubation time, the 
swimming cells were collected into falcon tubes and the attached cells were 
washed with 1xPBS once, trypsinized and harvested with the previously collected 
(swimming cells containing) medium. The cell suspension was centrifuged at 
1500rpm for 5 minutes. After discarding the supernatant, the cell pellet was 
resuspended in 5mL 1xPBS and re-centrifuged at 1500rpm for 5 minutes. Next, 
the cell pellet was resuspended in 1mL, ice-cold 1xPBS and fixed by adding 
2.5mL, 70% ice-cold ethanol dropwise on vortex. (The fixed cells can be stored at 
+4
o
C for one week.) 
  Prior to FACS-Propidium Iodide (PI) analysis, you should re-centrifuge 
the ethanol-fixed cell suspension and discard the supernatant. Next, the cell pellet 
was resuspended in 500L PI solution and incubated for at 37oC for 40 minutes at 
dark. After that, 3mL 1xPBS added (PI solution incubated) cell suspension was 
centrifuged at 1500rpm for 5 minutes. The PI stained cell pellet was resuspended 
in 500L – 1mL 1xPBS (according to the amount of cell pellet) and transferred 
into FACS analysis tubes. BD FACSCalibur and CellQuest Software was used for 
the further cell cycle analysis. 
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2.4.9 ER (Endoplasmic Reticulum) stress detection assay: 
 
Total RNAs were isolated from cancer cells, treated as planned, via the 
Nucleospin RNA II kit according to the manufacturer’s protocol. From these 
isolated total RNAs first strand cDNA synthesis was performed using RevertAid 
First Strand cDNA synthesis kit. All first strand cDNA samples (1L) were used 
for PCR amplification of glyceraldehydes-3-phosphate dehydrogenase (GAPDH), 
a housekeeping gene, transcript in order to normalize the PCR products.  
The spliced isoform of XBP1 (X box-binding protein 1) is accepted as an 
indicator of ER stress. In order to detect the presence of this spliced variant, semi-
quantitative reverse transcriptase PCR (RT-PCR) assay was performed using 
XBP1 specific primers. The PCR was run for 30 cycles (30 seconds at 95
o
C, 30 
seconds at 60
o
C, 30 seconds at 72
o
C) and the products were separated on 3% 
agarose gel. Agarose was dissolved in 1xTAE electrophoresis buffer in 
microwave oven and ethidium bromide was added to have 30g/mL final 
concentration prior to pour it into the gel mold. 100bp DNA ladder and the PCR 
products mixed with 6x loading dye were loaded onto the gel which was run in 
1xTAE buffer at 70V for 120 minutes. 
 
2.4.10 Reactive Oxygen Species (ROS) detection assay: 
 
Cancer cell lines were inoculated onto coverslips in 6-well plates. On the 
next day, wells were 1xPBS washed and the small molecule of interest and its 
DMSO control was administered to the cells. After the determined time of 
incubation, wells were washed thoroughly with 1xPBS three times and incubated 
with 1mL ROS assay solution for 15 minutes at 37
o
C in a humidified 5% CO2 and 
95% air incubator. Aspirating off the DCFH-DA containing ROS assay solution 
terminates the incubation. After washing wells twice with 1xPBS the coverslips 
were mounted on slides with glycerol. This assay utilizes DCFH-DA, a cell 
permeable, non-fluorescent probe which oxidizes to a fluorescent molecule, DCF. 
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2.4.11 in vivo drug treatment assay: 
 
Mahlavu liver cancer cells were grown in 150mm culture dishes to 70-75% 
confluency. Following thoroughly washing the cells with 1xPBS twice, minimum 
amount of trypsin was used to harvest the cells. Upon counting the cells through 
hemocytometer, Mahlavu suspensions were prepared as each contains 10,000,000 
cells. In order to get rid of the trypsin used, Mahlavu suspensions were 
centrifuged at 1200rpm for 5 minutes and the supernatants were aspirated off. 
Mahlavu pellets were washed with 1xPBS twice and then each was suspended in 
100L DMEM growth medium prior to subcutaneous (SC) injection to the flank 
of nude mice. The nude mice were 8-16 weeks old and spent a week upon arrival 
as acclimatization period. After the SC injection of Mahlavu cells, the nude mice 
were monitorized for tumor growth. Twice a week tumor dimensions were 
measured with vernier caliper and recorded. When the tumors had reached 
approximately 150mm
3
 volume, the drug treatment had started. Drug was 
suspended in simple syrup (100mg/kg) and given orally by means of venipuncture 
set, 23G inserted U-100 insulin syringe (without the needle). Drug treatments 
were done twice a week for 3 weeks and for the subsequent 3 weeks nude mice 
were non-treated. At the end of 3 rounds of chemotherapy the nude mice (both 
drug and control groups) were taken to magnetic resonance imaging (MRI).    
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CHAPTER 3. AIM and STRATEGY 
 
 
Cancer is one of the ongoing health problems, briefly defined as disordered growth 
and expansion of aberrant cells, which can eventually result in death. American Cancer 
Society’s report estimates that by the end of 2012, about 28,720 new cases will be 
diagnosed for primary liver cancer and 20,550 people will die from 
(http://www.cancer.org). Hepatocellular carcinoma is a serious global public health 
problem with a slow-growing multi-step setup, in which treatment options diminish as time 
passes for detection. Each year, 748,000 new HCC cases and 696,000 deaths from HCC 
arise according to the estimations of International Agency for Research on Cancer (IARC) 
(Ferlay J et al., 2010). Chronic hepatitis B, hepatitis C, alcohol abuse is among the major 
risk factors and the 5-year survival rate is approximately 10% for patients diagnosed for 
advanced HCC (Altekruse SF et al., 2009). Patients suffering with early-stage HCC, can 
benefit from surgical resection, liver transplantation, ablation, embolization, 
chemotherapy; but at an advanced stage of HCC, alternatives are very limited (Ye SL et 
al., 2010).  
 
Targeted therapy, which focuses on the inhibition of specific mediators involved in 
the altered signaling pathways, is a promising approach for the treatment of HCC (Chua 
CWL and Choo SP, 2011). Sorefenib is the only targeted therapy agent approved for the 
treatment of advanced HCC, which can prolong survival almost three months (Cao H et al., 
2012). Regarding to the accumulated data on targeted therapy of HCC, small molecules 
can successfully inhibit the abnormal protein-protein interactions leading a cell to cancer 
(White AW et al., 2008). In such a highly-challenging field, the main aim of this thesis is 
to identify novel, putative protein kinase inhibitors acting on liver cancer cells. The small 
molecules in this thesis, which were investigated for this ultimate aim, were designed and 
synthesized by two separate collaborating groups. The first group of small molecules was 
novel nucleoside analogues obtained from Prof. Dr. Meral Tuncbilek and the other group 
of aminotriazole and thiadiazine derivatives was obtained from Prof. Dr. Birsen 
Tozkoparan. 
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The newly synthesized small molecules were first tested for their anti-cancer 
activities against human breast, colon and liver cancer cell lines. The pre-screening 
approach, which was introduced by National Cancer Institute (NCI), was the strategy we 
applied (Shoemaker RH, 2006). Following the evaluation of cytotoxicites of these small 
molecules, the promising drug candidates were chosen according to the druggability of 
their half-maximal inhibitory concentration (IC50) values. Subsequent drug screening 
assays were used to analyze the cytotoxicity profile of these compounds against a panel of 
HCC cell lines. The distinctive features of the cell lines included to the panel, such as 
known mutations, gave us hints about the possible mechanisms of action which the small 
molecules exploit. Besides, the protein kinase inhibitory activities of these small molecules 
were demonstrated by a luminescence based, ATP detecting assay. 
 
The ultimate aim of this Ph.D. dissertation was not only to detect promising anti-
cancer agents, but also to characterize the form of death they induce and to identify the 
underlying mechanism of action. To achieve this goal, the selected, novel, promising 
small-molecules were further analyzed. Morphological analysis (e.g. light microscopy; 
Hoechst 33258 staining), protein based experiments, cell cycle analysis, specific assays 
(e.g. ROS accumulation, SA-β-gal), and eventually in vivo drug treatment assays were 
accomplished not only to define the type of induced-cell death, but also to figure out the 
mediators involved in this mechanism. Both, verifying the assumed mechanism for the 
drug candidate and reasoning the eliminated mechanisms were also included within the 
strategy we used.  
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56 
 
CHAPTER 4. RESULTS 
 
 
The small molecules analyzed in this thesis are classified into two main 
parts as shown in Table 4.1. The nucleobase and nucleoside analogues composing 
the first part can be further divided into three subgroups as purine analogues (36 
small-molecules), purine ribonucleoside analogues (5 small-molecules) and 
substituted purine and purine nucleoside analogues (155 small-molecules). The 
novel aminotriazole and thiadiazine derivatives (32 small molecules) were taken 
into consideration as the second part of results we obtained and presented in this 
thesis.  
 
Table 4.1: The small molecules analyzed in this thesis 
 # of small-
molecules 
PART 1. Nucleobase and nucleoside analogues  
      PART 1a.  Purine analogues 36 
      PART 1b.  Purine ribonucleoside analogues 5 
      PART 1c.  Substituted purine and purine nucleoside analogues 155 
PART 2. Aminotriazole and thiadiazine derivatives 32 
 
 
PART 1  
 
4.1 Nucleobase and nucleoside analogues 
 
The newly synthesized small molecules we obtained from Prof. Dr. Meral 
Tunçbilek, Ankara University were either nucleobase or nucleoside analogues. 
The structural modifications on the heterocyclic bases and/or on the sugar moiety 
of natural nucleosides are required for analogue development. Although 
nucleoside analogues are structurally similar antimetabolites, they show diverse 
activities generally affecting the structural integrity of DNA (Ewald B et al., 2008; 
Kumar V et al., 2010). 
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PART 1a 
 
4.1.1 Anti-cancer drug screening of novel, substituted purine analogues 
 
Novel purine analogues in the small molecule pool coded AUM were 
received in powdered (solid) form (Supplementary Table 1). Following the 
preparation of their stock solutions in DMSO, each compound was pre-screened 
against three different cancer cell types. Colon cancer cells (HCT116), breast 
cancer cells (T47D) and liver cancer cells (Huh7) were chosen to evaluate the 
cytotoxic activity of these small molecules. Starting from 40M, 5 serially diluted 
concentrations of each molecule were administered to the cancer cell-inoculated 
wells. After 72 hours-long incubation period, via Sulforhodamine B (SRB) assay 
as described in the chapter of Materials and Methods (page 45), the percent 
cytotoxicity of  these small molecules were calculated by comparing the cell 
growth in small molecule treated wells to control (DMSO-only treated) wells. The 
percent cytotoxicities of each small molecule were given as a chart 
(Supplementary Figure 1). The half-maximal inhibitory concentration (IC50) 
value of a compound is the required amount of that compound to cause 50% 
cytotoxicity. The IC50 values of these novel purine analogues were calculated 
according to the dose-response curves obtained from the percent cytotoxicity 
charts given in Supplementary Figure 1 and given in Supplementary Table 1.       
 
Among the 36 newly synthesized small molecules, AUM18, AUM23 and 
AUM32 exhibit significantly promising cytotoxicity profiles against Huh7, 
HCT116 and T47D cancer cells. Interestingly these three analogues were sharing 
4-(4-Trifluoromethylphenyl)piperazine common as a substituent at the 6
th
-position 
of the purine moiety (N
6
)  and their substituent at the 9
th
-position were creating 
the difference in their activities (Table 4.2). AUM18, AUM23 and AUM32 have 
shown cytotoxic percentages corresponding to IC50 values below 10M (except 
AUM18 and AUM23 have IC50 values 39.4 and 42.7 respectively, for breast 
(T47D) cancer cell line) (Supplementary Table 1). Not only due to their promising 
cytotoxic profile, but also because they are structurally very closely related we 
chose these three purine analogues to further investigate. These  three 6- and/or 9- 
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substituted novel purine analogues (AUM18, AUM23 and AUM32) were further 
analyzed for their anti-cancer activity on a HCC panel consisting of Huh7, 
HepG2, Hep3B, PLC, SK-Hep1, Mahlavu, FOCUS, Snu182, Snu475 cancer cell 
lines. The cancer cells inoculated into 96-well plates were treated with AUM18, 
AUM23, AUM32 and their DMSO controls in triplicates within 10 different 
concentrations. The cytotoxicity percentages and the IC50 values calculated 
accordingly demonstrate that these 3 small molecules are bioactive against HCC 
cell line panel composing of Huh7, HepG2, Hep3B, PLC, SkHep1, Mahlavu, 
FOCUS, Snu182 and Snu475 cells (Supplementary Figure 1 and Table 4.2). The 
IC50 values were in micromolar range, varying between 0.1M to 10M and 
among these 3 purine analogues, AUM32 is the most cytotoxic analogue with 
IC50 values below 1M for almost all cell lines in the HCC panel. However, we 
did not observe significant cytotoxic effect on Snu182 cells with AUM18 purine 
derivative and observed no inhibition on Snu475 with AUM32. The differential 
inhibition that we observe, can be considered as an indication of the specificity of 
these inhibitors against their target.   
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Table 4.2: IC50 values of AUM18, AUM23 and AUM32 against HCC cell line 
panel:  The liver cancer cells were incubated with each molecule for 72 hours and 
the IC50 values are in M range. NI stands for “no inhibition”. 
 
 
R :  
R1 
AUM18 AUM23 AUM32 
H 
 
 
HCC cell line: IC50 values (M) 
Huh7 3.2  0.07 1.4  0.01 0.2  0.04 
HepG2 3.7  0.25 1.2  0.2 0.3  0.01 
Hep3B 6.7  0.20 2.9  0.63 0.8  0.45 
PLC 10.5  0.40 3.8  0.46  6.4  1.19 
SK-Hep1 4.9  0.29 1.7  0.17 0.2  0.01 
Mahlavu 2.3  0.06 1.0  0.09 0.1  0.01 
FOCUS 2.9  0.27 1.0  0.02 0.2  0.06 
Snu182 51.0  4.7 8.4  0.26 9.8  2.48 
Snu475 9.6  0.20 5.4  0.49 NI 
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B) 
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C) 
 
Figure 4.1: Percent cytotoxicity in the presence of AUM18 (A), AUM23 (B) and AUM32 (C) purine analogues: AUM18 (A), AUM23 (B) 
and AUM32 (C) and their DMSO controls were administered to the HCC panel cancer cells, inoculated in 96-well plates, with ten different 
concentrations for 72 hours. Following the SRB assay, the cytotoxicity percentages were calculated in comparison to DMSO-only treated wells. 
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4.1.2 AUM18, AUM23 and AUM32 trigger nuclear condensation and DNA 
fragmentation but do not induce apoptosis 
 
To further clarify the cytotoxic effect emerged after the cancer cells were 
treated with these 3 novel purine derivatives, we used Hoechst 33258, a DNA-
specific dye, to reveal apoptotic morphology. The condensed DNA observed as 
horseshoe-like structures and shrunk cells following drug treatment most likely 
indicates apoptosis is induced (Figure 4.2). 
 
After detecting apoptotic bodies in the presence of AUM18, AUM23 and 
AUM32 by Hoechst 33258 staining, we wanted to confirm apoptosis through 
inspecting the expression levels of certain proteins known as apoptosis markers. 
Stauroporine was used as positive control at its apoptosis-inducing dose. No 
significant decrease in the expression levels of the anti-apoptotic protein Bcl-2 
and total Cytochrome-c levels was observed in FOCUS cells treated with these 
novel small molecules (Figure 4.3-A). 
 
Furthermore, the poly (ADP-ribose) polymerase (PARP-1), a 113 kDa 
nuclear protein, known to be cleaved not only into fragments of 89kDa and 24kDa 
fragments during apoptosis, but also into a main fragment of 55kDa if the cell is 
necrotic, was checked. The HCC cells treated with AUM18, AUM23 and AUM32 
at their cell-line-specific IC50 values for 72 hours were assessed for their PARP-1 
cleavage via western blot in order to characterize the cell death type. Neither 
89kDa and 24kDa apoptotic fragments, nor the 55kDa necrotic fragment were 
obtained, instead PARP-1 protein remained intact (Figure 4.3-B,C). In other 
words, we could not name the underlying mechanism of action of these three 
purine analogues as apoptosis. 
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Figure 4.2: Hoechst 33258 nuclear staining of purine analogues treated FOCUS (A) and Huh7 (B) cells. Each AUM small molecule was 
administered to the liver cancer cells plated on coverslips at their calculated cell line-specific IC50 values for 72 hours. CPT; camptothecin was 
used as positive control. Cells were visualized with 40x objective. 
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Figure 4.3: (A) Bcl-2 and Cyt-c protein expression levels of FOCUS cells 
treated with purine analogues Each AUM small molecule was applied to 
FOCUS cells at their calculated IC50 values for 24 hours. STS; staurosporine was 
used as positive control. Actin was used as equal loading. PARP cleavage 
analysis via western blot for AUM18, AUM23 and AUM32 treated Mahlavu 
cells (B) and only AUM32 treated Huh7, HepG2, FOCUS and Mahlavu cells 
(C). Liver cancer cell(s) were treated with indicated purine analogue(s) at their 
calculated IC50 values for 72 hours. STS; staurosporine was used as positive 
control. Calnexin was used as equal loading. 
 
4.1.3 Kinase inhibitory potential of AUM18, AUM23 and AUM32 
 
The growth inhibitory effects that we observed with these three purine 
derivatives were comparable to those of the known anticancer agents 
camptotechin (IC50 ~ 10 nM) and 5-fluorouracil (IC50 ~10µM). The differential 
(cell-line-dependent) cytotoxic activity of each molecule can be considered as an 
indication of the specificity of these inhibitors against their target.  They might 
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interfere with the activity of certain kinases instead of acting as a multi-kinase 
inhibitor.  Furthermore, we evaluated the protein kinase inhibitory activity of 
these small molecules. Therefore, the kinase assay based on the detection of the 
amount of ATP in the reaction mixture through bioluminescence (Figure 4.4) was 
performed with Huh7 and Mahlavu cells (Figure 4.5) (Lundin A, 1981; Singh P et 
al., 2004).  
 
The liver cancer cells incubated with these putative kinase inhibitors and 
staurosporine (STS), a multi-kinase inhibitor (used as a positive control) for 24 
hours. The blockage of ATP consumption, in other words increase in the light 
intensity, in the presence of these three purine analogues was more evident in 
Huh7 cells comparing to Mahlavu cells (Figure 4.5). Based on the results we 
obtained, the newly synthesized purine derivatives, AUM18, AUM23 and 
AUM32 may be suggested as putative protein kinase inhibitors,  which must be 
further analyzed at the molecular level. 
 
 
 
Figure 4.4: Schematic kinase assay principle: The enzyme luciferase generates 
light from luciferin and ATP-remained after the kinase activity. The intensity of 
the light is linearly proportional to the concentration of ATP. Hence, high levels 
of bioluminescence depict the inhibition of protein kinase activity.  
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Figure 4.5: Kinase inhibitory potential of AUM18, AUM23 and AUM32: The 
relative light units measured after the kinase assay was performed in duplicate for 
the Huh7 and Mahlavu cells treated with the purine derivatives at their given IC50 
values.  STS; staurosporine (0.25µM) was used as positive control. Lonza 
PKLight
TM
 assay kit was used to test the ATP content of 20g protein containing 
cell lysates.   
 
4.1.4 Time-dependent cytotoxicity and the real-time cell growth analysis in 
the presence of AUM32 
 
To thoroughly explain the mechanism behind the cytotoxic activity of 
AUM32 on cancer cells, we established a time- and dose- dependent assay with 
HCC cell lines including Huh7, HepG2, Mahlavu and FOCUS. The cancer cells 
inoculated into 96-well plates were treated with AUM32 and its DMSO control in 
triplicates within 10 different concentrations and incubated for 24, 48 and 72 
hours. Time-dependent cytotoxicity percentages and the IC50 values of AUM32 
were given in Figure 4.6 and Table 4.3 respectively. Although the AUM32 
induced-cytotoxicity was similar for all the cell lines at 72h, the 24h incubation 
with AUM32 was not effective in Mahlavu and FOCUS cells as it is in Huh7 and 
HepG2 cells (Figure 4.6). The time dependent IC50 values corresponding to the 
cytotoxicity percentage chart of AUM32 demonstrate that this novel purine 
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analogue induces cell-line-dependent “short term” cytotoxicity; while, the “long 
term” AUM32 response is comparable in all chosen liver cancer cells (Table 4.3).   
 
Table 4.3: Time-dependent IC50 values of AUM32:  AUM32 was applied in 
triplicates to liver cancer cells inoculated into 96-well plates and incubated for 24, 
48 and 72 hours. The IC50 values are in M range.  
 
 IC50 (M) 
 24h 48h 72h 
Huh7 2.7  0.31 1.4  0.30 0.6  0.04 
HepG2 1.2  0.25  0.8  0.04 0.2  0.04 
Mahlavu 50.1  11.66 0.3  0.03 0.2  0.01 
FOCUS 16.7   4.1 0.3  0.02 0.1  0.04 
 
Moreover, we performed the real-time, label-free cytotoxic activity of 
AUM32 on Huh7, HepG2 and Mahlavu cancer cells via real-time cell electronic 
sensing (RT-CES) experiment. The microelectronic sensors of the E-Plate 96, the 
wells we inoculated the cancer cells into, utilizes the dynamic monitoring of the 
logarithmic growth of these cells and correlates with cell index (CI). The data 
recorded clearly demonstrates that AUM32 suppresses the cell growth; in other 
words, AUM32 treated wells experience a decrease in their CI values after 
approximately 72h while DMSO-only treated wells (shown in black) display a 
proliferating profile (Figure 4.7).  
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4.1.5 The novel, purine analogue AUM32 induces cellular senescence 
 
Both the time-dependent SRB assays and the real-time cellular response of 
liver cancer cells with AUM32 clearly display that the cytotoxic activity of 
AUM32 is a “long-term” arising response. This fact indicates that the cell death 
type AUM32 inducing might be cellular senescence. In order to identify this 
possibility, we used SA-β-gal assay and BrdU incorporation assays 
simultaneously. Huh7 cells plated with coverslips to 6-well plates (5000 
cells/well) were incubated with IC50 and IC100 values of AUM32, doxorubicin 
and DMSO-only for 3 days and 6 days. Doxorubicin was used as a positive 
control at its senescence-inducing dose (25ng/mL) (Senturk S et al., 2010). BrdU 
(30M) was administered to test its incorporation into cellular DNA of Huh7 cells 
24h prior to the end of 3 days and 6 days long incubations. AUM32 treated Huh7 
cells showed senescence associated morphology (blue arrows) and also the blue-
stained (SA-β-gal positive) cells were negative for BrdU incorporation, whereas 
DMSO-only applied Huh7 cells were BrdU positive (brown arrows), proliferating 
cells (Figure 4.8). 
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Figure 4.6: Time- and dose- dependent percent cytotoxicity in the presence of AUM32: AUM32 and its DMSO control were administered to 
the liver cancer cells, inoculated in 96-well plates, in triplicate with ten different concentrations for 24, 48 and 72 hours. Following the SRB 
assay, the cytotoxicity percentages were calculated in comparison to DMSO-only treated wells. 
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Figure 4.7: Monitored real-time cell growth of Huh7, HepG2 and Mahlavu 
cells in the presence of AUM32: AUM32 and its DMSO control were 
administered to the liver cancer cells, inoculated in E-Plate 96, in triplicates. The 
cell growth index was monitored every 30 minutes in the presence of the five 
different concentrations of AUM32 (40M-red, 20M-green, 10M-blue, 5M-
pink, 2.5M-cyan and DMSO control-black). 
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 Figure 4.8: SA-β-gal and BrdU incorporation assays in the presence of AUM32: Huh7 cells (5000cells/well) inoculated into 6-well plates 
with coverslips were incubated with IC50 and IC100 values of AUM32, Doxorubicin (25ng/mL) and DMSO-only for 3 days and 6 days.  SA-β-
gal and BrdU incorporation assays were performed in parallel. BrdU (30M) was administered to the cells 24 hours prior to the end of 3rd and 
6
th
 days of incubation.  
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PART 1b 
 
4.1.6 Anti-cancer drug screening of novel purine ribonucleoside analogues 
 
Novel purine ribonucleoside analogues were received in powdered form. 
In Table 4.4, not only the structures of these derivatives but also the published, 
corresponding compound codes were given. Following the preparation of their 
stock solutions in DMSO, all were evaluated for their cytotoxicity against liver 
(Huh7, HepG2, Mahlavu and FOCUS), colon (HCT116) and breast (MCF7) 
cancer cells, by the previously explained SRB assay, in a dose- and time- 
dependent manner. The cancer cells inoculated into 96-well plates were treated 
with AUM40-44 and their DMSO controls in triplicates within 5 different 
concentrations prior to incubation for 24, 48 and 72 hours. Time-dependent cell 
death percentages and the IC50 values of AUM40-44 were given in 
Supplementary Figure 2 and Table 4.5 respectively. Although AUM42 and 
AUM43 both exhibit promising cytotoxic effects on liver (Huh7, HepG2, 
FOCUS, Mahlavu),  colon (Hct116) and breast (MCF7) cancer cell lines, we 
decided to choose AUM42 for further analysis because it cytotoxicity is slightly 
more distinguished (Table 4.5). Therefore we performed assays to characterize 
the cytotoxicity induced by AUM42 and identify the underlying mechanism of 
action.  
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Table 4.4: Novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl) 
purine analogues 
 
 
 
 
 
 
Compound 
Code*
 
R 
AUM40 9 
 
AUM41 10 
 
AUM42 11 
 
AUM43 12 
 
AUM44 13 
 
 
*Tuncbilek M, Bilget Guven E, Onder T, Cetin-Atalay R. 2012. Synthesis of 
novel 6-(4-substituted piperazine-1-yl)-9-(β-D-ribofuranosyl)purine derivatives, 
which lead to senescence-induced cell death in liver cancer cells. J Med Chem. 
Apr 12;55(7):3058-65.  
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Table 4.5: Time-dependent IC50 values of purine ribonucleoside analogues:  AUM40-
44 were applied in triplicates to the cancer cells inoculated into 96-well plates and 
incubated for 24, 48 and 72 hours. The IC50 values are in M range. NI stands for “no 
inhibition”. ND stands for “not determined”. 
  IC50 (M) 
  AUM40 AUM41 AUM42 AUM43 AUM44 5-FU CPT 
Huh7 
24h NI NI 2.50.1 26.93.1 NI ND < 0.1 
48h NI NI 9.00.7 10.10.6 NI ND < 0.1 
72h NI NI 7.80.3 7.21.2 NI 30.7 < 0.1 
HepG2 
24h NI NI 12.12.6 18.35.4 NI ND < 0.1 
48h NI NI 7.20.8 6.80.5 NI ND < 0.1 
72h NI NI 5.70.7 6.10.3 NI 5.0 < 0.1 
Mahlavu 
24h NI NI 14.40.3 31.73.2 NI ND < 0.1 
48h NI NI 8.60.5 13.91.8 NI ND < 0.1 
72h NI NI 9.20.4 7.00.5 NI 10.0 < 0.1 
FOCUS 
24h NI NI 10.80.6 26.01.6 NI ND < 0.1 
48h NI NI 4.90.5 8.71.0 NI ND < 0.1 
72h NI NI 5.20.7 5.50.1 NI 7.6 < 0.1 
HCT116 
24h 39.67.5 NI 11.60.7 20.86.5 NI ND < 0.1 
48h NI NI 6.30.7 8.22.0 40.37.9 ND < 0.1 
72h NI NI 6.70.7 7.81.4 44.95.5 6.0 < 0.1 
MCF7 
24h NI NI 12.61.7 18.83.5 NI ND < 0.1 
48h NI NI 8.71.5 12.82.1 43.35.5 ND < 0.1 
72h NI NI 7.40.5 9.50.4 42.25.6 3.5 < 0.1 
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4.1.7 Real-time cellular response of liver cancer cells in the presence of 
AUM42  
 
Real-time Cell Electronic Sensing (RT-CES) system was used to analyze 
the AUM42 mediated cytotoxicity on Huh7, HepG2, Mahlavu and FOCUS 
hepatocellular carcinoma cells in triplicate.  The real-time dynamic monitoring of 
the electrode impedance is indicated as Cell Index (CI) correlating with cell 
growth. AUM42, applied in 6 different concentrations (30-5µM), triggered a time- 
and dose- dependent decrease in CI for all cancer cells (Figure 4.9). The AUM42-
induced suppression of the cell growth was cell-line-dependent; in other words, 
Mahlavu cells were more resistant to AUM42-induced cytotoxicity which is 
correlative with the previous SRB data. IC50 values of AUM42 is highest for 
Mahlavu cells in the HCC panel. This observation might be indicating that 
AUM42 is an interfering molecule as a putative kinase inhibitor. 
 
4.1.8 Kinase inhibitory potential of AUM42 
 
Cellular response profiles exhibiting differences between cell lines bring to 
mind that AUM42 might be interfering with the cell signaling. To clarify if 
AUM42 possesses a kinase inhibition potential or not, we used a luminescent 
ATP-detection assay as explained previously (Figure 4.4). Luminescence (relative 
light unit), correlates with the amount of ATP in the milieu; therefore, an increase 
in the luminescence can be considered as a sign of the existence of a protein 
kinase inhibitor. We used staurosporine (STS), a potent multi-kinase inhibitor, 
and MeSAdo (5'-Deoxy-5'-methylthioadenosine), which has an open structure 
resembling that of AUM42 molecule, as positive controls of the assay. Huh7 cells 
incubated with IC50 and IC100 values of AUM42, 5M MeSAdo and 0.5M STS 
for 72h were then tested. The dose dependent ATP increase in the presence of 
AUM42, suggests that AUM42 might be a putative kinase inhibitor (Figure 4.10). 
High rlu obtained with the STS treated Huh7 cells is consistent with both the 
principle of the assay and the potential of STS as a multi-kinase inhibitor.  
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Figure 4.9: Monitored real-time cell growth of Huh7, HepG2, Mahlavu and 
FOCUS cells in the presence of AUM42: AUM42 and its DMSO control were 
administered to the cancer cells, inoculated in E-Plate 96, in triplicates. The cell 
growth index was monitored every 30 minutes in the presence of the six different 
concentrations of AUM42 (30M-red, 20M-blue, 15M-green, 10M-pink, 
7.5M-cyan, 5M-coral and DMSO control-black).  
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Figure 4.10: Kinase inhibitory potential of AUM42: The relative light units 
measured after the kinase assay performed for the Huh7 cells treated with the 
IC50 and IC100 values of AUM42, STS (staurosporine, 0.5µM), MeSAdo (5µM) 
and their corresponding DMSO controls for 72 hours. Kinase-GLO assay kit was 
used to test the ATP content of 80000 cells.    
 
4.1.9 The cytotoxic activity of AUM42 is neither apoptosis nor necrosis but it 
induces cellular senescence 
 
The indicator of an activated apoptotic pathway, Poly ADP-ribosyl 
polymerase (PARP) cleavage, was checked for AUM42 treated Huh7, HepG2, 
Mahlavu and FOCUS cells for 72 hours at its cell-line-specific IC50 values. 
Neither apoptotic fragments (89kDa and 24kDa) nor the necrotic fragment 
(55kDa) were obtained; instead PARP protein remained intact, 113kDa (Figure 
4.11).  
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Figure 4.11: PARP cleavage analysis via western blot. Huh7, HepG2 and 
Mahlavu cells were treated with AUM42 and AUM43 at their calculated IC50 
values for 72 hours. No cleaved PARP fragment was detected. 
 
 
To identify if the proliferative arrest generated by AUM42 is due to 
senescence or not, we performed SA-β-gal and BrdU incorporation assays in 
parallel. Huh7 cells plated with coverslips to 6-well plates were incubated with 
IC50 and IC100 values of AUM42, Doxorubicin and DMSO-only for 3 days and 
6 days. Doxorubicin was used as a positive control at its senescence-inducing 
dose (25ng/mL) (Senturk S et al., 2010). BrdU (30M) was administered to test 
its incorporation into cellular DNA of Huh7 cells 24h prior to the end of 3 days 
and 6 days long incubations. SA-β-gal assay positive, large, blue stained cells 
were obtained when treated with AUM42 or doxorubicin.  These senescent cells 
were also negative for BrdU incorporation where BrdU positive proliferating cells 
were excessive in the DMSO-only treated wells (Figure 4.12). 
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A) 
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B) 
 
 
Figure 4.12: SA-β-gal and BrdU incorporation assays in the presence of 
AUM42: (A) Huh7 cells inoculated into 6-well plates with coverslips 
(5000cells/well) were incubated with IC50 and IC100 values of AUM42, 
doxorubicin (25ng/mL) and DMSO-only for 3 days and 6 days.  SA-β-gal and 
BrdU incorporation assays were performed in parallel. BrdU (30M) was 
administered to the cells 24 hours prior to the end of 3
rd
 and 6
th
 days of 
incubation. (B) For each treatment condition, cells were counted and the SA- β-
gal and BrdU positive cell percentages were given.  
 
 
In addition to the most commonly used marker of senescence, SA- β-gal 
assay,  we aimed to check  p15(INK4b) levels as another senescence-associated 
marker, which is known to be increased in senescent cells. Total protein lysates 
were obtained from Huh7 cells treated with IC50 and IC100 values of AUM42, 
Doxorubicin (25ng/mL) and their DMSO controls and incubated for 3 and 6 days; 
afterwards, western blot analysis was done. For the  AUM42 treated  Huh7 cells, 
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the increase in the protein expression levels of p15(INK4b)
 
was both time- and 
dose- dependent (Figure 4.13-A). In order to verify this increase, next, we decided 
to check the downstream effect of p15(INK4b) on the Rb protein. It is known that 
p15(INK4b) activates Rb protein; in other words, p15(INK4b) inhibits the 
phosphorylation of Rb by inhibiting CyclinD1/CCDK4CD. The decrease 
observed in the phosphorylated form of Rb protein correlates with the AUM42-
induced accumulation of p p15(INK4b) (Figure 4.13-B,C).  
 
 
Figure 4.13: Senescence-associated proteins p15(INK4b) and Rb in the 
presence of AUM42:
 
Huh7 cells were treated with IC50 and IC100 values of 
AUM42, Doxorubicin (25ng/mL) and their DMSO controls for 3 days and/or 6 
days. Total cell lysates were obtained and the protein expression levels of 
p15(INK4b) (A), Rb and phospho-Rb (B) were checked. Doxorubicin at its 
senescence-inducing dose was used as positive control. Calnexin and actin were 
used to control equal loading. The relative phospho-Rb (P*Rb) intensities of each 
treatment (C) confirms senescence-induced cytotoxicity of AUM42.  
 
 
83 
 
Besides, when we checked the expression level of p21 in order to identify 
the action mechanism of senescence-inducing analogue, AUM42, we observed no 
significant change. Moreover, phosphorylated-H2AX, indicating DNA damage, 
was also not detectable (Figure 4.14). Therefore, we concluded that AUM42 is 
inducing senescence through the activation of Rb protein depending on the 
increased levels of p15(INK4b). 
 
 
Figure 4.14: p21 and phospho-H2AX (P*-H2AX) expression levels in the 
presence of AUM42:
 
Huh7 cells were treated with IC50 and IC100 values of 
AUM42, Doxorubicin (25ng/mL) and their DMSO controls for 3 days and/or 6 
days. Total cell lysates were obtained and the protein expression levels of p21 (A), 
P*-H2AX (B) were checked. Doxorubicin at its senescence-inducing dose was 
used as positive control. Calnexin was used to control equal loading.  
 
PART 1c 
 
4.1.10 Anti-cancer drug screening of novel, substituted purine and purine 
nucleoside analogues 
 
Novel purine and purine nucleoside analogues in the small molecule pool 
of AUM were received in powdered form (Table 4.6). Following the preparation 
of their stock solutions in DMSO, each and every compound was prescreened 
against three different cancer cell types. Colon cancer cells (HCT116), breast 
cancer cells (MCF7) and liver cancer cells (Huh7) were chosen to evaluate the 
cytotoxic potential of these small molecules via Sulforhodamine B (SRB) assay as 
described previously. The half-maximal inhibitory concentration (IC50) values of 
these molecules were given in Supplementary Tables 2-5. The IC50 values were 
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calculated according to the dose-response curves obtained from the percent 
cytotoxicity charts given in Supplementary Figures 3-5.  
 
The initial screening of these substituted purine and purine nucleoside 
analogues against liver, colon and breast cancer cell lines resulted with a high 
number of promising small molecules with anti-cancer activities. The percent 
cytotoxicity charts were used to calculate the IC50 values; but for some of the 
analogues (AUM 54, AUM53 and AUM168) the dose-response curves were 
extrapolating the IC50 value to a false negative region due to the high cytotoxicity 
percentages obtained with lower concentrations of the small molecules 
(Supplementary Figure 4). In other words, the IC50 values were “not applicable” 
which means that the starting concentration of the serial dilution should be 
deceased (Supplementary Table 3). 
 
Among the 155 newly synthesized purine derivatives, the small molecules, 
with IC50 values less than 20M against at least one of the cancer cell lines, were 
further analyzed for their anti-cancer activity against a HCC panel consisting of 
Huh7, HepG2, Mahlavu and FOCUS cancer cell lines (Table 4.6). The cancer 
cells inoculated into 96-well plates were treated with the promising purine 
derivatives and their DMSO controls in triplicates within five different 
concentrations. The cell death percentages and the IC50 values, calculated 
accordingly, exhibit the cytotoxic potential of these small molecules 
(Supplementary Tables 6-8, Supplementary Figures 6-8). Different from the initial 
screening conditions, the starting concentration for each small molecule was 
determined independently. Although 5 different serially diluted concentrations 
were applied for each novel small molecule, varying starting concentrations, 
chosen according to the first screening data obtained, were applied. Therefore the 
IC50 values were calculated by interpolating these 5 concentrations. For the 
compounds in PART 3, the calculated IC50 values of 37 analogues were lower 
than 10M for all four liver cancer cell lines and 14 small molecules were lower 
than 10M for all but Mahlavu cancer cells. Interestingly the 33 analogues out of 
37 are 6-(substituted piperazine) -9-(substituted benzyl) purine derivatives (Table 
4.6).  
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Table 4.6: Substituted purine and purine nucleoside analogues 
 
6-(substituted piperazine) -
9-(substituted phenyl) 
sulfonyl purine derivatives  
 
6-(substituted piperazine) -
9-(substituted benzyl) 
purine derivatives  
 
6-(4-substituted phenyl) - 
9-(4-substituted phenyl) 
sulfonyl purine derivatives  
 
2-amino/2-chloro/  
6-(4-substituted 
piperazine) /  
6-(4-substituted phenyl 
amino) /  
6-(2-substituted 
ethylamino) –  
9-(β-D-ribofuranosyl) 
purine derivatives  
 
   
 
# of small-molecules 59 64 16 16 
# of bioactive  molecules 
IC50 < 20M  
32 56 6 8 
# of bioactive  molecules 
IC50 < 10M 
12 39 0 1 
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4.1.11 Kinase inhibitory potential of AUM52, AUM53, AUM54, AUM56 and 
AUM57 
 
The newly synthesized small molecules, AUM52, AUM53, AUM54, AUM56 
and AUM57 are structurally very similar even among the members of the subgroup 
they belong. Moreover, their IC50 values are below 5µM. In order to evaluate their 
protein kinase inhibition potential we performed the kinase assay based on the 
detection of the amount of ATP in the reaction mixture through bioluminescence, 
previously explained in Figure 4.4  with Huh7 and Mahlavu cells (Figure 4.15). The 
liver cancer cells were incubated with these putative kinase inhibitors and 
staurosporine (STS), a multi-kinase inhibitor (used as a positive control) for 72 
hours. AUM54 and AUM57 inhibit the ATP consumption only in Huh7 cells while 
the other purine analogues were able to block the utilization of ATP in both Huh7 
and Mahlavu cell lines. AUM56 is the small molecule with the highest kinase 
inhibitory potential in this group (Figure 4.15).      
 
 
Figure 4.15: Kinase inhibitory activity of AUM52, AUM53, AUM54, AUM56 
and AUM57: The relative light units measured after the kinase assay performed in 
duplicate for the Huh7 and Mahlavu cells treated with the purine derivatives at their 
given IC100 values. STS; staurosporine (0.25µM) was used as positive control.  
Kinase GLO
®
 assay kit was used to test the ATP content of 25g protein containing 
cell lysates.   
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PART 2 
 
4.2 Novel aminotriazole and thiadiazine derivatives 
 
4.2.1 Anti-cancer drug screening of novel  4-amino-3-substituted-1,2,4-triazole-
5-thiones and 3,6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazines: 
 
Novel aminotriazole and thiadiazine derivatives, coded as HUBT, were 
received in solid form. Following the preparation of their stock solutions in DMSO, 
each and every compound was initially screened against three different cancer cell 
types. Colon cancer cells (HCT116), breast cancer cells (T47D) and liver cancer 
cells (Huh7) were chosen to evaluate the cytotoxic potential of these small 
molecules via Sulforhodamine B (SRB) assay as described in the chapter of 
Materials and Methods (page 45). The half-maximal inhibitory concentration 
(IC50) values of these molecules were given in Supplementary Table 9. The IC50 
values were calculated according to the dose-response curves obtained from the 
percent cell-death charts given in Supplementary Figure 9. Among the 32 newly 
synthesized small molecules, FAT-TM, ClAT-TM and n-AT-TM performed 
promising cytotoxic activities within M concentrations against Huh7 (HCC), 
HCT116 (colon) and T47D (breast) cancer cell lines. These three 1,2,4-triazolo[3,4-
b]-1,3,4-thiadiazine derivatives were further tested for their anti-cancer activities on 
a HCC panel composed of Huh7, HepG2, Hep3B, PLC, SK-Hep1, Mahlavu, 
FOCUS, Snu182, Snu475 cancer cell lines. The cancer cells inoculated into 96-well 
plates were treated with FAT-TM, ClAT-TM, n-AT-TM and their DMSO controls 
in quadruplicate within at least 5 different concentrations for 72 hours. The 
cytotoxicity percentages demonstrate the bioactivity of these 3 small molecules, 
FAT-TM, ClAT-TM, n-AT-TM, against liver cancer cells (Supplementary Figure 
10). ClAT-TM displays a promising cytotoxic profile against liver cancer cells. 
After 72 hour incubation, 1M ClAT-TM cause more than 50% cytotoxicity in all 
HCC cells. 
 
Afterwards, in order to inspect the time-dependent cytotoxic activities of 
these 3 small molecules, the same HCC panel was used. FAT-TM, ClAT-TM, n-
AT-TM and their DMSO controls were applied to these liver cancer cells in 
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triplicate within 5 different concentrations for 24 and 48 hours (Supplementary 
Figure 11). The cytotoxicity percentages for all time points were used to calculate 
the time-dependent, cell-line-specific IC50 values of FAT-TM, ClAT-TM and n-
AT-TM (Table 4.7). Comparing to the other derivatives, n-AT-TM and FAT-TM, 
the Cl- substituted small molecule, ClAT-TM has a very promising cytotoxicity 
profile with the lowest IC50 values of its group (Table 4.7). 
 
Table 4.7: IC50 values of FAT-TM, ClAT-TMN and n-AT-TM against HCC 
cell lines panel:  Each molecule was tested in triplicate/quadruplicate.  The IC50 
values are in M range and NI stands for “no inhibition”. 
  IC50 (M) 
  FAT-TM ClAT-TM n-AT-TM 
Huh7 
24h 33.918.4 < 0.1 4.41.0 
48h 10.66.0 < 0.1 1.60.02 
72h 16.51.1 0.30.02 8.60.5 
HepG2 
24h NI 0.50.4 10.03.75 
48h 14.08.8 < 0.1 3.61.0 
72h 7.82.2 0.20.06 5.60.7 
Hep3B 
24h 14.77.2 1.21.1 24.916.2 
48h NI 0.10.04 13.75.5 
72h 30.63.6 0.80.04 14.82.0 
PLC 
24h NI 2.10.6 NI 
48h NI 0.30.1 NI 
72h 46.68.0 1.70.13 24.24.1 
SK-Hep1 
24h NI 5.33.31 NI 
48h NI 0.10.02 42.917.4 
72h NI 6.11.4 24.63.5 
Mahlavu 
24h 27.60.4 < 0.1 35.811.8 
48h NI < 0.1 20.73.1 
72h NI 1.00.05 21.42.4 
FOCUS 
24h NI 0.40.7 33.939.9 
48h 33.26.7 < 0.1 12.85.2 
72h 41.73.3 0.60.04 13.70.4 
Snu182 
24h NI 2.31.2 NI 
48h NI < 0.1 NI 
72h 18.29.7 1.10.43 12.43.9 
Snu475 
24h NI 0.50.2 NI 
48h NI < 0.1 15.51.0 
72h 26.64.8 0.50.1 15.13.2 
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Figure 4.16: The time- and dose- dependent cytotoxicity of ClAT-TM on Huh7, HepG2, Mahlavu, FOCUS,  Snu475 and Snu387: Liver 
cancer cells were inoculated in 96-well plates and then, 6 different concentrations of ClAT-TM and their DMSO controls were administered to 
the cells in triplicates for 24, 48 and 72 hours. Following the SRB assay, the cytotoxicity percentages were calculated in comparison to DMSO-
only treated wells.  
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Table 4.8: IC50 values of ClAT-TM against liver cancer cells: were calculated 
from the cytotoxicity percentages (Figure 4.16) obtained with 6 different 
concentrations of ClAT-TM incubated for 24, 48 and 72 hours. The IC50 values 
are in M range.  
  IC50 (M) 
Huh7 
24h 0.7 ± 0.2 
48h 0.2 ± 0.1 
72h 0.2 ± 0.0 
HepG2 
24h 1.9 ± 0.8 
48h 1.1 ± 0.2 
72h 1.3 ± 0.3 
Mahlavu 
24h 1.3 ± 0.3 
48h 1.2 ± 0.1 
72h 1.3 ± 0.2 
FOCUS 
24h 0.8 ± 0.1 
48h 0.5 ± 0.1 
72h 0.4 ± 0.0 
Snu475 
24h 2.1 ± 0.2 
48h 1.6 ± 0.2 
72h 1.7 ± 0.2 
Snu387 
24h 4.7 ± 1.0 
48h 1.3 ± 0.2 
72h 2.5 ± 0.4 
 
 
4.2.2 The kinase inhibitory potential of ClAT-TM  
 
Protein kinases, as being responsible for the phosphorylation of various 
proteins, play one of the major roles in cell signaling networks. Through 
chemically adding phosphate groups to proteins, they manage many cellular 
processes such as cell growth, proliferation, division, differentiation and apoptosis. 
It is known that, synthetic 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine derivative CIAT-
TM was designed as a putative protein kinase inhibitor. The differential IC50 
values it has against HCC panel might be a consequence of its interference with 
cell signaling, since these cell lines have individual characteristics of cell signaling 
activities. Taking all these into consideration, we performed a kinase assay, based 
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on the detection of  the amount of ATP in the reaction mixture through 
bioluminescence (Figure 4.4), to assess the protein kinase inhibitory potential of 
ClAT-TM. The liver cancer cells were incubated with ClAT-TM at the calculated 
cell-line-specific IC50 and IC100 values, staurosporine (STS) and 
aminopurvalanol-A for 24 hours (Figure 4.17). STS is a potent, unselective, multi-
kinase inhibitor which stimulates both caspase dependent and independent 
apoptosis while aminopurvalanol-A, a purvalanol derivative, reversibly inhibits 
cyclin dependent kinases, causes cell cycle arrest in G2/M phase but does not 
induce massive apoptosis. These two commercially available protein kinase 
inhibitors were chosen as positive controls because of their distinctive kinase 
inhibitory potentials. The results we obtained suggests that ClAT-TM might be a 
putative protein kinase inhibitor acting on liver cancer cells. 
 
 
Figure 4.17: Kinase inhibitory potential of ClAT-TM against HCC cell lines: 
The relative light units were measured after the kinase assay performed in 
duplicate for the Huh7, HepG2, Hep3B, Mahlavu and FOCUS cells treated with 
ClAT-TM at their calculated IC50 and IC100 values.  STS; staurosporine (1µM) 
and aminopurvalanol-A (2.5µM) were used as positive controls for Huh7 and 
Mahlavu cells respectively. Lonza PKLight
TM
 assay kit was used to test the ATP 
content of 10g protein containing cell lysates.    
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4.2.3 Real-time cell growth analysis in the presence of ClAT-TM 
 
To figure out the real-time cytotoxic effect of ClAT-TM on a panel of  liver 
cancer cells, we used the label-free, real-time cell electronic sensing (RT-CES) 
system which utilizes an impedance read-out to quantify the cell growth. Dynamic 
monitoring of the logarithmic growth of these cells that correlates with cell index 
(CI), requires these cell lines to be adherent. Cell growth and proliferation directly 
correlate with the strength of cell attachment. Huh7, HepG2, Mahlavu, Focus, 
Snu475 and Snu387 cancer cells were inoculated into these E-Plate 96 and the  
data recorded demonstrates that ClAT-TM clearly suppresses the cell growth 
index values in a dose- and cell-line-  dependent manner (Figure 4.18).  
 
A) 
 
 
 
B) 
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Figure 4.18: Dynamic monitoring of ClAT-TM treated liver cancer cells: 
ClAT-TM and  its DMSO control were administered to Huh7 (A), HepG2 (B), 
Mahlavu (C), FOCUS (D), Snu475 (E) and Snu387 (F) cells, inoculated in E-Plate 
96, in triplicates. The cell growth index was monitored every 30 minutes in the 
presence of different concentrations of ClAT-TM. 
 
 
4.2.4 ClAT-TM induces G2/M cell-cycle arrest 
 
All the preliminary and further analysis results confirm that ClAT-TM 
triggers cytotoxicity in a dose- and time- dependent manner. In order to enlighten 
the triggered mechanism beneath this cell death, we checked the distribution of 
the cells in cell-cycle stages in the presence of ClAT-TM. Hence, we used 
propidium iodide (PI), a DNA-intercalating, fluorescent agent, commonly used to 
identify the cell-cycle distribution patterns of a cell suspension. PI labeling of the 
nuclei of cells in suspension allows correlating the fluorescence intensity with the 
cell-cycle stages. While quiescent (G0) and G1 cells have one copy of DNA, 
G2/M cells double their DNA. The cells in S phase have varying numbers of 
DNA since they synthesize DNA in the meantime. Cell-cycle analysis of ClAT-
TM treated HCC cells demonstrated that this novel, putative kinase inhibitor 
induces time- (data not shown) and dose- dependent G2/M arrest (Figure 4.19). 
Flow cytometric determination of DNA content for each condition was analyzed 
and the percentages of cells in each cell cycle stage were given as an overall chart 
(Figure 4.19-G). 
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Figure 4.19: Cell-cycle analysis of ClAT-TM treated HCC cells: Huh7 (A), 
HepG2 (B), Mahlavu (C), FOCUS (D), Snu475 (E) and Snu387 (F) cancer cells 
were treated with IC50 and IC100 values of ClAT-TM and their DMSO controls 
for 24 hours. Next, fixed cells were stained with propidium iodide (PI) prior to 
flow cytometry analysis. M1, M2, M3 and M4 stands for G1, S, G2/M and sub-
G1 (apoptotic cells) respectively. The peaks at 200 and 400 FL2-A signifies 2N 
cells (G1) and 4N cells (G2) respectively.  Percentage of cells in cell-cycle stage 
was analyzed by CELLQuest and given as an overall chart (G). Cell-line special 
colors Huh7 (red), HepG2 (cyan), Mahlavu (purple), FOCUS (green), Snu475 
(blue) and Snu387 (pink) are representing G2/M stage, while G1 (dark gray), S 
(light gray), sub-G1 (black) are shown in same colors for all cell lines. The images 
were taken with 20x objective.   
 
ClAT- TM induced cytotoxicity also changed the morphology of the cancer 
cells obviously. Rounded, swollen and eventually detached cells were 
accumulated. (Figure 4.20). The cell morphology in the presence of ClAT-TM is 
distinctive when compared to DMSO treated cells. It is clear that upon the 
application of ClAT-TM, cell proliferation ceases and depending on the dose and  
incubation time blebbing cells and apoptotic bodies appear. The morphology of 
the ClAT-TM treated liver cancer cells is correlative with the G2/M arrest they 
experience upon treatment (Figure 4.19 and 4.20).  
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Figure 4.20 : Morphological effect of ClAT-TM on liver cancer cell lines :  Cancer cell lines were incubated with DMSO and ClAT-TM at its  
IC50 and IC100 values of  the corresponding cell line for 24 hours. The images were taken with both 10x (A) and 20x (B) objectives.   
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4.2.5 ClAT-TM induces apoptosis 
 
In addition to the dramatic changes in the morphology of ClAT-TM treated cells, we 
performed a western blot analysis to verify the ClAT-TM induced apoptosis in the protein 
level. Unlike the drug treatments done so far, this time we incubated the cells with 2.5M 
ClAT-TM (not with cell-line-specific IC50/IC100 values of) for 24 hours. The activated-
apoptotic pathway indicator, cleaved Poly-ADP-ribosyl-polymerase (PARP) fragments, were 
detectable in most of the HCC cells treated with ClAT-TM (Figure 4.21).  
 
 
 
 
Figure 4.21 : Western blot analysis of ClAT-TM treated HCC cells for cleaved PARP:  
All HCC cell lines were treated  with 2.5M ClAT-TM, its corresponding DMSO and left un-
treated for 24 hours. Cleaved PARP’s expression levels were detected. Calnexin protein was 
used as an equal loading control. 
 
 
Although PARP cleavage was detectable in ClAT-TM treated liver cancer cells, ClAT-
TM did not induce sub-G1 accumulation, which is characteristic for the “typical” apoptosis 
pattern (Figure 4.19 and 4.21). “Atypical” apoptosis pattern has been reported to occur in 
cells treated with acetylsalicylate or aspirin like non-steroidal anti-inflammatory drugs 
(NSAID) (Shiff SJ et al., 1995; Smith ML et al., 2000; Reinacher-Schick A et al., 2003). It 
was previously demonstrated that, synthetic 1,2,4-triazolo[3,4-b]-1,3,4-thiadiazine derivative 
CIAT-TM is a NSAID with analgesic and anti-inflammatory activities (Tozkoparan B et al., 
2009). 
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4.2.6 Not the endoplasmic reticulum (ER), but the oxidative stress is the underlying 
mechanism of ClAT-TM induced cell death 
 
ER-stress and the accumulation of reactive oxygen species (ROS) are the most typical 
underlying mechanisms triggering cells to G2/M arrest and eventually to apoptosis 
(Bouruugaa K et al, 2010; Wu SH et al, 2010; Macip S et al, 2006). One of the alternative 
methods to detect ER-stress is to trace the XBP-1 splicing via semi-quantitative PCR (Samali 
A et al., 2010). Huh7 cells were treated with ClAT-TM at its IC50 and IC100 values, DMSO 
and 500ng/mL tunicamycin (TN) as positive control for 24 hours. Tunicamycin was used as 
positive control at ER stress-inducing dose (Ilieva EV et al., 2007). Although spliced XBP-1 
mRNA could be detected with TN treated cells, ClAT-TM did not induce ER-stress-specific 
XBP-1 splicing (Figure 4.22). 
 
Figure 4.22 : Endoplasmic reticulum (ER) stress detection assay with ClAT-TM 
treated Huh7 cells: Huh7 cells untreated and treated with ClAT-TM at its IC50 and IC100 
values, the corresponding DMSO, and the positive control tunicamycin (TN) were checked 
for splicing variants of XBP-1 as an indicator of ER stress. 
 
 
ROS, the major players of oxidative stress, is known to induce G2/M arrest and 
apoptosis (Lee et al, 2009). We aimed to detect the accumulation of ROS, if the triggered 
mechanism upon ClAT-TM treatment is oxidative stress. Huh7 and Mahlavu liver cancer 
cells were treated with the IC50 and IC100 values of ClAT-TM and DMSO for 8, 12 and 24 
hours. At the termination of each incubation period, oxidant-sensitive, non-fluorescent dye 
DCFH-DA was administered to the cells. Oxidation of DCFH-DA to DCF, which gives green 
fluorescent signals, visualizes oxidative stress (Figure 4.23). 
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Figure 4.23: ROS assay images of ClAT-TM treated liver cancer cells :  Both Huh7 (A) 
and Mahlavu (B) HCC cells  ClAT-TM (IC50 and IC100) and  corresponding DMSO for 8, 
12 and 24 hours. Microscopic images were taken with 20x objectives following DCFH-DA 
staining.  
 
 
4.2.7 ClAT-TM induces the phosphorylation of c-Jun N-terminal kinase 
 
Accumulation of ROS has long been correlated with permanent c-Jun N-terminal kinase 
(JNK) activation (Zhang Y and Chen F, 2004). Moreover it is reported that JNK activation is 
vital for the induction of G2/M arrest (Cho SD et al, 2009 ; Yamamoto K et al, 1999). To find 
out the influence of ClAT-TM on JNK activation we checked the phosphorylated-JNK (P-
JNK) protein levels by means of western blotting. Huh7, HepG2, Mahlavu and FOCUS liver 
cancer cells were treated with IC100 values of ClAT-TM, JNKInhV at its cell-line-specific 
IC50 values (Huh7: 2M, HepG2: 2M, Mahlavu: 5M, FOCUS: 0.5M) and corresponding 
DMSO for 24 hours. ClAT-TM increased the phosphorylated-JNK protein levels in both cell-
line- and JNK isoform- dependent manner  (Figure 4.24). 
 
 
 
Figure 4.24: Effect of ClAT-TM on the expression and activation of c-Jun N-terminal 
kinase:  Huh7, HepG2, Mahlavu and FOCUS cells were treated with ClAT-TM (with IC100 
values), JNKInhV (with cell line specific IC50) and corresponding  DMSO for 24 hours. 
Calnexin was used as equal loading control.  
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Activated JNK1 and JNK2 isoforms translocate to the nucleus and there phosphorylate 
transcription factor c-Jun. Therefore, we verified the ClAT-TM induced JNK activation by 
evaluating the phosphorylated-c-Jun (P-c-Jun) protein levels. We treated Huh7, HepG2, 
Mahlavu, FOCUS, Snu475 and Snu387 cells, with 2.5µM ClAT-TM and  corresponding  
DMSO for 24 hours. The western blotting analysis performed subsequently clearly  
demonstrated the ClAT-TM induced phosphorylation of c-Jun (Figure 4.25). 
 
 
 
 
Figure 4.25: The phosphorylated-c-Jun protein levels upon ClAT-TM treatment:  Huh7, 
HepG2, Mahlavu, FOCUS, Snu475 and Snu387 cells were treated with ClAT-TM (2.5µM), 
corresponding  DMSO and left  un-treated for 24 hours. Calnexin was used as equal loading 
control. 
 
 
4.2.8 The upstream components of JNK signaling pathway in the presence of ClAT-TM  
 
To further investigate how JNK signaling is activated, we checked the upstream 
components of JNK pathway. It has been reported that JNKs are phosphorylated at their Thr 
and Tyr residues which are conserved in a dual phosphorylation Thr-Pro-Tyr motif of their 
activation loop (Kallunki T et al., 1996). MAP2Ks, in other words MKK4 and MKK7, are the 
activators of JNKs (Figure 1.18). TNF mostly stimulate MKK7 which phosphorylates only 
JNKs; whereas, other environmental stress factors activate MKK4 which in turn 
phosphorylates both JNKs and p38 (Min L et al., 2010; Haeusgen W et al., 2011). To find out 
the activator of JNK in the presence of ClAT-TM, we checked both the phosphorylated-
MKK7 (P-MKK7) and phosphorylated-MKK4 (P-MKK4) protein levels by means of western 
blotting. Huh7, HepG2, Mahlavu and FOCUS liver cancer cells were treated with cell-line-
specific IC50 and IC100 values of ClAT-TM and corresponding DMSO for 24 hours. ClAT-
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TM increased the P-MKK7 protein levels in a cell-line-dependent manner; despite, no 
difference was observed in the P-MKK4 protein levels (Figure 4.26).  
 
 
 
Figure 4.26: The protein levels of phosphorylated-MKK7, phosphorylated-MKK4 and 
phosphorylated-ASK1(S83)) upon ClAT-TM treatment:  Huh7, HepG2, Mahlavu and 
FOCUS cells were treated with ClAT-TM (with IC50 and IC100 values) and corresponding  
DMSO for 24 hours. Calnexin was used as equal loading control.  
 
 
One of the MAP3Ks, ASK1, might be the upstream activator of MKK7 which has been 
confirmed as the activator of JNK upon ClAT-TM treatment. ASK1 is composed of an 
internal kinase domain, a regulatory domain and an inhibitory domain with three separate 
phosphorylation sites. Thus, pro-survival factors intend to keep ASK1 in an inactive status 
while pro-apoptotic ones do the opposite. In order to activate ASK1, phosphorylation at 
Thr845 is required, whereas phosphorylation at either Ser967 or Ser83 maintains ASK1 
inactive (Zhang R et al., 2005). We checked the protein levels of phosphorylated-ASK1 at 
Ser83 (P-ASK1 at S83) through western blotting. Huh7, HepG2, Mahlavu and FOCUS liver 
cancer cells were treated with cell-line-specific IC50 and IC100 values of ClAT-TM and 
corresponding DMSO for 24 hours. ClAT-TM decreased the protein levels of P- ASK1 at S83 
in a cell-line-dependent manner (Figure 4.26).  
110 
 
Furthermore, it has been demonstrated that Akt phosphorylates ASK1 at Ser83 in order 
to negatively regulate apoptosis (Kim AH et al., 2001). With respect to this data, we 
hypothesized that ClAT-TM might have inhibitory effect on Akt which in turn prevent the 
phosphorylation of ASK1 atSer83. Hence, we checked the protein levels of phosphorylated-
Akt (P-Akt) at Ser473 through western blotting. Huh7, HepG2, Mahlavu and FOCUS liver 
cancer cells were treated with cell-line-specific IC50 and IC100 values of ClAT-TM and 
corresponding DMSO for 24 hours. Indeed, ClAT-TM decreased the levels of P-Akt (Figure 
4.27). Hyperactivation of Akt in Mahlavu cancer cells has been associated with PTEN loss 
(Buontempo F et al., 2010). Therefore, in order to catch the cell line-dependent differences in 
the P-Akt levels, different exposure times were presented collectively.   
 
 
 
 
Figure 4.27: The phosphorylated-Akt (P-Akt) (Ser473) protein levels upon ClAT-TM 
treatment:  Huh7, HepG2, Mahlavu and FOCUS cells were treated with ClAT-TM (with 
IC50 and IC100 values) and corresponding  DMSO for 24 hours. Calnexin was used as equal 
loading control.  
 
 
4.2.9 KINOMEscan
TM
 Profiling of  ClAT-TM  
 
The experiments have done so far demonstrated that ClAT-TM is  involved in the JNK 
signaling pathway. To further clarify any existing direct interaction of ClAT-TM with the 
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human kinome, we preferred KINOMEscan
TM
 Profiling which is a highthroughput (HTP) 
approach based on active site-directed competition binding of the sample to be tested and the 
selected list of human kinases. The primary or secondary activators of JNK signaling pathway 
constituted our list of selected possible protein kinases. The screen report from 
KINOMEscan
TM
 Profiling Service found only inefficient interaction between ClAT-TM and 
the protein kinase candidates in our list (Figure 4.28). With respect to this report, ClAT-TM-
interacting protein kinase should be further searched in an extended list of kinases or the 
ClAT-TM interacting proteins other than the kinases, might be investigated for their  
involvement in the JNK signaling pathway. 
 
4.2.10 in vivo anti-tumor activity of ClAT-TM in Mahlavu xenografts 
 
The in vivo anti-tumor effects of ClAT-TM were tested on Mahlavu xenografts in nude 
(immunodeficient) mice. Considering the results of previously done in vitro experiments, we 
chose Mahlavu cell line not only due to its significant response to ClAT-TM, but also because 
it is known as one of the poorly-differentiated; highly metastatic HCC cell lines. Following 
the SC injection of Mahlavu cells, the nude mice were monitorized until the tumors reach 
150mm
3
 volume. From that time on, ClAT-TM, suspended in simple syrup (100mg/kg), was 
given orally (as described in Materials and Methods-2.4.11) to nude mice. Drug treatments 
were twice a week for 3 weeks and for the following 3 weeks nude mice were un-treated. At 
the end of 3 rounds of chemotherapy, the nude mice (both drug and control groups) were 
taken to magnetic resonance imaging (MRI). The recorded tumor sizes and the MRI data were 
given in Figure 4.29.  
 
ClAT-TM was able to increase the overall survival of nude mice; moreover, the longest 
dimension of tumors in un-treated nude mice (#2 and #4 in Figure 4.29) was almost twice of 
the ClAT-TM treated nude mice (#1 and #3 in Figure 4.29). Besides, tumor volumes were 
dramatically decreased if the nude mice are in the ClAT-TM treated group. Collectively, our 
in vivo findings demonstrate that ClAT-TM is a novel, potent drug candidate against liver 
cancer which is also orally tolerable in nude mice. 
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Figure 4.28: TREEspot
TM
 Kinase Interaction Mapping for ClAT-TM  
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Figure 4.29: in vivo anti-tumor activity of ClAT-TM in Mahlavu xenografts: A) Mahlavu 
xenografted nude mice were treated with (100mg/kg) ClAT-TM suspended in simple syrup or 
simple syrup-only twice a week and the tumor sizes were recorded accordingly. B) The MRI 
images were taken at the 181
st
 day for #1, 60
th
 day for #2, 135
th
 day for #3 and 105
th
 day for 
#4. (#1 and #3 are ClAT-TM treated; #2 and #4 are controls)   
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CHAPTER 5. DISCUSSION 
 
 
The process of developing novel molecular-targeted therapeutic agents, 
from gene to drug, requires cooperation between chemical biology and structural 
biology both using the small molecules. The small-molecules we obtained from 
our collaborators were either nucleobase and nucleoside analogues (from Prof. Dr. 
Meral Tunçbilek, Ankara University) or triazole and thiadiazine derivatives (from 
Prof. Dr. Birsen Tozkoparan, Hacettepe University). 
 
Nucleobase and nucleoside analogues are structurally, metabolically and 
pharmacodynamically similar drugs and all aim to destroy the integrity of DNA; 
but, they show diverse biological activities (Sampath D et al., 2003). Nucleobase 
analogue, 5-fluorouracil is the first antimetabolite chemotherapeutic agent on 
cancer cells (Kuhn JG, 2001). Later, pyrimidine analogues such as 
arabinofuranosyl cytidine (Ara-C) and gemcitabine were investigated in cancer 
treatments (Sampath D et al., 2003). Purine nucleoside analogues such as 
cladribine, fludarabine and pentostatin are the currently used group of 
antimetabolites against hematological malignancies (Lech-Maranda E et al., 
2006). 
 
 Nucleobase and nucleoside analogues, analyzed in this thesis can be 
classified into three sub-groups: adenine and purine derivatives, purine 
ribonucleoside derivatives and substituted purine and purine nucleoside 
derivatives were tested for their bioactivities initially on human breast, colon and 
liver cancer lines; the calculated IC50 values were used to select the promising 
ones. Eventually, the selected small molecules through the initial screening were 
further analyzed for their anti-cancer activities against a panel of HCC cell lines. 
Among the newly synthesized 196 nucleobase and nucleoside analogues AUM18, 
AUM23, AUM32, AUM42 and AUM43 were the selected ones with IC50 values 
less than 10M.  
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The cell-line-dependent differences between the cytotoxicities of these 
selected novel nucleoside analogues, might be indicating that they are small 
molecule putative kinase inhibitors and interfering with cell signaling pathways. 
Therefore, their kinase inhibition potentials were assessed. Among them, AUM42 
and AUM56 were the analogues with kinase inhibition potentials comparable to 
the positive controls used in the assays. 
 
In spite of the nuclear condensation and DNA fragmentation observed in the 
presence of AUM18, AUM23and AUM32 (in Huh7 and FOCUS cells), the 
further data we obtained; namely, no significant decrease in Bcl-2 and Cyt-C 
protein expression levels and the absence of PARP cleavage, prevented us to 
name the underlying mechanism of the cytotoxicity, induced by these small 
molecules, as apoptosis. Moreover, the cytotoxicity analysis demonstrated that the 
long term (72 hour) drug response of liver cancer cells is considerably more 
effective comparing to short term (24 hour) drug response. Our results indicated 
that AUM32 induces senescence-associated cytotoxicity; in other words, AUM32 
treatment causes cancer cells to stop proliferation and initiates senescence in a 
dose- and time- dependent manner, which has been considered as a therapeutic 
target of small molecule inhibitors recently (Nardella C et al., 2011). The similar 
mechanism of action was also verified for AUM42 nucleoside analogue.  
 
Cellular senescence is accompanied by the activation of the cyclin-
dependent kinase inhibitors.  The INK4b-ARF-INK4a locus, which is also known 
as senescence promoting locus, has an extraordinary gene structure encoding both 
INK4 family of cyclin-dependent kinase inhibitors, p15(INK4b) and p16(INK4a) 
and a completely unrelated protein, ARF (Gil J and Peters G., 2006). When 
overexpressed, p15 (INK4b), which is a closely related protein to p16 (INK4a), 
engages the Rb pathway in order to promote a permanent senescent state which 
involves the stable silencing of E2F target genes (Serrano M et al., 1997; Erickson 
S et al., 1998; Kuilman T et al., 2010)  .  
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Additionally, p15 (INK4b) levels as another senescence-associated marker, 
which is known to be increased in senescent cells, were also shown to be 
increased in AUM42 treated liver cancer cells. Moreover, the associated decrease 
in the phosphorylated form of Rb protein was correlative with the AUM42-
induced accumulation of p15 (INK4b). In AUM42 treated Huh7 cells, we could 
not observe a significant change in the p21 protein expression levels; therefore, 
we did not involve p21 to the action mechanism of AUM42. Ultimately, we were 
able to identify the small molecule, purine ribonucleoside analogue, AUM42, 
acting on liver cancer cells with an unraveled mechanism of action (Figure 5.1). 
 
Nucleoside analogs block nucleotide mechanism by incorporating into DNA 
and by inhibiting ribonucleotide reductase (RR). Inhibition of the enzyme RR 
leads to a decrease in dNTP pools which ends in impaired DNA synthesis (Wilson 
P et al., 2004). Therefore, the most commonly observed cell death induced by 
nucleoside analogues is apoptosis (Sampath D et al., 2003). However, significant 
decrease in the RR levels and changes in the dNTP pools have been reported for 
the senescence in diploid fibroblasts (Dick J and Wright J, 1985; Nakamura J et 
al., 2010). Therefore, nucleoside analogues may induce senescence; such as 
toyocamycin and decitabine (Kurihara Y et al., 2002; Amatori S et al., 2011).  
 
Besides the reported nucleoside analogs, which were known to induce 
senescence, AUM32 and AUM42 are the two newly synthesized, small molecules, 
both containing a 4-substituted piperazine in the substituent at N
6
, were shown to 
induce senescence-associated cytotoxicity against liver cancer cells. Moreover, 
the activation of the Rb protein by AUM42-induced p15 (INK4b) overexpression 
also confirmed the mechanism of action we identified for this novel purine 
ribonucleoside analogue. Senescence is an effective barrier to tumor development 
which recently started to be considered as a promising approach for cancer 
therapy (Ewald JA et al., 2010).  Recent findings disclose that cancer cells can 
also undergo senescence. Thus, inducing senescence in tumors; namely, pro-
senescence therapy is a new strategy in the fight against cancer (Nardella C et al., 
2011). Senescence, the irreversible arrest of proliferation, can prevent 
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immortalization; thus senescence-inducing drugs emerge rapidly (Cairney CJ et 
al., 2012). 
 
 
Figure 5.1. Novel purine ribonucleoside analogue, AUM42, leads to 
senescence-induced cell death in liver cancer cells (Tuncbilek M et al., 2012). 
 
 
Aminotriazole and thiadiazine derivatives, composing the second group of 
small molecules (also analyzed in this thesis), were initially screened against 
human breast, colon and liver cancer cell lines and then, the calculated IC50 
values were used to select the promising ones. Among this group of compounds, 
three small molecules (FAT-TM, ClAT-TMN and n-AT-TM) were further 
analyzed for their anti-cancer activities against a panel of HCC cell lines. Time 
dependent IC50 values calculated for ClAT-TM demonstrated that this small 
molecule was able to create a cytotoxic response even in 24 hours within 
micromolar concentrations.  
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It was previously demonstrated that, synthetic 1,2,4-triazolo[3,4-b]-1,3,4-
thiadiazine derivative, CIAT-TM was designed as a putative protein kinase 
inhibitor with analgesic and anti-inflammatory activities (Tozkoparan B et al., 
2009). Besides, it has differential IC50 values against HCC panel, which might be 
a consequence of its interference with cell signaling. Thus, we performed a kinase 
assay to assess the protein kinase inhibitory potential of ClAT-TM. It revealed a 
cell line-specific profile; moreover, except HepG2, a dose-dependent protein 
kinase inhibitory potential in all cell lines.  
  
ClAT-TM induced-cytotoxicity changed the morphology of the cancer cells 
dramatically. It is clear that upon the administration of ClAT-TM, cell 
proliferation stopped and depending on the dose and incubation time, first, 
rounded, swollen and eventually detached cells were accumulated and next, 
blebbing cells and apoptotic bodies were appeared.  
 
In addition to the distinctive changes in the morphology of ClAT-TM 
treated cells, we performed a western blot analysis to verify the ClAT-TM 
induced apoptosis in the protein level. In spite of the detectable cleaved PARP in 
ClAT-TM treated liver cancer cells, ClAT-TM did not induce sub-G1 
accumulation, a well-known indicator of “typical” apoptosis, during cell cycle 
analysis. “Atypical” apoptosis, lacking the characteristic features of apoptosis, 
such as an increase in the sub-G1 fraction, has been reported to occur in cells 
treated with acetylsalicylate or aspirin like non-steroidal anti-inflammatory drugs 
(NSAID) (Shiff SJ et al., 1995; Smith ML et al., 1999; Reinacher-Schick A et al., 
2003). It was previously demonstrated that, synthetic 1,2,4-triazolo[3,4-b]-1,3,4-
thiadiazine derivative CIAT-TM is a NSAID with analgesic and anti-
inflammatory activities (Tozkoparan B et al., 2009). Therefore, the apparently 
conflicting results we obtained, are actually correlative. 
 
Cell-cycle analysis in the presence of ClAT-TM demonstrated time- and 
dose- dependent G2/M arrest. The most typical triggering mechanisms of G2/M 
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arrest are either ER-stress or the accumulation of reactive oxygen species (ROS) 
(Macip S et al., 2006; Bouruugaa K et al, 2010; Wu SH et al, 2010). After 
eliminating the possibility of ER-stress, we were able to show the ROS 
accumulation upon ClAT-TM treatment. 
 
The cell line specific IC50 values and the kinase assay results indicating the 
kinase inhibition potential of 5Cl-ATTM reinforced the idea that this small-
molecule interferes with cell signaling. Among the signaling pathways involved in 
hepatocarcinogenesis, we analyzed first the stress-activated protein kinase/c-Jun 
NH2-terminal kinase (SAPK/JNK), due to the evident oxidative stress induced by 
ClAT-TM. It is known that prolonged JNK activation depends on the ROS 
generation. ROS induces JNK activation, and JNK induces ROS accumulation 
(Nakano H, 2004). The accumulated ROS prolongs the JNK activation which 
leads cell to apoptosis (Zhang Y and Chen F, 2004).  
 
In fact, phosphorylated-JNK (P-JNK), and in parallel (its downstream 
target) phosphorylated-c-Jun (P-c-Jun) were both shown to be increased. Indeed c-
Jun N-terminal kinase (JNK) activation upon ROS accumulation was shown to be 
vital for the induction of G2/M arrest (Yamamoto K et al., 1999; Zhang Y and 
Chen F, 2004; Cho SD et al., 2009). JNK is regulated by two upstream kinases, 
MAP2Ks (MKK4 and MKK7). We checked the protein expression levels and the 
phosphorylation status of (MKK4/P-MKK4) and (MKK7/P-MKK7) and detected 
a cell line-specific activation of MKK7 after ClAT-TM treatment, while the other 
JNK activator MKK4 was unaltered. 
 
One of the MAP3Ks activating JNK signaling pathway is ASK1 (apoptosis 
signal-regulating kinase 1) and its regulation is highly intricate. ASK1 has three 
phosphorylation sites and among them Ser83 is the inhibitory site. Akt 
phosphorylates ASK1 on Ser83 and promotes cell survival (Kim et al., 2001). It is 
reported that Ser83 of ASK1 becomes dephosphorylated upon cellular stress in 
order to restore ASK1 activity which eventually induces apoptosis (Zhang et al., 
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2005). Indeed, we detected a decrease not only in the levels of P-ASK1 (Ser83) 
but also P-Akt (Ser473) upon ClAT-TM treatment. 
 
In order to identify any existing direct interaction of ClAT-TM with one of 
the mediators of JNK signaling pathway, we screened a large number of proteins 
with KINOMEscan
TM
 Profiling Service. However we could not find any direct 
interaction between ClAT-TM and the “protein kinases” in our list. It has been 
shown that ROS also inhibits MAPK phosphatases in order to promote TNF- 
induced apoptosis associated with prolonged activation of JNK (Kamata H et al., 
2005). Therefore, all these findings indicate that ClAT-TM causes cell death 
through activating JNK pathway by inducing ROS accumulation in these cells. 
(Fig 5.2) 
 
Following the in vitro cytotoxicity experiments, in vivo anti-tumor effects of 
ClAT-TM were tested on Mahlavu xenografts in nude mice. The increased overall 
survival and the decrease in the tumor size upon ClAT-TM treatment clearly 
strengthen our data revealing that ClAT-TM is a novel small molecule acting on 
liver cancer cells. 
 
In this thesis, we found that the novel small-molecule, ClAT-TM sensitized 
the liver cancer cells to growth inhibition in a time- and dose- dependent manner. 
Exposure to ClAT-TM resulted in dramatic morphological changes in HCC cell 
lines and the triggered underlying molecular mechanism forced cancer cells first, 
to G2/M stage cell cycle arrest and finally, to apoptosis. Throughout this period, 
ClAT-TM treatment increased the protein levels of not only phospho-JNK but 
also phospho-c-Jun, a downstream target of JNK pathway.  The accumulated data 
provided a molecular mechanism for ClAT-TM as a chemopreventive agent in 
human HCC cell lines (Figure 5.2). Further investigations are required to identify 
the roles of the other members of the JNK pathway in the ClAT-TM induced 
G2/M arrest and apoptosis.  
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Figure 5.2. The molecular mechanism that ClAT-TM is involved in.   
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CHAPTER 6. FUTURE PERSPECTIVES 
 
 
Drug candidates, nucleobase and nucleoside analogues (AUM series) and 
aminotriazole and thiadiazine derivatives (HUBT series) were designed as 
putative protein kinase inhibitors. The results of this thesis demonstrated that 
AUM32 and AUM42 lead liver cancer cells to senescence-induced cell death; 
while, ClAT-TM is another small-molecule with kinase inhibition potential, able 
to force liver cancer cells initially to G2/M stage cell cycle arrest and eventually 
to apoptosis.  
 
From the first group of putative kinase inhibitors, substituted purine and 
purine nucleoside derivatives (Supplementary Tables 2-5) were evaluated for their 
anti-cancer activity and protein kinase inhibition potentials. Further analysis, in 
order to identify their mechanism of action, is required. The type of cell death 
induced by these groups of small-molecules should be characterized. 
 
Senescence is known to control not only the cell proliferation but also the 
invasion of malignant cells, as a tumor suppressor mechanism (Kraus S et al., 
2011). Therefore, the effect of both AUM32 and AUM42 on cell motility can be 
evaluated by wound healing assay. These two senescence-inducing small-
molecules might be able to prevent migration and invasion.   
 
DNA damage response upon treatment of nucleobase and nucleoside 
analogues can be further investigated. The phosphorylation status of ATM and 
ATR can be checked.  
 
From the other group of molecules, ClAT-TM is a powerful anti-cancer 
agent and its mechanism of action is mostly clarified. ROS accumulation is the 
initiative response of cancer cells in the presence of ClAT-TM. We were able to 
figure out that ClAT-TM both leads to G2/M arrest and ROS accumulation. 
Furthermore, ROS levels can be checked throughout the cell cycle by flow 
cytometry. 
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The phosphorylation status of ASK1 upon ClAT-TM treatment was checked 
only for Ser83. There are two more phosphorylation sites for ASK1: Ser967 and 
Thr845. ASK1 associates with 14-3-3 protein and promotes cell survival when 
gets phosphorylated at Ser 967 (Zhang L et al., 1999). Moreover, oxidative stress 
is known to induce not only the de-phosphorylation of ASK1 at Ser967 but also 
the phosphorylation of ASK1 at Thr845 (Goldman EH et al., 2004). In addition to 
the western blot analysis which have done to check the phosphorylation status of 
ASK1 at Ser83, these two other phosphorylation sites can be further investigated.  
 
In order to identify any existing direct interaction of ClAT-TM with the 
human kinome, an extended list of protein kinases can be used for the report 
request from KINOMEscan
TM
 Profiling Service. The ClAT-TM interacting 
proteins other than the kinases might be investigated for their involvement in the 
JNK signaling pathway. 
 
The results obtained in the in vivo evaluation of the anti-cancer activity of 
ClAT-TM are encouraging. Both, the dose and the application conditions chosen 
are well suited. Nevertheless, it may be worth to increase the number of the nude 
mice. Moreover, after MRI images are taken, the nude mice can be sacrificed and 
the tumor tissue samples, taken from both ClAT-TM treated and un-treated nude 
mice, can be analyzed through immonuhistochemistry.  
 
As another approach to the identification of newly synthesized, promising 
anti-cancer drug candidates, microarray analysis can be envisaged. The ultimate 
aim of this analysis is to focus on the genes that are up- or down- regulated upon 
drug treatment. The related and responsible genes that change expression profile 
would disclose the mechanism of action that the drug candidate is involved in. 
Therefore, the microarray analysis of AUM32, AUM42 and ClAT-TM treated 
liver cancer cells, with comparison to their DMSO controls, would be informative.  
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SUPPLEMENTARY 
 
Supplementary Table 1: IC50 values of AUM purine analogues: All molecules 
were tested in duplicate and incubated for 72 hours. The IC50 values are in M 
range. NI stands for “no inhibition”. 
 
   IC50 (M) 
AUM code R R1 Huh7 HCT116 T47D 
AUM5 NH2 
 
NI NI NI 
AUM6 NH2 
 
NI NI NI 
AUM7 NH2 
 
NI NI NI 
AUM8 NH2 
 
NI NI NI 
AUM12 NH2 
 
NI NI NI 
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AUM13 NH2 
 
NI NI NI 
AUM9 NH2 
 
NI NI NI 
AUM10 NH2 
 
NI NI NI 
AUM11 NH2 
 
NI NI NI 
AUM34 Cl 
 
20.8 22.8 13.9 
AUM26 
 
H NI NI NI 
AUM35 
 
H NI NI NI 
AUM18 
 
H 3.2 5.1 39.4 
126 
 
AUBMC13 
 
H NI NI NI 
AUM31 
 
H NI NI NI 
AUM30 
 
H NI NI NI 
AUM25 
 
H NI 86.6 NI 
AUM16 
 
H 68.3 102.1 NI 
AUM14 
 
H NI NI NI 
AUM15 
 
H NI NI 146.8 
AUM19 
 
H NI 131.6 NI 
AUBMC10 
 
H 14.2 12.9 40.3 
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AUM17 
 
H NI NI NI 
AUM23 
 
 
6.6 4.5 42.7 
AUM37 
 
 
17.8 14.6 22.5 
AUM38 
  
NI NI NI 
AUM22 
  
NI NI NI 
AUM21 
 
 
NI NI 116.4 
AUM28 
  
NI NI NI 
AUM36 
  
9.4 8.7 34.5 
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AUM32 
 
 
< 2.5 < 2.5 < 2.5 
AUBMC30 
  
17.4 16.6 21.0 
AUM39 
 
 
NI NI NI 
AUM20 
  
NI NI 99.9 
AUM33 
  
NI NI NI 
AUM29 
 
 
53.3 72.4 NI 
5-FU   15.6 10.1 7.9 
CPT   < 1 < 1 < 1 
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Supplementary Table 2: IC50 values of 6-(substituted piperazine)-9-
(substituted phenyl) sulfonyl purine analogues: All molecules were tested in 
duplicate and  incubated for 72 hours and the IC50 values are in M range. NI 
stands for “no inhibition”.  
                                             
   IC50 (M) 
AUM 
codes 
R1 R2 Huh7 HCT116 MCF7 
AUM122 2-pyrimidinyl H NI NI NI 
AUM123 Ph H 22.9 54.1 NI 
AUM124 4-CH3-Ph H 11.0 17.7 16.6 
AUM125 4-CF3-Ph H 1.6 2.4 0.8 
AUM126 4-F-Ph H 20.9 22.7 NI 
AUM127 3,4-diCl-Ph H 5.5 3.9 5.5 
AUM128 (Ph)2CH H 94.8 NI NI 
AUM82 2-pyrimidinyl 4-CH3 NI NI 52.9 
AUM48 Ph 4-CH3 NI NI NI 
AUM62 4-CH3-Ph 4-CH3 22.9 41.4 36.9 
AUM50 4-F-Ph 4-CH3 54.3 NI NI 
AUM83 2,4-diF-Ph 4-CH3 16.8 15.0 NI 
AUM137 3,4-diCl-Ph 4-CH3 4.3 4.2 4.1 
AUM51 (Ph)2CH 4-CH3 NI NI NI 
AUM87 C6H11 4-OCH3 NI NI NI 
AUM88 2-pyrimidinyl 4-OCH3 87.4 NI 54.6 
AUM84 Ph 4-OCH3 14.6 14.5 74.5 
AUM89 4-CH3-Ph 4-OCH3 8.4 5.2 75.5 
AUM85 4-CF3-Ph 4-OCH3 <1.0 <0.1 32.7 
AUM63 4-F-Ph 4-OCH3 26.4 12.1 15.6 
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AUM90 2,4-diF-Ph 4-OCH3 12.2 9.7 76.9 
AUM138 3,4-diCl-Ph 4-OCH3 0.2 2.3 2.8 
AUM86 (Ph)2CH 4-OCH3 NI NI NI 
AUM111 C6H11 4-F 77.1 NI 88.6 
AUM112 2-pyrimidinyl 4-F 39.7 NI 34.2 
AUM108 Ph 4-F 12.2 14.6 17.7 
AUM113 4-CH3-Ph 4-F 10.2 11.5 16.0 
AUM110 4-CF3-Ph 4-F 1.7 0.4 9.2 
AUM109 4-F-Ph 4-F 16.5 18.1 40.0 
AUM114 2,4-diF-Ph 4-F 36.4 NI 34.1 
AUM139 3,4-diCl-Ph 4-F 3.1 4.7 6.0 
AUM107 (Ph)2CH 4-F NI NI NI 
AUM49 4-F-Ph 3-CF3 28.4 38.1 NI 
AUM103 C6H11 4-Cl 32.5 NI 55.4 
AUM104 2-pyrimidinyl 4-Cl 15.5 25.5 22.8 
AUM100 Ph 4-Cl 20.5 17.1 36.4 
AUM105 4-CH3-Ph 4-Cl 10.7 9.8 15.1 
AUM102 4-CF3-Ph 4-Cl 2.9 1.0 12.23 
AUM101 4-F-Ph 4-Cl 24.5 34.5 72.9 
AUM106 2,4-diF-Ph 4-Cl 15.5 18.3 17.1 
AUM140 3,4-diCl-Ph 4-Cl 4.8 6.2 7.5 
AUM99 (Ph)2CH 4-Cl NI NI NI 
AUM129 C6H11 4-Br NI NI NI 
AUM130 2-pyrimidinyl 4-Br 15.0 24.3 46.3 
AUM131 Ph 4-Br 13.6 28.2 NI 
AUM132 4-CH3-Ph 4-Br 13.5 25.5 NI 
AUM133 4-CF3-Ph 4-Br 2.1 3.7 1.6 
AUM134 4-F-Ph 4-Br 17.9 25.1 37.1 
AUM135 2,4-diF-Ph 4-Br 8.2 17.9 16.0 
AUM136 3,4-diCl-Ph 4-Br 3.9 4.6 5.3 
AUM95 C6H11 2-Cl-4-F 20.4 7.8 NI 
AUM96 2-pyrimidinyl 2-Cl-4-F NI NI NI 
AUM92 Ph 2-Cl-4-F 23.1 23.2 NI 
AUM97 4-CH3-Ph 2-Cl-4-F 21.8 33.3 45.2 
AUM94 4-CF3-Ph 2-Cl-4-F 1.1 0.5 20.7 
AUM93 4-F-Ph 2-Cl-4-F 21.4 18.5 NI 
AUM98 2,4-diF-Ph 2-Cl-4-F 41.9 39.9 NI 
AUM141 3,4-diCl-Ph 2-Cl-4-F 2.9 5.6 6.7 
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AUM91 C6H11 2-Cl-4-F NI NI NI 
CPT   <0.1 <0.1 <0.1 
5-FU   30.7 6.0 3.5 
 
 
Supplementary Table 3: IC50 values of 6-(substituted piperazine)-9-
(substituted benzyl) purine analogues: All molecules were tested in duplicate 
and  incubated for 72 hours and the IC50 values are in M range. NI stands for 
“no inhibition”. NA stands for “not applicable”. 
                                           
   IC50 (M) 
AUM 
codes 
R1 R2 Huh7 HCT116 MCF7 
AUM157 2-pyrimidinyl H 17.2 16.5 22.5 
AUM158 Ph H 3.9 2.7 0.9 
AUM159 4-CH3-Ph H 5.9 NI NI 
AUM160 4-CF3-Ph H 0.3 <1.0 <1.0 
AUM161 4-F-Ph H 53.0 1.3 3.4 
AUM162 3,4-diCl-Ph H 0.2 1.2 <1.0 
AUM163 (Ph)2CH H 9.5 14.3 15.4 
AUM174 HOCH2CH2 4-CH3 36.1 43.8 NI 
AUM175 2-pyrimidinyl 4-CH3 5.2 9.7 11.2 
AUM176 Ph 4-CH3 2.8 2.8 0.8 
AUM177 4-CH3-Ph 4-CH3 <1.0 5.1 1.1 
AUM178 4-CF3-Ph 4-CH3 0.1 <1.0 2.6 
AUM179 4-F-Ph 4-CH3 0.1 0.2 <1.0 
AUM180 2,4-diF-Ph 4-CH3 1.4 5.3 88.0 
AUM181 3,4-diCl-Ph 4-CH3 <1.0 <1.0 <1.0 
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AUM182 (Ph)2CH 4-CH3 NI NI 13.2 
AUM147 HOCH2CH2 4-F 79.4 NI NI 
AUM148 cyclohexyl 4-F 9.0 13.1 15.3 
AUM149 2-pyrimidinyl 4-F 70.7 NI NI 
AUM52 Ph 4-F 5.0 2.5 0.7 
AUM150 4-CH3-Ph 4-F 29.8 24.3 NI 
AUM54 4-CF3-Ph 4-F NA NA NA 
AUM53 4-F-Ph 4-F NA 1.1 NA 
AUM151 3,4-diCl-Ph 4-F <1.0 <1.0 4.7 
AUM55 (Ph)2CH 4-F 19.1 18.7 22.1 
AUM173 HOCH2CH2 4-Br 12.8 15.8 30.3 
AUM164 Cyclohexyl 4-Br 3.6 6.0 7.0 
AUM165 2-pyrimidinyl 4-Br 10.6 23.9 NI 
AUM166 Ph 4-Br 0.7 0.7 0.8 
AUM167 4-CH3-Ph 4-Br <1.0 3.0 1.5 
AUM168 4-CF3-Ph 4-Br <1.0 <1.0 NA 
AUM169 4-F-Ph 4-Br 0.1 <0.1 8.0 
AUM170 2,4-diF-Ph 4-Br 13.9 71.7 NI 
AUM171 3,4-diCl-Ph 4-Br 9.4 44.5 1.8 
AUM172 (Ph)2CH 4-Br 11.2 14.8 16.6 
AUM72 HOCH2CH2 2,4-diCl 10.8 9 9.2 
AUM142 Cyclohexyl 2,4-diCl 5.1 11.8 NI 
AUM143 2-pyrimidinyl 2,4-diCl 4.0 3.3 7.3 
AUM56 Ph 2,4-diCl 2.9 <1.0 0.4 
AUM144 4-CH3-Ph 2,4-diCl 1.8 4.7 8.1 
AUM57 4-CF3-Ph 2,4-diCl <1.0 <1.0 <1.0 
AUM145 2,4-diF-Ph 2,4-diCl 8.4 7.2 61.2 
AUM146 3,4-diCl-Ph 2,4-diCl 0.1 0.9 <1.0 
AUM73 (Ph)2CH 2,4-diCl 20.4 19.5 18.1 
AUM78 HOCH2CH2 4-CF3 18.1 19.1 17.9 
AUM79 Cyclohexyl 4-CF3 7.8 7.8 6.5 
AUM154 2-pyrimidinyl 4-CF3 9.6 11.2 17.9 
AUM74 Ph 4-CF3 <1.0 <1.0 <1.0 
AUM155 4-CH3-Ph 4-CF3 <1.0 <1.0 <1.0 
AUM76 4-CF3-Ph 4-CF3 0.1 0.4 0.4 
AUM75 4-F-Ph 4-CF3 1.5 1.3 1.1 
AUM80 2,4-diF-Ph 4-CF3 5.0 5.5 4.3 
AUM156 3,4-diCl-Ph 4-CF3 0.6 0.7 <1.0 
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AUM77 (Ph)2CH 4-CF3 15.4 13 12.2 
AUM68 HOCH2CH2 4-Cl 21.7 19 21.1 
AUM69 Cyclohexyl 4-Cl 9.3 8.9 8.6 
AUM71 2-pyrimidinyl 4-Cl 37.7 56.4 93.9 
AUM64 Ph 4-Cl <1.0 <1.0 0.4 
AUM70 4-CH3-Ph 4-Cl <1.0 <1.0 0.5 
AUM66 4-CF3-Ph 4-Cl 0.1 <1.0 0.05 
AUM65 4-F-Ph 4-Cl 0.6 <1.0 1.4 
AUM152 2,4-diF-Ph 4-Cl 10.0 NI NI 
AUM153 3,4-diCl-Ph 4-Cl 0.3 <1.0 <1.0 
AUM67 (Ph)2CH 4-Cl 18.8 13.2 13.9 
CPT   <0.1 <0.1 <0.1 
5-FU   30.7 6.0 3.5 
 
 
Supplementary Table 4: IC50 values of 6-(4-substituted phenyl)-9-(4-
substituted phenyl) sulfonyl purine analogues: All molecules were tested in 
duplicate and  incubated for 72 hours and the IC50 values are in M range. NI 
stands for “no inhibition”. 
                                  
   IC50 μM 
AUM  
codes 
R1 R2 Huh7 HCT116 MCF7 
AUM197 H F NI 68.3 NI 
AUM198 H CF3 19.8 NI 54.7 
AUM199 H C(CH3)3 NI NI NI 
AUM200 F F NI 59.7 NI 
AUM201 F CF3 NI 58.1 NI 
AUM202 F C(CH3)3 NI NI NI 
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AUM203 Cl F NI 59.1 NI 
AUM204 Br F NI NI NI 
AUM205 CF3 F NI NI NI 
AUM206 C CF3 NI NI NI 
AUM207 CF3 C(CH3)3 NI NI NI 
AUM208 C(CH3)3 F 28.3 NI NI 
AUM209 C(CH3)3 CF3 12.8 30.1 27.1 
AUM210 OPh F 13.7 14.7 22.7 
AUM211 OPh CF3 13.4 12.7 16.9 
AUM212 OPh C(CH3)3 8.6 18.41 21.1 
CPT   <0.1 <0.1 <0.1 
5-FU   30.7 6.0 3.5 
 
 
Supplementary Table 5: IC50 values of 2-amino/2-chloro/6-(4-substituted 
piperazine)/6-(4-substituted phenyl amino)/6-(2-substituted ethylamino)-9-(β-
D-ribofuranosyl) purine analogues: All molecules were tested in duplicate and  
incubated for 72 hours and the IC50 values are in M range. NI stands for “no 
inhibition”. 
                                                        
   IC50 μM 
AUM     
codes 
X R1 Huh7 HCT116 MCF7 
AUM213 H 4-cyclohexylpiperazine NI NI NI 
AUM214 H 4-(2-pyrimidinyl)piperazine NI NI 43.1 
AUM215 H 4-methylphenylpiperazine 78.1 64.7 NI 
AUM225 NH2 2-pyrimidinylpiperazine NI NI NI 
AUM223 NH2 Phenylpiperazine 46.6 33.4 NI 
AUM226 NH2 4-methylphenylpiperazine NI NI NI 
AUM224 NH2 4-fluorophenylpiperazine 93.5 28.1 NI 
AUM222 NH2 diphenylmethylpiperazine 22.0 16.3 16.4 
AUM217 H 4-(methylthiophenyl)amino NI NI NI 
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AUM218 H 4-(dimethylaminophenyl) amino NI 36,9 32.4 
AUM216 H 4-(isopropylphenyl) amino 23.2 14.6 47.4 
AUM219 H 4-(morpholinophenyl) amino NI NI 66.6 
AUM220 H (2-cyclohexenylethyl) amino NI 6.6 2.6 
AUM221 H (2-phenylaminoethyl) amino NI 30.2 83.5 
AUM228 Cl 4-(4-trifluoromethylphenyl) 
piperazine 
2.1 1.1 3.7 
AUM229 Cl (2- cyclohexenylethyl) amino 20.7 62.3 28.0 
CPT   <0.1 <0.1 <0.1 
5-FU   30.7 6.0 3.5 
 
Supplementary Table 6: IC50 values of 6-(substituted piperazine)-9-
(substituted phenyl) sulfonyl purine analogues: All molecules were tested in 
triplicate and  incubated for 72 hours and the IC50 values are in M range. NI 
stands for “no inhibition”. 
 IC50 (M) 
AUM codes Huh7 HepG2 MAHLAVU FOCUS 
AUM123 12.3 25.4 17.0 17.0 
AUM124 9.7 16.3 32.0 19.0 
AUM125 0.4 < 0.1 < 1.0 1.0 
AUM126 17.2 69.0 1.7 NI 
AUM127 1.5 < 1.0 12.9 3.6 
AUM83 12.4 15.2 25.83 30.0 
AUM137 1.8 6.7 20.5 6.4 
AUM88 38.3 54.5 NI NI 
AUM84 12.0 22.1 NI NI 
AUM89 15.2 9.1 5.8 NI 
AUM85 0.3 0.2 < 0.1 < 0.1 
AUM63 15.0 12.4 34.8 14.2 
AUM90 11.0 13.8 15.0 17.4 
AUM138 < 1.0 2.9 64.5 3.3 
AUM113 9.1 10.9 11.8 13.7 
AUM110 1.9 1.1 0.3 0.5 
AUM139 2.7 7.7 33.9 7.9 
AUM105 9.3 14.9 11.8 12.7 
AUM102 2.7 2.4 1.2 1.2 
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AUM106 12.9 15.4 27.9 21.8 
AUM140 4.6 8.9 15.2 8.0 
AUM130 19.2 37.4 20.5 25.0 
AUM131 21.0 23.3 26.2 30.2 
AUM132 11.0 13.4 18.4 17.3 
AUM133 1.8 2.7 13.6 3.8 
AUM134 25.7 22.1 79.5 78.7 
AUM135 5.3 17.3 14.2 10.2 
AUM136 3.0 7.5 17.3 7.0 
AUM92 14.2 23.0 NI NI 
AUM94 2.0 1.7 0.5 1.2 
AUM93 15.6 26.0 33.4 68.8 
AUM141 4.3 9.5 19.8 7.1 
5-FU 5.4 0.8 10.1 3.7 
CPT < 0.1 < 0.1 < 0.1 < 0.1 
 
 
Supplementary Table 7: IC50 values of 6-(substituted piperazine)-9-
(substituted benzyl) purine analogues: All molecules were tested in triplicate 
and  incubated for 72 hours and the IC50 values are in M range. NI stands for 
“no inhibition”. 
 IC50 (M) 
AUM codes Huh7 HepG2 MAHLAVU FOCUS 
AUM157 7.2 14.1 13.2 24.3 
AUM158 3.1 3.3 1.0 4.9 
AUM159 1.6 < 1.0 35.0 9.6 
AUM160 < 0.1 < 0.1 11.7 1.0 
AUM162 0.2 < 0.1 77.2 2.2 
AUM163 9.9 7.4 17.9 8.7 
AUM174 24.7 44.2 29.2 49.8 
AUM175 5.0 7.1 7.4 9.4 
AUM176 1.6 1.3 0.3 3.4 
AUM177 < 1.0 < 1.0 51.5 2.2 
AUM178 0.1 < 0.1 8.3 1.4 
AUM179 0.5 < 0.1 5.9 2.4 
AUM180 1.4 < 1.0 11.8 4.4 
AUM181 0.1 < 0.1 6.3 2.5 
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AUM148 8.5 6.6 11.8 9.4 
AUM52 4.4 0.8 5.0 < 1.0 
AUM150 12.7 26.9 14.4 19.0 
AUM54 1.3 0.7 0.5 0.4 
AUM53 2.7 2.3 3.4 2.4 
AUM151 < 1.0 < 1.0 2.9 < 1.0 
AUM173 10.5 11.1 11.5 22.1 
AUM164 4.0 2.5 6.3 4.3 
AUM165 7.7 15.5 9.1 NI 
AUM166 0.6 1.0 < 0.1 0.1 
AUM167 < 1.0 < 1.0 9.3 1.5 
AUM168 < 0.1 < 0.1 8.0 1.2 
AUM169 0.1 < 0.1 8.1 3.1 
AUM170 2.5 5.4 11.2 29.9 
AUM172 < 1.0 13.6 12.7 8.2 
AUM72 13.0 7.1 45.7 7.7 
AUM142 10.1 17.2 20.6 17.5 
AUM143 5.4 4.8 9.5 8.2 
AUM56 1.4 10.9 3.5 1.6 
AUM144 2.6 2.2 2.2 1.0 
AUM57 0.5 1.2 4.6 0.6 
AUM145 1.1 0.7 0.5 0.3 
AUM146 3.5 3.2 5.9 6.2 
AUM73 0.1 < 0.1 5.7 1.6 
AUM78 25.6 29.0 40.3 15.5 
AUM79 28.3 24.8 NI NI 
AUM154 5.4 6.4 8.0 6.4 
AUM74 3.3 4.3 6.0 7.1 
AUM155 1.4 1.4 1.9 1.5 
AUM76 0.2 < 1.0 94.4 0.5 
AUM75 0.1 < 0.1 < 0.1 < 0.1 
AUM80 2.1 1.6 2.3 1.9 
AUM156 5.5 3.8 4.8 5.1 
AUM77 0.2 < 0.1 8.1 1.4 
AUM68 19.2 24.6 10.8 11.6 
AUM69 23.9 61.3 80.3 83.3 
AUM64 6.7 7.1 13.0 9.1 
AUM66 1.9 1.5 2.3 < 1.0 
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AUM65 0.2 < 0.1 < 0.1 < 0.1 
AUM152 2.3 188 3.2 4.5 
AUM153 2.2 1.2 10.8 5.0 
AUM67 < 0.1 < 0.1 5.6 1.2 
5-FU 5.4 0.8 10.1 3.7 
CPT < 0.1 < 0.1 < 0.1 < 0.1 
 
 
Supplementary Table 8: IC50 values of 6-(4-substituted phenyl)-9-(4-
substituted phenyl) sulfonyl and 2-amino/2-chloro/6-(4-substituted 
piperazine)/6-(4-substituted phenyl amino)/6-(2-substituted ethylamino)-9-(β-
D-ribofuranosyl)  purine analogues: All molecules were tested in triplicate and  
incubated for 72 hours and the IC50 values are in M range. NI stands for “no 
inhibition”. 
 IC50 (M) 
AUM codes Huh7 HepG2 MAHLAVU FOCUS 
AUM198 41.2 NI 89.9 82.2 
AUM208 40.4 NI 29.6 33.3 
AUM209 16.0 48.6 17.3 NI 
AUM210 14.4 32.8 16.5 17.3 
AUM211 13.6 23.4 21.0 26.3 
AUM212 11.0 14.6 23.4 22.3 
AUM215 NI NI 93,2 39,6 
AUM223 78,4 NI NI 9,1 
AUM222 11,5 19,0 7,5 17,0 
AUM218 50,9 28,4 27,2 22,2 
AUM216 39,4 40,4 37,4 21,2 
AUM220 NI < 1,0 NI NI 
AUM228 2,1 0,1 5,1 23,7 
AUM229 20,7 46,6 30,2 45,2 
5-FU 5.4 0.8 10.1 3.7 
CPT < 0.1 < 0.1 < 0.1 < 0.1 
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Supplementary Table 9: IC50 values of HUBT coded 4-amino-3-substituted-
1,2,4-triazole-5-thiones (1-8) and 3,6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-
thiadiazines (1a-8c): All molecules were tested in duplicate and  incubated for 72 
hours. The IC50 values are in M range. NI stands for “no inhibition”. 
 
(CH2)n
N
NHN
NH2
S
R
1-8
 
 
     IC50 (M) 
 HUBT 
Code 
R R1 n Huh7 HCT116 T47D 
1 AA-2M 2-OCH3 - 1 NI NI NI 
2 PA-2M 2- OCH3 - 2 NI NI NI 
3 AA-3M 3- OCH3 - 1 NI 99.9 NI 
4 PA-3M 3- OCH3 - 2 NI NI NI 
5 AA-4M 4- OCH3 - 1 NI 89.7 NI 
6 PA-4M 4- OCH3 - 2 NI 97.8 NI 
7 AA-TM 3,4,5- OCH3 - 1 NI NI NI 
8 PA-TM 3,4,5- OCH3 - 2 NI NI NI 
       
(CH2)n
N
NN
N
S
R1
1a-8c
R
 
     IC50 (M) 
 HUBT Code R R1 n Huh7 HCT116 T47D 
1a n-AT-2M 2-OCH3 H 1 37.6 48.1 NI 
1b ClAT-2M 2-OCH3 Cl 1 NI NI 32.5 
1c FAT-2M 2-OCH3 F 1 90.3 NI 33.2 
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2a n-PT-2M 2-OCH3 H 2 NI NI NI 
2b ClPT-2M 2-OCH3 Cl 2 23.0 NI 10.4 
2c FPT-2M 2-OCH3 F 2 44.6 NI 95.9 
3a n-AT-3M 3-OCH3 H 1 24.7 30.9 23.7 
3b ClAT-3M 3-OCH3 Cl 1 56.1 NI 76.2 
3c FAT-3M 3-OCH3 F 1 NI NI NI 
4a n-PT-3M 3-OCH3 H 2 78.4 NI NI 
4b ClPT-3M 3-OCH3 Cl 2 43.9 NI NI 
4c FPT-3M 3-OCH3 F 2 NI NI NI 
5a n-AT-4M 4-OCH3 H 1 64.8 73.6 35.5 
5b ClAT-4M 4-OCH3 Cl 1 72.4 NI 50.2 
5c FAT-4M 4-OCH3 F 1 28.6 NI 77.6 
6a n-PT-4M 4-OCH3 H 2 18.8 35.4 26.2 
6b ClPT-4M 4-OCH3 Cl 2 30.1 47.6 95.8 
6c FPT-4M 4-OCH3 F 2 NI NI 61.0 
7a n-AT-TM 
3,4,5- 
OCH3 
H 1 5.0 15.0 14.3 
7b ClAT-TM 
3,4,5- 
OCH3 
Cl 1 < 1.0 < 1.0 < 1.0 
7c FAT-TM 
3,4,5- 
OCH3 
F 1 5.3 17.2 13.0 
8a n-PT-TM 
3,4,5- 
OCH3 
H 2 27.8 NI NI 
8b ClPT-TM 
3,4,5- 
OCH3 
Cl 2 13.7 41.9 NI 
8c FPT-TM 
3,4,5- 
OCH3 
F 2 40.9 NI NI 
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C) 
 
Supplementary Figure 1: Percent cytotoxicity in the presence of novel substituted purine analogues: Huh7 (A), HCT116 (B) and T47D (C) 
cells, inoculated in 96-well plates, were treated with these small molecules and their DMSO controls in duplicate with five different 
concentrations for 72 hours. Following the SRB assay, the cytotoxicity percentages were calculated in comparison to DMSO-only treated wells. 
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F) 
 
 
Supplementary Figure 2: Time- and dose- dependent percent cytotoxicity in the presence of novel purine ribonucleoside analogues: Huh7 
(A), HepG2 (B), Mahlavu (C), FOCUS (D), HCT116 (E) and MCF7 (F) cells were inoculated in 96-well plates. All small molecules and their 
DMSO controls were applied to the cells in triplicate with five different concentrations for 24, 48 and 72 hours. Following the SRB assay, the 
cytotoxicity percentages were calculated in comparison with DMSO-only treated wells. 
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F) 
 
Supplementary Figure 3: Percent cytotoxicity in the presence of novel  6-(substituted piperazine)-9-(substituted phenyl) sulfonyl purine 
analogues  given in Supplementary Table 2: Huh7 (A, B), HCT116 (C,D) and MCF7 (E,F) cells, inoculated in 96-well plates, were treated 
with these small molecules and their DMSO controls in duplicate with five different concentrations for 72 hours. Following the SRB assay, the 
cytotoxicity percentages were calculated in comparison to DMSO-only treated wells.  
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F) 
 
Supplementary Figure 4: Percent cytotoxicity in the presence of novel 6-(substituted piperazine)-9-(substituted benzyl) purine analogues 
given in Supplementary Table 3: Huh7 (A, B), HCT116 (C,D) and MCF7 (E,F) cells, inoculated in 96-well plates, were treated with these 
small molecules and their DMSO controls in duplicate with five different concentrations for 72 hours. Following the SRB assay, the cytotoxicity 
percentages were calculated in comparison to DMSO-only treated wells.  
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C) 
 
Supplementary Figure 5: Percent cytotoxicity in the presence of novel  6-(4-substituted phenyl)-9-(4-substituted phenyl) sulfonyl purine 
analogues given in Supplementary Table 4 and 2-amino/2-chloro/6-(4-substituted piperazine)/6-(4-substituted phenyl amino)/6-(2-
substituted ethylamino)-9-(β-D-ribofuranosyl) purine analogues given in Supplementary Table 5:   Huh7 (A), HCT116 (B) and MCF7 (C) 
cells, inoculated in 96-well plates, were treated with these small molecules and their DMSO controls in duplicate with five different 
concentrations for 72 hours. Following the SRB assay, the cytotoxicity percentages were calculated in comparison to DMSO-only treated wells.  
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D) 
 
 
Supplementary Figure 6: Percent cytotoxicity of the further analyzed novel 6-(substituted piperazine)-9-(substituted phenyl) sulfonyl 
purine analogues given in Supplementary Table 6: Huh7 (A), HepG2 (B), Mahlavu (C) and FOCUS (D) cells, inoculated in 96-well plates, 
were treated with these small molecules and their DMSO controls in triplicate with five different concentrations for 72 hours. Following the SRB 
assay, the cytotoxicity percentages were calculated in comparison to DMSO-only treated wells.  
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H) 
 
 
 
Supplementary Figure 7: Percent cytotoxicity of the further analyzed novel 6-(substituted piperazine)-9-(substituted benzyl) purine 
analogues given in Supplementary Table 7: Huh7 (A, B), HepG2 (C, D), Mahlavu (E, F) and FOCUS (G, H) cells, inoculated in 96-well plates, 
were treated with these small molecules and their DMSO controls in triplicate with five different concentrations for 72 hours. Following the SRB 
assay, the cytotoxicity percentages were calculated in comparison to DMSO-only treated wells.  
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Supplementary Figure 8: Percent cytotoxicity of the further analyzed novel 6-(4-substituted 
phenyl)-9-(4-substituted phenyl) sulfonyl AND 2-amino/2-chloro/6-(4-substituted 
piperazine)/6-(4-substituted phenyl amino)/6-(2-substituted ethylamino)-9-(β-D-ribofuranosyl)  
purine analogues given in Supplementary Table 8: Huh7 (A), HepG2 (B), Mahlavu (C) and 
FOCUS (D) cells, inoculated in 96-well plates, were treated with these small molecules and their 
DMSO controls in triplicate with five different concentrations for 72 hours. Following the SRB 
assay, the cytotoxicity percentages were calculated in comparison to DMSO-only treated wells.  
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C)
 
Supplementary Figure 9: Percent cytotoxicity in the presence of HUBT coded novel aminotriazole and thiadiazine derivatives: Huh7 (A), 
HCT116 (B) and T47D (C) cells, inoculated in 96-well plates, were treated with these small molecules and their DMSO controls in duplicate with 
five different concentrations for 72 hours. Following the SRB assay, the cytotoxicity percentages were calculated in comparison to DMSO-only 
treated wells. 
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C) 
 
Supplementary Figure 10: Percent cytotoxicity in the presence of novel 1,2,4 triazolo[3,4-b]-1,3,4-thiadiazine derivatives (72hour): FAT-
TM (A), ClAT-TM (B), n-AT-TM (C) derivatives and their DMSO controls were applied to the liver cancer cells, inoculated in 96-well plates, in 
quadruplicate with indicated concentrations for 72 hours. Following the SRB assay, the cytotoxicity percentages were calculated in comparison to 
DMSO-only treated wells. 
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C) 
 
Supplementary Figure 11: Percent cytotoxicity in the presence of novel 1,2,4 triazolo[3,4-b]-1,3,4-thiadiazine derivatives (24hour and 48 
hour): Huh7 (A), HCT116 (B) and T47D (C) cells, inoculated in 96-well plates, were treated with these small molecules and their DMSO 
controls in quadruplicate with five different concentrations for 24 and 48  hours. Following the SRB assay, the cytotoxicity percentages were 
calculated in comparison to DMSO-only treated wells.                                     
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ABSTRACT: Novel purine ribonucleoside analogues (9−13)
containing a 4-substituted piperazine in the substituent at N6
were synthesized and evaluated for their cytotoxicity on Huh7,
HepG2, FOCUS, Mahlavu liver, MCF7 breast, and HCT116
colon carcinoma cell lines. The purine nucleoside analogues
were analyzed initially by an anticancer drug-screening method
based on a sulforhodamine B assay. Two nucleoside derivatives
with promising cytotoxic activities (11 and 12) were further
ana l yz ed on the hepa toma ce l l s . The N 6 - (4 -
Trifluoromethylphenyl)piperazine analogue 11 displayed the
best antitumor activity, with IC50 values between 5.2 and 9.2
μM. Similar to previously described nucleoside analogues,
compound 11 also interferes with cellular ATP reserves, possibly through influencing cellular kinase activities. Furthermore, the
novel nucleoside analogue 11 was shown to induce senescence-associated cell death, as demonstrated by the SAβ-gal assay. The
senescence-dependent cytotoxic effect of 11 was also confirmed through phosphorylation of the Rb protein by p15INK4b
overexpression in the presence of this compound.
■ INTRODUCTION
Nucleobase analogues and nucleoside analogues are significant
drugs used in chemotherapy for the treatment of solid tumors
and hematological malignancies.1 These groups of compounds
are considered antimetabolites because nucleobases and
nucleosides are the metabolic precursors of nucleotides.
Nucleotides and their derivatives are involved in a large
number of cellular processes, including cell growth and division,
and for this reason nucleobase and nucleoside analogues have
been exploited as anticancer agents.2 Initially, nucleobase
analogues such as fluorinated pyrimidines were investigated as
antimetabolite chemotherapeutic agents on cancer cells. Later,
pyrimidine analogues Ara-C and Gembicitabine were used in
cancer therapy.3 Success with pyrimidine nucleoside analogues
in cancer therapy led to the discovery of purine nucleoside
analogues. For more than six decades, 6-mercaptopurine and 6-
thioguanine have been used as inhibitors of nucleic acid
metabolism in pediatric acute lymphoblastic leukemia.4
Currently, the purine nucleoside analogues fludarabine,
cladribine, and pentostatin are used for treating hematological
malignancies.5 The synthetic nucleoside analogues fludarabine
and cladribine are synthesized into the dATP analogues, and
the natural substance pentostatin leads to an increase in the
dATP levels in the cell. Nucleoside analogues create an
imbalance in the cellular dNTP reserve by inhibiting the
ribonucleotide reductase enzyme, which in turn leads to
impaired DNA synthesis.6 For this reason, nucleoside analogues
often cause apoptosis-induced cell death.3 Recently, expression
levels of ribonucleotide reductase subunits have been proposed
as molecular markers for nucleoside analogue-induced cell
death in cancer therapy response; nevertheless, it was
previously shown that reduced ribonucleotide reductase and
altered dNTP pools have been associated with cellular
senescence in diploid fibroblasts.7−9 Hence, nucleoside
analogues too, may induce senescence-associated cell death.
Apoptosis and necrosis are the most-studied chemother-
apeutic-induced cell death mechanisms. However, in the past
decade, senescence, autophagy, and mitotic catastrophe have
been shown to be induced by cytotoxic agents.10 Senescence-
associated growth arrest is a significant cellular event in tumor
development and progression. Initially, replicative senescence
was reported to be due to telomere shortening during
replication.11 Later, Serrano et al. showed that premature
senescence was associated with cancer.12 Studies on the
molecular analysis of senescence in cancer revealed oncogene-
induced senescence (OIS) and tumor-suppressor-dependent
senescence (PICS).13,14 Therefore, senescence-induced cell
death through pro-senescence therapy is currently the target of
small-molecule inhibitors.14
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Recently, studies focusing on evading senescence in murine
premalignant hepatocytes have revealed a mechanism called
senescence surveillance during hepatocarcinogenesis.15 Fur-
thermore, replacement of the tumor suppressor p53 in murine
liver cancer models has led to senescence and therefore to
regression of these tumors. Primary liver cancer, hepatocellular
carcinoma (HCC), is the fourth most common cause of cancer
mortality and the third most common malignancy in human
cancers. Chronic liver injury is due to viral diseases, exposure to
chemicals, and other environmental or autoimmune conditions
that are the risk factors for HCC. These factors induce an
acquired tolerance to genotoxic stress, but ultimately a
cancerous state that does not respond to the cellular death
mechanisms.16 Recently, Sorafenib, a multikinase inhibitor, was
approved by the FDA and the EU for hepatocellular carcinoma
treatment.17 Sorafenib prolongs median survival and the time to
progression by nearly three months in patients with advanced
hepatocellular carcinoma. Therefore, there is a need for new
liver-cancer-specific drugs based on the molecular mechanisms
involved in liver carcinogenesis. In this study, we synthesized
novel purine ribonucleoside analogues (9−13) containing a 4-
substituted piperazine in the substituent at N6 as putative
cytotoxic agents. The newly obtained compounds were then
characterized for their anticancer senescence-inducing activity
in liver cancer cells.
■ RESULTS AND DISCUSSION
Chemistry. The 6-(4-substituted piperazine-1-yl)-9-(β-D-
ribofuranosyl)purine derivatives (9−13) were synthesized as
shown in Scheme 1. 6-Chloropurine (1) was condensed with
the sugar 1,2,3,5-tetra-O-acetyl-β-D-ribofuranose (2) under
microwave irradiation (30 min) to obtain 6-chloro-9-(2,3,5-
tri-O-acetyl-β-D-ribofuranosyl)-9H-purine (3) as a yellowish
foam in good yield of 75.7%. This reaction gave significantly
higher yields than the previously published method.18 Displace-
ment of the 6-chloro was accomplished by nucleophilic
substitution with appropriate N-substituted piperazines. Re-
moval of the acetyl-protecting groups was performed with
NaOMe in MeOH to produce nucleosides 9−13.
Biological Evaluation and Discussion. The newly
synthesized compounds 9−13 were first evaluated for their
antitumor activities against human liver (Huh7), colon
(HCT116), and breast (MCF7) carcinoma cell lines (Figure
1A). The IC50 values were in micromolar concentrations with
N6-(substituted phenyl)piperazine purine nucleoside derivatives
(Figure 1A and Table 1). We then tested the cytotoxic effect of
these molecules on additional hepatocellular carcinoma (HCC)
cell lines: HepG2, Mahlavu, and FOCUS (Figure 1B). We
observed strong cell growth inhibition in the presence of the
novel nucleosides 11 and 12. Time-dependent IC50 values for
each molecule were also calculated in comparison with the
nucleobase analogue 5-fluorouracil (5-FU) and DNA top-
oisomerase inhibitor camptothecin (CPT) (Table 1). N6-(4-
Trifluoromethylphenyl)piperazine derivative 11 displayed the
best cytotoxic activity, with IC50 values of 5.2−9.2 μM (Table
1). The (3,4-dichlorophenyl)piperazine derivative 12 was also
very active (IC50 values in the range of 5.5−9.7 μM) against all
tested cell lines. When there was a larger substituent at the 4-
position of piperazine moiety (diphenylmethyl group, 13),
cytotoxic activity was decreased. On the other hand, compound
9, which has no substitution at the phenyl ring, did not show
any significant cytotoxic activity; the compound 10, with 4-
fluorophenyl, had some cytotoxicity (Table 1). Nucleosides 11
and 12 demonstrated significant cytotoxicity for all the cell lines
tested. When we compared their IC50 values with the known
cell growth inhibitors CPT and 5-FU, we observed that our
compounds 11 and 12 had showed lower values in micromolar
concentrations. Compounds 11 and 12 had a better cytotoxic
activity on Huh7 cells (7.8 and 7.1 vs 30.7 μM for 5-FU).
Considering the cytotoxic activity of our novel nucleosides
9−13 on hepatoma cell lines, we further analyzed the cellular
activity of the most potent inhibitor (11) on these cell lines as a
promising candidate anticancer agent.
Real-Time Cellular Response of Hepatocellular Carci-
noma Cells with Compound 11 Treatment. Real-time cell
electronic sensing (RT-CES) was used to evaluate compound
11's mediated cytotoxicity on Huh7, HepG2, Mahlavu, and
FOCUS hepatoma cells in triplicate (Figure 2). Real-time
dynamic monitoring of the electrode impedance indicates a cell
index (CI) that correlates with cell growth. Compound 11
triggered a time- and dose-dependent decrease in CI cell
growth indexes in all hepatoma cells (Figure 2). A cell growth
index with 30−5 μM of compound 11 treatment clearly
demonstrates the potent inhibitor action of compound 11,
which correlates with our initial observation with the NCI-SRB
assay. The PTEN-deficient cell line Mahlavu was the least
Scheme 1a
aReagents: (i) silica gel 60, EtOAc, microwave irradiation; (ii) the
appropriate piperazine, TEA, EtOH; (iii) NaOMe, MeOH.
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affected by 11 (Mahlavu cells have a hyperactive PI3K/Akt
pathway due to PTEN deficiency).19 Higher nucleoside−11
concentrations were needed for the cytotoxicity on Mahlavu
cells. This observation indicated that compound−11 might be a
putative kinase−protein interfering molecule. For that reason,
we tested a nontargeted broad-spectrum kinase assay with the
aim of detecting cellular ATP levels affected by the presence of
11.
Nucleoside Analogue 11 Possesses Kinase-Inhibitor
Potential. With the aim of elucidating the possible kinase-
interfering activity of 11, we used a luminescent ATP-detection
assay. Luminescence correlates with the amount of ATP in the
milieu, therefore an increase in the luminescence might indicate
the presence of a protein kinase inhibitor. Because of their
established kinase-inhibition potentials, we used staurosporine
(STS), a multikinase inhibitor, and the nucleoside analogue 5′-
deoxy-5′-methylthioadenosine (MeSAdo) as positive controls
for the experiment. Huh7 cells were incubated with IC50 and
IC100 values of 11 (Table 1), 5 μM MeSAdo, and 0.5 μM STS
for 72 h. A luminescent ATP-detection assay was then achieved.
The luminescence (measured as relative light units (rlu))
indicated a dose-dependent ATP amount in the presence of 11
similar with MeSAdo (Figure 3) with the same cell count. High
rlu values obtained with the STS-treated Huh7 cells are
consistent with both the principle of the assay and the
molecular mechanism of STS as a multikinase inhibitor.
The Cytotoxic Activity of 11 Is Neither Apoptosis nor
Necrosis. We then characterized the cytotoxic pathways
involved in the molecular action of 11. The apoptotic pathway
activation indicator Poly-ADP-ribosyl-polymerase (PARP)'s
protein cleavage was assessed on Huh7, HepG2, Mahlavu,
and FOCUS cells in the presence of 11. For each cell line, 11
was used as its cell-line-specific IC50 value for 72 h (Table 1).
The endogenous PARP protein has an atomic mass of 113 kDa.
During apoptosis, PARP is cleaved into 89 kDa and 24 kDa
fragments, and when the cytotoxic effect is due to necrosis, the
cleaved PARP is detected as a 50 kDa fragment band in
Western blot analysis.20 Seventy-two hours of treatment with
11 did not induce cleavage of the PARP protein in all treated
liver cancer cell lines (data not shown). This cleavage analysis
demonstrated that the cytotoxic activity of 11 was neither
apoptosis nor necrosis.
Compound 11 Induces Cellular Senescence. Replicative
senescence has long been characterized as proliferative arrest
that occurs in normal cells after a limited number of population
doublings. Recently, premature senescence has been associated
with cancer cells. INK4a and INK4b proteins inhibit CyclinD1/
CCDK4, leading to pRB activation and therefore induction of
senescence. For this reason, higher expression of these proteins
is among the premature senescence markers (in addition to
Figure 1. Percent cell death in the presence of compounds 9−13. Huh7, HCT116, MCF7 (A) and HepG2, Mahlavu and FOCUS (B) cells were
inoculated in 96-well plates. All molecules and their DMSO controls were administered to the cells in triplicate with five different concentrations: 40,
20, 10, 5, and 2.5 μM. After 72 h of incubation, SRB assays were generated and the cell death percentages were calculated in comparison with
DMSO-treated wells.
Table 1. IC50 Values in μM Concentrations for 9−13 with 72
h of Treatmenta
9 10 11 12 13 5-FU CPT
Huh7 >100 49.7 7.8 7.1 44.4 30.7 <0.1
HepG2 >100 >100 5.7 6.1 63.5 5.0 <0.1
Mahlavu >100 >100 9.2 7.0 92.7 10.0 <0.1
FOCUS >100 >100 5.2 5.5 >100 7.6 <0.1
HCT116 >100 >100 6.7 8.4 48.5 6.0 <0.1
MCF7 >100 >100 7.5 9.7 40.1 3.5 <0.1
aIC50 values were calculated from the cell growth inhibition
percentages obtained with five different concentrations.
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senescence-associated β-galactosidase (SAβ-gal) activity at pH
6.0 due to increased lysosomal activity).
With the aim of identifying the possible senescence-involved
cytotoxic activity of 11, we performed a SAβ-gal assay and
BrdU incorporation assays in parallel. Huh7 cells were plated in
six-well plates on coverslips at low density for the logarithmic
phase growth. The next day, Huh7 cells were treated with 11 at
its IC50 and IC100 values both for three or six days. Doxorubicin
(25 ng/mL) was used as a positive control for senescence-
inducing agent, and DMSO was used as the negative control.
Twenty-four hours prior to the end of the incubation with the
compound, BrdU was administered to test its incorporation
into the cellular DNA. The large blue-stained senescent (SAβ-
gal-assay-positive) cells were negative for BrdU incorporation
for compound 11 and doxorubicin (Figure 4A,B) when
compared to the DMSO control. However, BrdU-positive
proliferating cells were marked visible in DMSO-treated wells
only.
Compound 11-Induced Senescence Is Associated
with the Induction of p15INK4b and a Decrease in Rb
Phosphorylation. In addition to testing for the most widely
used and accepted marker of senescent cells (an increase in
SAβ-gal activity), we tested another senescence-associated
marker (p15INK4b levels) in 11-treated Huh7 cells. Huh7 cells
were treated in the presence of IC50 and IC100 concentrations of
11 both for three and six days, then Western blot analysis was
realized. Indeed, we observed an increase in the protein
Figure 2. Real-time cell growth of Huh7, HepG2, Mahlavu, and
FOCUS cells in the presence of compound 11. Cells were inoculated
in triplicate in E-plates. The cell growth index was monitored every 30
min in the presence of the different concentrations of compound 11
(30 μM,red; 20 μM, blue; 15 μM, green; 10 μM, magenta; 7.5 μM,
cyan; 5 μM, coral; DMSO control, black).
Figure 3. Whole cell protein kinase activity in the presence of 11.
Huh7 cells were incubated with IC50 and IC100 values of 11 (Table 1),
staurosporine (STS, 0.5 μM), MeSAdo (0.5 μM), and their
corresponding DMSO controls for 72 h. Then, using the Kinase-Glo
assay kit, 80000 were cells tested for their ATP content by
chemoluminesce.
Figure 4. SAβ-gal and BrdU assays with compound 11. Huh7 cells
were plated on coverslips in six-well plates (5000 cells/well). (A)
Huh7 cells were incubated with IC50 and IC100 values of 11,
doxorubicin, and DMSO only controls for three and six days.
Doxorubicin was used as a positive control at its senescence-inducing
dose (25 ng/mL). BrdU (30 μM) was administered to the cells 24 h
prior to the end of three and six days of incubation. (B) Cells were
counted and the percent distribution between SAβ-gal and BrdU
positive was presented.
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expression levels of p15INK4b in a dose- and time-dependent
manner (Figure 5A). Next, we determined the downstream
effect of p15INK4b on the phosphorylation of the Rb protein. It
is known that p15INK4b activates the Rb protein by inhibiting
CyclinD1/CCDK4CD and therefore inhibits the phosphor-
ylation of Rb. An observed decrease in the phosphorylated-
form of the Rb protein correlates with the 11-induced
accumulation of p15INK4b (Figure 5A,B). This observation
thus also confirmed the senescence-induced cytotoxic activity
of compound 11.
■ CONCLUSION
We synthesized a novel group of nucleoside analogues (N6-
substituted piperazine derivatives) as putative anticancer agents.
We identified their cytotoxic activity and determined the
minimum required concentration for their action. Two
molecules, 11 and 12, were promising as candidate chemo-
therapeutic agents and had IC50 values less than 10 μM. We
selected the most active compound (11) to pursue further
experiments on with the aim of analyzing its molecular
cytotoxic action on hepatoma cells. Our results indicated that
the novel candidate chemotherapeutic agent 11 induces
senescence-associated cell death through the inhibition of
some kinase proteins (Figures 3 and 4). In addition our analysis
with p15INK4b protein levels in 11-treated cells indicates that the
target kinases could be upstream of this protein; this must be
further investigated in detail.
Recent studies on the involvement of senescence-associated
cell death in cancer have established the concept stress or
aberrant signaling-induced senescence (STASIS), which is
telomere independent.21 Reprogramming senescence in cancer
cells was extensively discussed as one of the hallmarks of
cancer.22 Targeting replicative immortality and inducing
senescence has also been proposed for mechanism-based drug
discovery. For this reason, induction of irreversible cell cycle
arrest by senescence with novel candidate chemotherapeutic
agents has become an important strategy against cancer.
■ EXPERIMENTAL SECTION
Chemistry. Melting points were recorded with a capillary melting
point apparatus (Electrothermal 9100) and are uncorrected. NMR
spectra were recorded on a VARIAN Mercury 400 FT-NMR
spectrometer (400 for 1H, 100.6 MHz for 13C). TMS was used as
internal standard for the 1H and 13C NMR spectra; values are given in
δ (ppm) and J values are in Hz. High resolution mass spectra data
(HRMS) were collected in-house using a Waters LCT Premier XE
mass spectrometer (high sensitivity orthogonal acceleration time-of-
flight instrument) operating in ESI (+) method, also coupled with an
AQUITY Ultra Performance liquid chromatography system (Waters
Corporation, Milford, MA, USA). All compounds were of >95%
purity. Elemental analyses (C, H, N) were determined on a Leco
CHNS 932 instrument and gave values within ±0.4% of the theoretical
values. Microwave reactions were carried out using a domestic
microwave oven (White Westinghouse SG-KM97VL, 50 Hz, 1400 W).
Column chromatography was accomplished on silica gel 60 (40−63
mm particle size). The chemical reagents used in synthesis were
purchased from E. Merck, Fluka, Sigma, and Aldrich.
6-Chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine
(3). 6-Chloropurine (1) (154 mg, 1 mmol) and 1,2,3,5-tetra-O-acetyl-
β-D-ribofuranose (2) were dissolved in EtOAc, and then 500 mg of
silica gel 60 (200−400 mesh) was added. The mixture was
concentrated in vacuo, and the dry residue was irradiated for 30 min
in a White Westinghouse SG-KM97VL domestic microwave oven (50
Hz, 1400 W). The residue was purified by flash chromatography on
silica gel (EtOAc−hexane, 3:1) to yield 3 as yellowish viscous oil
(312.3 mg, 75.72%). 1H NMR (CDCl3) δ 2.07 (s, 3H, OAc), 2.10 (s,
3H, OAc), 2.14 (s, 3H, OAc), 4.34−4.48 (m, 3H, H-4′, H-5′), 5.63 (t, J
= 5.2 Hz, 1H, H-3′), 5.93 (t, J = 5.6 Hz, 1H, H-2′), 6.21 (d, J = 5.2 Hz,
1H, H-1′), 8.28 (s, 1H, H-8), 8.76 (s, 1H, H-2). 13C NMR (CDCl3) δ
Figure 5. Senescence-associated proteins p15INK4bp and pRb proteins in the presence 11. Huh7 cells were treated with IC50 and IC100 values of 11,
doxorubicin, and DMSO for three and six days. Doxorubicin was used as a positive control at its senescence-inducing dose (25 ng/mL). (A) p15INK4b
protein expression by Western blotting after three and six days of treatment in comparison with positive control doxorubicin and negative control
DMSO. Treatment of Huh7 cells with 11 induced the accumulation of p15INK4b in a dose- and time-dependent manner. (B) Rb activity is detected
with anti-Rb and antiphospho-Rb antibodies. (C) Comparative Rb phosphorylation levels confirmed senescence-induced cytotoxicity by compound
11. Calnexin protein was used as an equal loading control.
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20.59, 20.74, 20.97 (3 × CH3), 63.09 (CH2-5′), 70.67 (CH-4′), 73.32
(CH-3′), 80.74 (CH-2′), 87.08 (CH-1′), 132.57 (C-5), 143.79 (C-8),
151.44 (C-6), 151.87 (C-4), 152.54 (C-2), 169.56, 169.78, 170.48 (3
× CO). HRMS (ESI+) m/z calcd for C16H18ClN4O7 (M + H)
+
413.0864, found 413.0859. Anal. Calcd for C16H17ClN4O7·0.6EtOAc:
C, 47.46; H, 4.71; N, 12.03. Found C, 47.84; H, 4.59; N, 11.89.
General Procedure for the Synthesis of Compounds 4−8. 6-
Chloro-9-(2,3,5-tri-O-acetyl-β-D-ribofuranosyl)-9H-purine (3) was dis-
solved in 10 mL of absolute EtOH, and then 1-substituted piperazines
and (Et)3N (3 equiv) were added. The mixture was refluxed for 3−8 h.
The reaction mixture was concentrated in vacuo, and the residue was
purified by column chromatography.
6-(4-Phenylpiperazine-1-yl)-9-(2,3,5-tri-O-acetyl-β-D-ribofurano-
syl)-9H-purine (4). The compound was prepared from (3) (174.4 mg,
0.4 mmol) and 1-phenylpiperazine (0.13 mL, 0.8 mmol) at reflux for 4
h according to the general procedure and was purified by column
chromatography (EtOAc−hexane, 1:1) to yield 4 (209 mg; 92%); mp
62−64 °C. 1H NMR (CDCl3) δ 2.08 (s, 3H, OAc), 2.14 (s, 6H, OAc),
3.32 (t, 4H, piperazine CH2), 4.34−4.50 (m, 7H, H-4′, H-5′, piperazine
CH2), 5.66 (t, J = 5.6 Hz, 1H, H-3′), 5.91 (t, J = 5.2 Hz, 1H, H-2′),
6.22 (d, J = 5.6 Hz, 1H, H-1′), 6.91 (t, 1H, J = 7.2 Hz, H-4 in phenyl),
6.98 (d, 2H, J = 7.6 Hz, H-2,6 in phenyl), 7.30 (t, 2H, J = 7.6 Hz, H-
3,5 in phenyl), 7.92 (s, 1H, H-8), 8.37 (s, 1H, H-2). 13C NMR
(CDCl3) δ 20.65, 20.78, 21.03 (3 × CH3), 45.24, 49.85 (CH2 in
piperazine), 63.41 (CH2-5′), 70.95 (CH-3′), 73.32 (CH-2′), 80.40
(CH-4′), 86.12 (CH-1′), 116.78, 120.63, 129.45 (C in phenyl), 136.71
(C-5), 150.99 (C-8), 151.37 (C-6), 152.98 (C-2), 154.01 (C-4),
169.63, 169.85, 170.57 (3 × CO). HRMS (ESI+) m/z calcd for
C26H31N6O7 (M + H)
+ 539.2254, found 539.2253. Anal. Calcd for
C26H30N6O7·0.5H2O: C, 57.03; H, 5.70; N, 15.34. Found C, 57.35; H,
5.58; N, 14.97.
6-[4-(4-Fluorophenyl)piperazine-1-yl]-9-(2,3,5-tri-O-acetyl-β-D-ri-
bofuranosyl)-9H-purine (5). The compound was prepared from (3)
(140.1 mg, 0.3 mmol) and 1-(4-fluoropheny)piperazine (61.1 mg, 0.3
mmol) at reflux for 7 h according to the general procedure and was
purified by column chromatography (EtOAc−hexane, 1:1) to yield 5
(151 mg; 80.3%); mp 57−59 °C. 1H NMR (CDCl3) δ 2.08 (s, 3H,
OAc), 2.14 (s, 6H, OAc), 3.22 (t, 4H, piperazine CH2), 4.35−4.47 (m,
6H, H-4′, H-5′, piperazine CH2), 5.66 (t, J = 4.8 Hz, 1H, H-3′), 5.91 (t,
J = 5.2 Hz, 1H, H-2′), 6.22 (d, J = 5.6 Hz, 1H, H-1′), 6.91−7.02 (m,
4H, H-2,3,5,6 in phenyl), 7.92 (s, 1H, H-8), 8.37 (s, 1H, H-2). 13C
NMR (CDCl3) δ 20.64, 20.77, 21.02 (3 × CH3), 45.29, 50.88 (CH2 in
piperazine), 63.39 (CH2-5′), 70.92 (CH-3′), 73.32 (CH-2′), 80.39
(CH-4′), 86.16 (CH-1′), 115.77, 115.99, 118.67 (2), 120.63 (C in
phenyl), 136.75 (C-5), 148.02 (C-8), 150.99 (C-6), 152.95 (C-2),
153.98 (C-4), 169.62, 169.84, 170.56 (3 × CO). HRMS (ESI+) m/z
calcd for C26H30FN6O7 (M + H)
+ 557.2160, found 557.2163. Anal.
Calcd for C26H29FN6O7·1.3EtOAc: C, 55.84; H, 5.91; N, 12.52. Found
C, 56.10; H, 5.87; N, 12.14.
6-[4-(4-Trifluoromethylphenyl)piperazine-1-yl]-9-(2,3,5-tri-O-ace-
tyl-β-D-ribofuranosyl)-9H-purine (6). The compound was prepared
from (3) (92.8 mg, 0.23 mmol) and 1-(α,α,α-trifluoro-p-tolyl)-
piperazine (52.1 mg, 0.23 mmol) at reflux for 2.5 h according to the
general procedure and was purified by column chromatography
(EtOAc−hexane, 1:1) to yield 6 (106.4 mg; 78.23%); mp 68−70 °C.
1H NMR (DMSO-d6) δ 2.04 (d, 6H, OAc), 2.13 (s, 3H, OAc), 3.45
(br s, 4H, piperazine CH2), 4.25−4.43 (m, 7H, H-4′, H-5′, piperazine
CH2), 5.63 (t, 1H, H-3′), 6.03 (t, 1H, H-2′), 6.26 (d, J = 5.6 Hz, 1H,
H-1′), 6.13 (d, Jo = 8.8 Hz, 2H, H-2,6 in phenyl), 7.54 (d, Jo = 8.4 Hz,
2H, H-3,5 in phenyl), 8.33 (s, 1H, H-8), 8.46 (s, 1H, H-2). 13C NMR
(DMSO-d6) δ 20.87, 21.03, 21.17 (3 × CH3), 44.50, 47.61 (CH2 in
piperazine), 63.47 (CH2-5′), 70.73 (CH-3′), 72.58 (CH-2′), 80.11
(CH-4′), 86.24 (CH-1′), 115.05, 118.78 (q), 120.23, 124.29 (C in
phenyl), 126.87 (q) (CF3), 139.91 (C-5), 150.93 (C-8), 152.89 (C-6),
153.76 (C-2), 153.81 (C-4), 169.96, 170.14, 170.72 (3 × CO). HRMS
(ESI+) m/z calcd for C27H30F3N6O7 (M + H)
+ 607.2128, found
607.2115. Anal. Calcd for C27H29F3N6O7·0.3EtOAc: C, 53.51; H, 5.00;
N, 13.28. Found C, 53.88; H, 5.04; N, 13.03.
6-[4-(3,4-Dichlorophenyl)piperazine-1-yl]-9-(2,3,5-tri-O-acetyl-β-
D-ribofuranosyl)-9H-purine (7). The compound was prepared from
(3) (241.5 mg, 0.58 mmol) and 1-(3,4-dichloropheny)piperazine
(135.1 mg, 0.58 mmol) at reflux for 8 h according to the general
procedure and was purified by column chromatography (EtOAc−
hexane, 1:1) to yield 7 (166.2 mg; 46.69%); mp 67−69 °C. 1H NMR
(CDCl3) δ 2.08 (s, 3H, OAc), 2.15 (s, 6H, OAc), 3.29 (t, 4H,
piperazine CH2), 4.34−4.48 (m, 7H, H-4′, H-5′, piperazine CH2), 5.67
(t, J = 4.8 Hz, 1H, H-3′), 5.92 (t, J = 5.2 Hz, 1H, H-2′), 6.22 (d, J = 5.6
Hz, 1H, H-1′), 6.79 (dd, Jo = 8.8 Hz, Jm = 2.8 Hz, 1H, H-6 in phenyl),
7.0 (d, Jm = 2.8 Hz, 1H, H-2 in phenyl), 7.29 (d, Jo = 9.2 Hz, 1H, H-5
in phenyl), 7.93 (s, 1H, H-8), 8.37 (s, 1H, H-2). 13C NMR (CDCl3) δ
20.64, 20.77, 21.02 (3 × CH3), 44.94, 49.21 (CH2 in piperazine),
63.37 (CH2-5′), 70.91 (CH-3′), 73.33 (CH-2′), 80.39 (CH-4′), 86.23
(CH-1′), 115.92 (CH in phenyl), 117.86 (CH in phenyl), 120.66 (CH
in phenyl), 122.98 (C in phenyl), 130.76 (C in phenyl), 133.09 (C in
phenyl), 136.91 (C-5), 150.76 (C-8), 150.99 (C-6), 152.92 (C-2),
153.91 (C-4), 169.62, 169.83, 170.55 (3 × CO). HRMS (ESI+) m/z
calcd for C26H29Cl2N6O7 (M + H)
+ 607.1475, found 607.1475. Anal.
Calcd for C26H28Cl2N6O7·0.2EtOAc: C, 51.50; H, 4.77; N, 13.44.
Found C, 51.43; H, 4.65; N, 13.08.
6-(4-(Diphenylmethyl)piperazine-1-yl)-9-(2,3,5-tri-O-acetyl-β-D-ri-
bofuranosyl)-9H-purine (8). The compound was prepared from (3)
(312 mg, 0.7 mmol) and 1-(diphenylmethyl)piperazine (190.9 mg, 0.7
mmol) at reflux for 5 h according to the general procedure and was
purified by column chromatography (EtOAc−hexane, 1:1) to yield 8
(166.8 mg; 35.1%); mp 81−83 °C. 1H NMR (CDCl3) δ 2.06 (s, 3H,
OAc), 2.12 (s, 3H, OAc), 2.13 (s, 3H, OAc), 2.52 (t, 4H, piperazine
CH2), 4.19−4.44 (m, 8H, CH, H-4′, H-5′, piperazine CH2), 5.63 (t, J =
4.8 Hz, 1H, H-3′), 5.87 (t, J = 5.2 Hz, 1H, H-2′), 6.20 (d, J = 5.2 Hz,
1H, H-1′), 7.19 (t, 2H, Jo = 7.6 Hz, H-4 in phenyl), 7.29 (t, 4H, Jo =
7.6 Hz, H-3,5 in phenyl), 7.44 (d, 4H, Jo = 7.2 Hz, H-2,6 in phenyl),
7.84 (s, 1H, H-8), 8.30 (s, 1H, H-2). 13C NMR (CDCl3) δ 20.65,
20.78, 21.02 (3 × CH3), 45.46 (CH2 in piperazine), 52.26 (CH2 in
piperazine), 63.39 (CH), 70.93 (CH2-5′), 73.30 (CH-3′), 76.35 (CH-
2′), 80.34 (CH-4′), 85.96 (CH-1′), 120.52 (CH in phenyl), 127.31
(CH in phenyl), 128.19 (CH in phenyl), 128.78 (C in phenyl), 136.32
(C-5), 142.47 (C-8), 150.88 (C-6), 152.99 (C-2), 154.03 (C-4),
169.61, 169.85, 170.57 (3 × CO). HRMS (ESI+) m/z calcd for
C33H37N6O7 (M + H)
+ 629.2724, found 629.2719. Anal. Calcd for
C33H36N6O7·0.7H2O: C, 61.80; H, 5.87; N, 13.10. Found C, 61.57; H,
5.89; N, 13.07.
General Procedure for the Deacetylation of the Protected
Nucleosides 9−13. The protected nucleosides (4−8) were dissolved
in 10 mL of absolute MeOH, and then NaOMe (30% in MeOH) (2
equiv) was added and stirred at room temparature for 1−12 h. The
reaction mixture was concentrated in vacuo. The residue was dissolved
with CH2Cl2:MeOH and purified by column chromatography.
6-(4-Phenylpiperazine-1-yl)-9-(β-D-ribofuranosyl)-9H-purine (9).
The compound was prepared from (4) (209.1 mg, 0.388 mmol) at
room temperature for 1 h according to general procedure and was
purified by column chromatography (EtOAc−hexane, 3:1) to yield 9
(27 mg; 16.3%); mp 99−100 °C. 1H NMR (DMSO-d6) δ 3.26 (t, 4H,
piperazine CH2), 3.53−3.70 and 3.65−3.73 (2m, 2H, CH2-5′), 3.96−
4.16 (m, 2H, H-2′,3′), 4.38 (br s, 4H, piperazine CH2), 4.58 (q, 1H, H-
4′), 5.21 (d, 1H, 3′-OH), 5.33 (t, 1H, 5′-OH), 5.48 (d, 1H, 2′-OH),
5.93 (d, 1H, 1′-H), 6.81 (t, 1H, J = 7.2 Hz, H-4 in phenyl), 7.0 (d, 2H,
J = 8.4 Hz, H-2,6 in phenyl), 7.24 (t, 2H, J = 8.4 Hz, H-3,5 in phenyl),
8.28 (s, 1H, H-8), 8.45 (s, 1H, H-2). 13C NMR (DMSO-d6) δ 49.15
(CH2 in piperazine), 62.14 (CH2-5′), 71.13 (CH-3′), 74.20 (CH-2′),
86.42 (CH-4′), 88.44 (CH-1′), 116.51, 119.97, 120.32, 129.65 (C in
phenyl), 139.66 (C-5), 150.99 (C-8), 151.61 (C-6), 152.47 (C-2),
153.81 (C-4). HRMS (ESI+) m/z calcd for C20H25N6O4 (M + H)
+
413.1937, found 413.1938. Anal. Calcd for C20H24N6O4·1.2H2O: C,
55.34; H, 6.13; N, 19.36. Found C, 54.97; H, 6.07; N, 18.98.
6-[4-(4-Fluorophenyl)piperazine-1-yl]-9-(β-D-ribofuranosyl)-9H-
purine (10). The compound was prepared from (5) (151 mg, 0.27
mmol) at room temperature for 5 h according to the general
procedure and was purified by column chromatography (EtOAc−
hexane, 4:1 and then EtOAc) to yield 10 (42.4 mg; 36.5%); mp 189−
191 °C. 1H NMR (DMSO-d6) δ 3.21 (t, 4H, piperazine CH2), 3.56
and 3.68 (2 × dd, 2H, CH2-5′), 3.97 (q, 1H, H-4′), 4.16 (t, 1H, H-2′),
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4.38 (br s, 4H, piperazine CH2), 4.59 (t, 1H, H-3′), 5.23 (br s, 1H, 3′−
OH), 5.48 (br s, 1H, 5′−OH), 5.94 (d, 1H, 1′-H), 7.01−7.10 (m, 4H,
H-2,3,5,6 in phenyl), 8.28 (s, 1H, H-8), 8.45 (s, 1H, H-2). 13C NMR
(DMSO-d6) δ 45.16, 49.96 (CH2 in piperazine), 62.15 (CH2-5′), 71.14
(CH-3′), 74.22 (CH-2′), 86.42 (CH-4′), 88.45 (CH-1′), 115.91,
116.13, 118.37 (2), 120.33 (C in phenyl), 139.67 (C-5), 148.51 (C-8),
150.99 (C-6), 152.47 (C-2), 153.79 (C-4). HRMS (ESI+) m/z calcd
for C20H24FN6O4 (M + H)
+ 431.1843, found 431.1846. Anal. Calcd
for C20H23FN6O4·0.5H2O: C, 54.66; H, 5.50; N, 19.12. Found C,
54.62; H, 5.32; N, 19.25.
6-[4-(4-Trifluoromethylphenyl)piperazine-1-yl]-9-(β-D-ribofura-
nosyl)-9H-purine (11). The compound was prepared from (6) (106.4
mg, 0.17 mmol) at room temperature for 1 h according to the general
procedure and was purified by column chromatography (EtOAc) to
yield 11 (15 mg; 17.8%); mp 108−110 °C. 1H NMR (DMSO-d6) δ
3.45 (t, 4H, piperazine CH2), 3.52−3.60 and 3.64−3.72 (2m, 2H,
CH2-5′), 3.96−4.17 (m, 2H, H-2′, 3′), 4.38 (br s, 4H, piperazine CH2),
4.59 (q, 1H, H-4′), 5.21 (d, 1H, 3′-OH), 5.33 (t, 1H, 5′-OH), 5.48 (d,
1H, 2′-OH), 5.93 (d, 1H, 1′-H), 7.14 (d, Jo = 8.8 Hz, 2H, H-2,6), 7.54
(d, Jo = 8.8 Hz, 2H, H-3,5), 8.29 (s, 1H, H-8), 8.46 (s, 1H, H-2).
13C
NMR (DMSO-d6) δ 44.87, 47.65 (CH2 in piperazine), 62.15 (CH2-
5′), 71.14 (CH-3′), 74.24 (CH-2′), 86.42 (CH-4′), 88.46 (CH-1′),
115.06, 118.79 (q), 120.37, 124.29 (C in phenyl), 126.87 (q) (CF3),
139.73 (C-5), 151.01 (C-8), 152.48 (C-6), 153.79 (C-2), 153.82 (C-
4). HRMS (ESI+) m/z calcd for C21H24F3N6O4 (M + H)
+ 481.1811,
found 481.1810. Anal. Calcd for C21H23F3N6O4·0.6H2O: C, 51.34; H,
4.96; N, 17.10. Found C, 51.65; H, 4.74; N, 16.73.
6-[4-(3,4-Dichlorophenyl)piperazine-1-yl]-9-(β-D-ribofuranosyl)-
9H-purine (12). The compound was prepared from (7) (166.2 mg,
0.27 mmol) at room temperature for 12 h according to the general
procedure and was purified by column chromatography (EtOAc−
hexane,4:1 and then EtOAc) to yield 12 (90 mg; 68.7%); mp 211 °C.
1H NMR (DMSO-d6) δ 3.34 (t, 4H, piperazine CH2), 3.51−3.60 and
3.65−3.73 (2m, 2H, CH2-5′), 3.92−4.63 (m, 7H, H-2′,3′,4′, piperazine
CH2), 5.21 (d, 1H, 3′-OH), 5.33 (t, 1H, 5′-OH), 5.47 (d, 1H, 2′-OH),
5.94 (d, J = 5.6 Hz, 1H, 1′-H), 7.00 (d, Jo = 7.2 Hz, 1H, H-6 in
phenyl), 7.21 (s, 1H, H-2 in phenyl), 7.29 (d, J = 9.2 Hz, 1H, H-5 in
phenyl), 8.29 (s, 1H, H-8), 8.45 (s, 1H, H-2). 13C NMR (DMSO-d6) δ
29.69 (CH2 in piperazine), 48.30 (CH2 in piperazine), 62.18 (CH2-5′),
71.16 (CH-3′), 74.25 (CH-2′), 86.44 (CH-4′), 88.47 (CH-1′), 116.26
(CH in phenyl), 117.25 (CH in phenyl), 120.37 (CH in phenyl),
120.60 (C in phenyl), 131.21 (C in phenyl), 132.24 (C in phenyl),
139.76 (C-5), 151.03 (C-8), 151.31 (C-6), 152.50 (C-2), 153.81 (C-
4). HRMS (ESI+) m/z calcd for C20H23Cl2N6O4 (M)
+ 481.1158,
found 481.1156. Anal. Calcd for C20H22Cl2N6O4·0.2C6H14: C, 51.07;
H, 5.01; N, 16.86. Found C, 51.46; H, 4.88; N, 16.56.
6-(4-(Diphenylmethyl)piperazine-1-yl)-9-(β-D-ribofuranosyl)-9H-
purine (13). The compound was prepared from (8) (166.8 mg, 0.26
mmol) at room temparature for 8 h according to the general
procedure and was purified by column chromatography (EtOAc and
then EtOAc-MeOH, 6:1)) to yield 13 (60.5 mg; 45.5%): mp 117−119
°C. 1H NMR (DMSO-d6) δ 2.43 (br s, 4H, piperazine CH2), 3.50−
3.58 ve 3.62−3.69 (2m, 2H, CH2-5′), 3.92−4.38 (m, 7H, piperazine
CH2, CH, H-2′, 3′), 4.55 (q, 1H, H-4′), 5.19 (d, J = 4.4 Hz, 1H, 3′−
OH), 5.31 (t, J = 5.2 Hz, 1H, 5′−OH), 5.46 (d, J = 6 Hz, 1H, 2′−OH),
5.90 (d, J = 5.6 Hz, 1H, H-1′), 7.21 (t, Jo = 7.2 Hz, 2H, H-4 in phenyl),
7.32 (t, Jo = 7.2 Hz, 4H, H-3,5 in phenyl), 7.45 (d, Jo = 8 Hz, 4H, H-
2,6 in phenyl), 8.22 (s, 1H, H-8), 8.39 (s, 1H, H-2). 13C NMR
(DMSO-d6) δ 52.18 (CH2 in piperazine), 62.14 (CH), 71.13 (CH2-
5′), 74.20 (CH-3′), 75.48 (CH-2′), 86.39 (CH-4′), 88.42 (CH-1′),
120.27 (CH in phenyl), 127.65 (CH in phenyl), 128.35 (CH in
phenyl), 129.26 (C in phenyl), 139.54 (C-5), 143.12 (C-8), 150.93
(C-6), 152.41 (C-2), 153.82 (C-4). HRMS (ESI+) m/z calcd for
C27H31N6O4 (M + H)
+ 503.2407, found 503.2406. Anal. Calcd for
C27H30N6O4·0.2EtOAc·1.0H2O: C, 62.03; H, 6.29; N, 15.61. Found C,
61.72; H, 6.05; N, 15.21.
Cells and Culture. The human primary liver cancer cell lines
(Huh7, HepG2, Mahlavu, and FOCUS) were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Invitrogen GIBCO), with 10%
fetal bovine serum (FBS) (Invitrogen GIBCO), nonessential amino
acids, and 1% penicillin (Biochrome). It was incubated at 37 °C with
5% CO2. DMSO (Sigma) was used as a solvent for the compounds.
The concentration of DMSO was always less than 1% in the cell
culture medium. The cytotoxic drugs (Camptothecin, 5FU, doxor-
ubicin, and MeSAdo) used as positive controls were from Calbiochem.
Sulforhodamine B (SRB) Assay for Cytotoxicity Screening.
Huh7, HCT116, MCF7, HepG2, Mahlavu, and FOCUS cells were
inoculated (2000−10000 cells/well in 200 μL) in 96-well plates. The
next day, the media were refreshed and the compounds dissolved in
DMSO were applied in concentrations between 1 and 40 μM in
parallel with DMSO-only treated cells as negative controls. At the
72nd hour of treatment with compounds 9−13 and the other drugs,
the cancer cells were fixed with 100 μL of 10% (w/v) trichloroacetic
acid (TCA) and kept at +4 °C in the dark for one hour. TCA fixation
was terminated by washing the wells with ddH2O five times. Air-dried
plates were stained with 0.4% sulphorhodamine B (SRB) dissolved in
1% acetic acid solution for 10 min in the dark and at room
temperature. The protein-bound and dried SRB dye was then
solubilized with 10 mM Tris-Base pH 8. The absorbance values
were obtained at 515 nm in a microplate reader. The data normalized
against DMSO only treated wells, which were used as controls in serial
dilutions. In all experiments, a linear response was observed, with serial
dilutions of the compounds and the drugs; R2 ≥ 0.9.
Real-Time Cell Electronic Sensing (RT-CES) for Cytotoxicity
Profiling. The proliferation of primary liver cancer cell lines was
monitored in real-time cell electronic sensing (RT-CES) (xCELLi-
gence-Roche Applied Science), and the cell index (CI) was measured
every 30 min for 96 h. Huh7, HepG2, Mahlavu, and FOCUS cells were
inoculated (2000 cells/well in 200 μL) in the 96 well E-plate on the
xCELLigence station in 5% CO2 at 37 °C. The CI values were
recorded every 30 min. The next day, 150 μL of medium from each
well was replaced with 100 μL of fresh medium containing compound
11 applied in the indicated concentrations. The CI values were
recorded every 30 min to monitor real-time drug response. DMSO-
only and medium-only wells were also included in the monitoring to
account for their possible solitary effects on cancer cells.
Kinase Assay. Kinase-Glo-Plus luminescence kinase activity assay
(Promega) was performed according to the manufacturer’s protocol.
First, the Kinase-Glo reaction buffer (40 mM Tris-HCl pH7.6, 20 mM
MgCl2, 0.1 mg/mL BSA) was placed in the wells of a 96-well Elisa
plate. Then, Huh7 cells treated with 11, Staurosporin (STS), and
MeSAdo for 72 h. Next, lysates from 80000 cells were placed into the
wells. DMSO used as negative control. The total volume of the lysates
and the kinase reaction buffer was 50 μL. Then, 50 μL of Kinase-Glo
reagent (Kinase-Glo plus substrate + Kinase-Glo-Plus buffer) was
applied. After 10 min of dark incubation at room temperature, the
luminescence was detected with a luminometer. If kinase activity is
diminished, ATP concentration will increase and so will luminescence.
Senescence Associated-β-gal Assay and BrdU Proliferation
Co-staining. Huh7 cells (5000cell) were inoculated in two identical
six-well plates on coverslips. The next day, compound 11 and
doxorubicin at the indicated concentrations, and their corresponding
DMSO controls were applied to the plates. On day three and the day
six, the senescence-associated-β-gal (SAβgal) assay and BrdU
costaining were performed as described previously.23,24
Western Blot Analysis. Proteins from Huh7 cells treated with
compound 11 and doxorubicin for three and six days were separated
on a 10% SDS-PAGE, transferred onto nitrocellulose membranes, and
visualized, as described previously.19 The total homogenates from the
cells were resuspended in 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1
mM EGTA, 150 mM NaCl, 1% Triton X-100, and 0.1% SDS with a
protease−inhibitor cocktail and phosphatase inhibitors. p15, Rb and
pRb were detected by Western blotting. Actin protein was used for
equal loading control.
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